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1.1 Hematopoiesis 
Blood cell formation or hematopoiesis normally occurs in the bone marrow and is 
a highly dynamic process. On the average, an adult will produce over 1011 
granulocytes and erythrocytes per day to compensate for normal losses. In periods of 
stress, such as infection or hemorrhage, the blood cell production may increase by at 
least tenfold. All blood cells are derived from a population of pluripotent stem cells 
that are capable of self renewal and can give rise to distinct progenitor cells (1,2) (Fig. 
1). Progenitor cells are irreversibly committed to either the erythroid, 
megakaryocytic, granulocytic, monocytic or lymphoid lineages. Progenitor cells have 
a great proliferative potential and generate up to 105 functional end cells, which are 
released into the circulation. The maintenance of sufficient terminally differentiated 
cells is essential for the defense against micro organisms (neutrophils and 
monocytes) as well as for hemostasis (platelets) and tissue oxygenation 
(erythrocytes). 
Hematopoiesis is controlled by a tightly organized regulatory system in which the 
bone marrow stroma cells (the so-called micro environment), and the hematopoietic 
growth factors (HGFs) play crucial roles (Fig. 1). HGFs are produced by the 
accessory cells such as monocytes, lymphocytes, fibroblasts or endothelial cells, or by 
nonhematopoietic tissues/ for example renal cortex cells/ which produce 
erythropoietin (EPO). The hematopoietic organ maintains its homeostatic condition 
by virtue of a precisely adjusted balance between positive and negative stimuli 
delivered by this regulatory system. 
The development of clonogenic assays and the molecular cloning of many HGFs 
acting on myelopoietic progenitors have enabled investigators to study the basic 
principles of hematopoiesis and hematologic malignancies in vitro (3,4). One of the 
objectives of these investigations is to obtain insight into the role of the 
hematopoietic growth factors and their receptors in normal and malignant 
hematopoiesis, in particular also in acute myeloid leukemia (AML). 
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figure 1. Scheme depicting the different types of blood cells that originate from the bone 
marrow stem cells. 
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1.2 Acute myeloid leukemia (AML) 
AML is characterized by neoplastic proliferation of immature myeloid cells 
(mostly blast cells) in the bone marrow and blood (5). Until today, AML remains a 
highly lethal malignancy. Untreated it will lead to death, due to infections or 
hemorrhage, usually within a few months after diagnosis. Although the cause of 
AML remains largely unknown, environmental and occupational factors, such as 
exposure to chemicals and radiation, may play an important role (6,7). 
AML is a clonal disease. All leukemic cells originate from a single ancestor cell, 
which somehow escapes from the regulatory system that normally controls 
hematopoiesis. The malignant cells have lost their ability to mature, and start to 
grow seemingly uncontrolled (8-13). A major consequence of this escape is the 
infiltration of the bone marrow and suppression of normal hematopoiesis. 
Subsequently, this leads to the accumulation of immature leukemic cells in the 
circulation and depletion of functional blood cells. Although the majority of AML 
cells are blasts, often differentiated cells of the three myelopoietic lineages can also 
be found (14). This is explained by the fact that the AML clone can arise at different 
levels of maturation and some cells still have the ability to bypass the maturation 
block to a limited extent (15-19). 
1.3 Hematopoietic growth factors (HGFs) 
Many different glycoproteins are involved in the control of hematopoiesis (1,20-
24). More than 20 HGF eDNA's have now been cloned and their recombinant 
products have become available. HGFs are glycosylated proteins ranging in size 
from 14 to 50 kilodaltons. The glycoprotein moieties are not required for the 
biological function of HGFs, but may facilitate their transport to various tissues. 
Certain HGFs, like kit-ligand (KL, also called steel factor (SLF), mast cell growth 
factor (MGF) or stem cell factor (SCF)), TNF or M-CSF are produced both in a soluble 
and a nonsoluble, i.e., membrane bound form, as a result of alternative RNA 
splicing. Cells expressing membrane bound HGF can stimulate target cells only after 
direct cell contact (25-30). Most of the HGFs are active as single (monomeric) 
molecules. However, some HGFs form multimers of identical subunits. For example 
IL-5 and M-CSF are kept in a dimeric form via disulfide bridges, and the biologically 
active form of tumor necrosis factor (TNF) is a trimer (31). The actions of HGFs are 
initiated after the interaction of HGF with specific receptors expressed on the cell 
membrane (see 1.4) followed by intracellular molecular interactions leading to 
biological responses. 
Generally, HGFs play a role in coordinating proliferation/ differentiation/ survival, 
and function of hematopoietic cells. Many of the HGFs are pleiotropic in their 
activities. They are active in more than one hematopoietic differentiation lineage or 
at different levels of maturation. Furthermore, they are also frequently involved in 
functional activities including the maintenance of membrane transport mechanisms, 
phagocytosis and the production and release of other cytokines (32). For example, IL-
3 and GM-CSF stimulate the development of various lineages of hematopoietic cells, 
and act at immature and terminally differentiated cells (1,22,23). G-CSF is more 
restricted in its actions and is mainly involved in the production and activation of 
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neutrophilic granulocytes (33). Different HGFs may exert their effects in overlapping 
target cell populations, often resulting in similar biological activities (1,21,34-38). 
A single cytokine, e.g., GM-CSF, can trigger different cellular responses in various 
cell types. Vice versa, similar biological effects can be induced by different cytokines 
(IL-3, GM-CSF). These observations raise questions regarding the structure of 
cytokine receptors and their signaling pathways: (i) Are there different types of 
receptor structures for GM-CSF? (ii) Can a single receptor bind lL-3 and GM-CSF? 
The studies presented in this thesis in Chapters 7 and 8 were performed to 
specifically address these questions. 
1.4 HGF control of AML cell growth 
Despite the apparent escape from regulation in vivo, most AML blasts have 
retained their ability to respond to HGFs stimulation in vitro (34,39-44). AML colony 
growth in semi-solid media fully depends on HGFs, whereas AML cells in 
suspension culture require HGFs for proliferation, as assayed by 3H-TdR uptake, in 
approximately 50% of the cases. IL-3, GM-CSF, and G-CSF are the most important 
HGFs for AML cell proliferation in vitro. Of note is the strikingly parallel 
proliferative response of different AML cases to GM-CSF and IL-3. From studies in 
mice carrying mutations in the Sl or W loci it has become apparent that KL and its 
receptor (c-kit) are essential for normal hematopoiesis. KL also directly stimulates 
AML blast cell proliferation in 50% to 80% of the AML cases (45-47). Above all, KL is 
a strong synergistic factor. In combination with IL-3, GM-CSF and G-CSF it has 
profound enhancing effects on AML blast cell proliferation in vitro (48,49,Chapter 4). 
The cooperative actions of KL with other HGFs does not result from enhanced 
expression of HGF receptors (Chapter 4). M-CSF, IL-6 and EPO are to a lesser extent 
active as exogenous stimulators of AML blast cell DNA synthesis (34,42). In vitro, 
TNF acts as a modulator of HGF controlled growth of normal hematopoietic and 
leukemic cells. In combination with IL-3 or GM-CSF, TNF acts synergistically on 
proliferation and colony formation of AML cells and CD34+ cells. On the other hand, 
TNF inhibits the G-CSF induced proliferation of AML cells (50-52). IL-l and to a 
lesser extent also TNF can stimulate AML growth via induction of endogenous HGF 
release through activation of transcription or stabilization of HGF mRNA in AML 
cells (53-57). AML cells can become independent of endougenous growth factors 
through autocrine mechanisms. In approximately 50% of the cases AML cells show 
significant DNA synthesis in the absence of HGFs (34,54,58-60). In about 40% of the 
cases this proliferation can be blocked by antibodies against HGFs, including GM-
CSF, G-CSF, M-CSF, IL-l and IL-6. 
While HGFs still play an important role in controlling the proliferation of AML 
progenitor cells in vitro, HGFs do not induce differentiation of primary human 
leukemia cells in vitro. Only in a limited number of AML cases, in particular those 
expressing the cytogenetic abnormality t(8;2l)(q22;q22) G-CSF can induce 
neutrophilic maturation (19). Thus, in general AML cells proliferate in response to 
(endogenously released) HGFs in vitro, but the ability of AML cells to mature is 
disturbed and cannot be restored by HGFs. 
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KL stimulates the in vitro proliferation of AML. Particularly, it acts as a synergistic 
factor in combination with other HGFs including IL-3 GM-CSF, and G-CSF. The 
expression of KL receptor (encoded by the proto-oncogene c-kit) and the effects of 
KL on HGF receptors and vice versa were studied in AML (Chapter 4). The following 
questions have been addressed: (i) what is the status of KL-receptor in AML, in 
relationship to the proliferative response? (ii) Does KL upregulate IL-3 or GM-CSF 
receptors in AML cases that show synergy between KL and IL-3 or GM-CSF, and 
vice versa, what is the effect of IL-3 and GM-CSF on KL-receptor expression in these 
AMLcases? 
In addition to its capacity to induce endogenous HGF production, TNF acts 
synergistically with IL-3 and GM-CSF in inducing the proliferation of AML cells. In 
contrast, G-CSF responses are strongly inhibited by TNF. The following questions 
have been addressed in Chapters 5 and 6: (i) Does TNF upregulate IL-3 or GM-CSF 
receptors in AML cases that show synergy between TNF and IL-3 or GM-CSF? (ii) 
Does TNF down modulate G-CSF receptors in AML cases in which the proliferative 
response to G-CSF is abrogated by TNF? 
1.5 Hematopoietic growth factor receptors 
Hematopoietic growth factor receptors (HGF-Rs) are transmembrane glycoprotein 
complexes, often of 2 or more subunits that (i) form a specific ligand recognition site 
and (ii) have the ability to activate intracellular mechanisms of signal transduction 
(Fig. 2). It is now generally accepted that di- or multimerization of subunits is 
required for high affinity binding and signaling (61-68). Cloning of the eDNA's 
encoding these receptors has been achieved using expression cloning techniques and 
cross hybridization of eDNA libraries. The cDNAs of many HGF receptors have been 
isolated, and their structures characterized at the molecular level. The availability of 
the genetic sequence of these receptors offers the possibility to investigate the 
structure-function relationship of these proteins and has led to further 
understanding of the mechanism by which hematopoietic cells communicate with 
their environment. 
1.5.1 Structural versus functional classification of receptors 
Based on the nucleotide homology of HGF-R genes, several families of receptors 
have been identified. By comparing the relative alignment scores of the extracellular 
domains using computer programs, a distinct subdivision can be made on basis of 
structural features (69-73). Five receptor categories can be distinguished: (i) The 
hematopoietin receptor superfamily (Class I cytokine receptors), which is the most 
recently identified subcategory of membrane receptors, comprises most of the 
receptors for the HGFs. The structural and functional characteristics of these 
receptors will be discussed in detail in Chapter 9. (ii) The relatively small interferon 
(IFN) receptor family (Class II cytokine receptors), comprise type I and II IFN 
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receptors, and Tissue Factor (TF), which is the receptor for coagulation protease 
factor VII (70). (iii) TNF receptors, FAS, CD40, and nerve growth factor (NGF) 
binding protein belong to the Class III cytokine receptors. The extracellular domains 
of these receptors are cysteine rich and share significant homology (74-79). (iv) The 
immunoglobulin superfamily (Class IV cytokine receptors), includes receptors such 
as the IL-l receptor, the M-CSF receptor and the platelet derived growth factor 
(PDGF) receptor (72,80). The extracellular domains of these receptors have an 
immunoglobulin-like structure with 3 or 5 homologous repeatsf analogous to the 
immunoglobulin constant domain. Apparently, these receptors and the 
immunoglobulines have evolved distinctively from common ancestral genes. (v) 
Many hormones bind to a group of G-protein coupled receptors such as for example 
the IL-8 receptor (81-82). These receptors are characterized by a stretch of amino acid 
residues that span the membrane seven times and are intracellularly coupled to 
guanine nucleotide binding (G) proteins (83). 
An alternative classification of receptors is made on functional characteristics. For 
example the receptors for KL, CSF-1, PDGF, EGF and insulin, all possess a highly 
conserved tyrosine kinase catalytic region in their intracellular domains (84-86). 
Hence, these receptors are also referred to as the group of receptor tyrosine kinases 
(RTK). The steroid and thyroid hormone receptor super family, a group of nuclear 
receptors which act as hormone responsive transcription factors (87) have both a 
ligand and a DNA binding domain. Retinoic acid receptors, which are members of 
this group are involved in differentiation control of many different tissues including 
Hematopoietic 
Growth Factor 
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Figure 2. Scheme depicting a hematopoietic growth factor receptor composed of two subunits 
that is activated by its specific ligand through dimerization. The activated receptor dimer, via 
secondary messengers, regulates expression of genes that are involved in proliferation, 
differentiation and function of hematopoietic cells. 
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myeloid cells (88-90). 
1.5.21L-3-, GM-CSF-, and G-CSF receptors 
IL-3-, GM-CSF-, and G-CSF receptors are members of the cytokine receptor 
superfamily. Binding studies have revealed that IL-3 and/ or GM-CSF receptors are 
widely expressed on the membranes of human hematopoietic cells, including 
immature rnyeloblasts, acute myeloid leukemia cells, several leukemia cell lines, 
normal monocytes, neutrophils, eosinophils, and basophils (91-101). Although in 
earlier reports only single affinity class IL-3 and GM-CSF receptors were described, it 
appeared later that both receptors have high and low affinity binding sites. The 
dissociation constants of these receptors are in the order of 10-100 pmol/L and 10-
100 nmol/L for high and low affinity sites, respectively. In addition, for GM-CSF a 
third receptor was found with intermediate affinity (102-106). G-CSF receptors are 
expressed by various cells, from the myeloblast to mature neutrophils, AML cells 
and leukemic cell lines, but not on erythroid or megakaryocytic cells (107-109). In 
various hematopoietic cells, single class high affinity G-CSF receptors are apparent 
with Kct values 100-400 pmol/L. More detailed information about these receptors is 
provided in Chapter 9. 
Immature myeloid cells express GM-CSF receptors with binding characteristics that 
differ from those expressed on mature myeloid cells (Chapter 7). These observations 
raise two questions: (i) At which stage of maturation are GM-CSF binding features of 
immature myeloblasts changed into those of terminally differentiated neutrophils? 
(ii) What is the mechanism responsible for these differences. The experiments 
presented in Chapter 8 address these questions. 
1.6 Hematopoietic growth factor receptors in AML 
Oncogenes were first described as retrovirally transduced genes that could induce 
tumor growth in birds and rodents. These genes later turned out to be activated or 
modified forms of cellular genes (proto-oncogenes). The study of oncogenic animal 
retroviruses and the cloning of breakpoints in chromosomal translocations in 
malignancies, have led to the identification of many proto-oncogenes involved in 
regulatory systems that control cell growth and cell differentiation. They are 
involved in the cascade of events of normal cell division: (i) growth factors such as 
PDGF or KL (110,111); (ii) growth factor receptors such as kit, erbB, fms or mpl (112-
115); (iii) signal transducers of growth factor responses such as src, raf or ras 
(116,117); (iv) transcription factors that mediate growth factor-induced gene 
expression like fos and jun (116,118). 
In vitro studies with AML have shown that AML blast cells can still proliferate, 
but have essentially lost their ability to show neutrophilic maturation (in response to 
G-CSF). Furthermore, in 25% of the AML cases, spontaneous proliferation has been 
demonstrated that is not dependent on autocrine mechanisms. These observations 
suggest that leukemic outgrowth of immature blast cells may involve abnormal 
growth factor receptor function. Ensuing the identification of the cellular homologs 
of v-fms and v-erbB, which encode mutated forms of the receptors for M-CSF and 
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EGF respectively, it was apparent that there might be an association between 
leukemia and abnormal receptor function (114,119). Expression of other viral 
oncogenes that carry altered hematopoietic growth factor receptors such as v-kit or 
v-mpl (a truncated form of a novel hematopoietic growth factor receptor transduced 
by the myeloproliferative leukemia virus) have been shown to cause hematological 
disorders in mice. Artificially introduced point mutations or deletions in cellular 
genes encoding growth factor receptor genes were able to induce cell transformation. 
Single point mutations in the extracellular domain of M-CSF receptor resulted in 
constitutive receptor activation, alleviating the growth factor dependency of murine 
hematopoietic cell lines and transformed 3T3 fibroblasts. A point mutation in the 
extracellular domain of the murine EPO receptor has been found to induce 
erythroleukemia in mice (120,121). There have been few reports of genetic lesions 
found in receptor genes isolated from patient material. In ten percent of patients with 
MDS or AML, point mutations of the M-CSF receptor were described (122). 
However, these mutations were either also found in normal individuals or lacked 
transforming capacities when expressed in 3T3 fibroblasts. 
In addition to structural abnormalities, abnormal transcriptional regulation of a 
receptor gene can lead to disturbed receptor function. Overexpression may render a 
cell hyper responsive to the ligand, or even cause transformation. For example 
overexpression of either EGF receptors or HER2/neu, an EGF receptor-like protein, 
in 3T3 fibroblasts results in ligand-independent neoplastic transformation (123). The 
EGF receptor gene is often amplified in breast carcinoma and myc in lung carcinoma 
(124). Similarly, overexpression of the M-CSF receptor in a murine myeloid cell line 
renders these cells growth factor independent and tumorigenic (125). 
One of the initial goals of this thesis was to document the binding status of GM-CSF, 
IL-3 and G-CSF receptors on primary AML cells, to investigate whether these 
receptors may be overexpressed or have an altered ligand binding affinity as 
compared to normal hematopoietic cells (Chapters 2 and 3). 
CHAPTER2 
IL-3 AND GM-CSF RECEPTORS ON HUMAN AML CELLS AND 
RELATIONSHIP TO THE PROLIFERATIVE RESPONSE. 
L.M. Budel, J.P. Touw, R. Delwel, S.C. Clark and B. Lowenberg 
Blood, Vol74: pp 565-571, 1989 
10 CHAPTER TWO 
SUMMARY 
Interleukin-3 (IL-3) and granulocyte macrophage colony-stimulating factor (GM-
CSF) stimulate proliferation of human acute myeloid leukemia (AML) in vitro, 
although patterns of response among clinical cases are diverse. Whether regulatory 
abnormalities related to growth factor responses in human AML may establish the 
outgrowth of the neoplasm remains unclear. We determined receptor numbers and 
affinity for IL-3 and GM-CSF on human AML cells using human recombinant IL-3 
and GM-CSF. In 13 of 15 cases of primary AML high affinity (Kd 26 to 414 pmol/L) 
receptors for IL-3 were demonstrable on the cells. The average numbers of IL-3 
receptors ranged from 21 to 145 receptors per cell. Normal white blood cells showed 
IL-3 receptors on their surface at similar densities. IL-3 receptor positivity often 
correlated with GM-CSF receptor positivity of AML, GM-CSF receptors were 
demonstrated on the cells of 11 of 15 cases although average numbers of GM-CSF 
receptors were ten times greater. The in vitro response of the cells to exogenous IL-3 
or GM-CSF was examined by measuring thymidine uptake. Because IL-3 and GM-
CSF were potent inducers of DNA synthesis in vitro, apparently relatively few 
receptors are required to permit activation of growth. These experiments did not 
provide evidence for overexpression or increased receptor sensitivity as an 
explanation for AML growth. In a minority of cases however, the cells were unable 
to respond to IL-3 (four of 15 cases) or GM-CSF (four of 15 cases) despite normal 
receptor availability on the cell surface. 
INTRODUCTION 
IL-3 and GM-CSF belong to the class of CSFs which regulate survival, 
proliferation and differentiation of hematopoietic progenitor cells in humans 
(1,2,3,4). Most cases of human AML are dependent on CSF for growth, but some 
leukemia's appear to proliferate spontaneously as the consequence of autocrine CSF 
production (5,6,7,8). The growth pattern of AML cells cultured in vitro in the 
presence of different CSFs shows considerable variation (9 ,10,11,12). However 
regulatory abnormalities of growth have not been established in human AML since 
this diverse growth reactivity may resemble the heterogeneity of response of 
different stages of normal marrow precursor cells rather than cellular alterations as 
the result of malignant transformation. CSFs are believed to react with their target 
cells through membrane-bound receptors (13,14). Little is known about the role that 
growth factor receptors play in the pathophysiology of human AML. The 
relationship between growth factor receptor expression and the stimulability of AML 
cells in vitro has not been investigated. Overexpression of a receptor may have a role 
in the outgrowth of AML in vivo, but no experimental evidence to support this 
possibility has yet been provided. One study reported that GM-CSF receptor density 
on AML cells is not increased; hence overexpression of GM-CSF receptors apparently 
does not account for a leukemic growth advantage (15). IL-3 is also an effective 
growth factor for blast cells of AML (9,10,11,12), but no information on IL-3 receptor 
properties on human AML cells is available. For a better understanding of the 
mechanisms that lead to proliferation of AML cells in response to IL-3 and GM-CSF, 
we investigated numbers and affinity of IL-3 and GM-CSF receptors on cells of 
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Figure 1. Autoradiography of 125 1 labeled ll-3 
and GM-CSF. Radiolodinated IL-3 and GM-
CSF 4 x 105 cpm were electrophoresed in 
12% SDS polyacrylamide gel. Autoradiograms 
were obtained by exposing the gel to Kodak 
X-Omat AR film at -70°C. Lanes 1 and 4: 
iodine-labeled mol-wt markers. 
patients with AML and correlated these data with the proliferative response of the 
cells to both molecules, 
MATERIALS AND METHODS 
Preparation of cells. AML cells were obtained from 15 cases of AML classified 
according to the criteria of the French-American-British (FAB) committee (16,17): M1 
(n=2), M2 (n=3), M4 (n=8) and M5 (n=2). The cells were separated from bone marrow 
(BM) or peripheral blood (PB) after bovine serum albumin density gradient (BSA) or 
Ficoll-lsopaque centrifugation (18) and subsequent removal of E-rosette forming 
cells. The AML cells were cryopreserved in 7.5% dimethyl sulfoxide and 20% 
inactivated fetal calf serum (FCS). The viability of the cells after thawing was always 
>95%. Normal BM was obtained by posterior iliac crest puncture from healthy adults 
and the mononuclear cells were separated over Ficoll-Isopaque density gradient. 
Eosinophilic cells were separated from the blood of a patient with hypereosinophilia 
(80 x 109 cells/L) and WBCs from the blood of healthy subjects after sedimentation in 
0.1% methyl cellulose. The latter cell preparations were used fresh. 
Hematopoietic growth factors. Recombinant IL-3 (Escherichia coli derived) (19) 
and GM-CSF (CHO cell derived) (20) was prepared and purified at Genetics Institute 
(Cambridge, MA). GM-CSF used was glycosylated and had a molecular weight 
(MW) of 20-30 kDa (biological activity 6 to 10 x 1010 U I g). IL-3 was not glycosylated 
(MW 15 kDa; 2 to 3 x 1010 U/g). 
Radioiodination of IL-3 and GM-CSF. Purified recombinant IL-3 and GM-CSF 
were radiolabeled according to the method described by Bolton and Hunter (21). 
Bolton-Hunter reagent (BHR) 1 mCi (Amersham laboratories, Amersham, UK) 
dissolved in benzene was dried under a stream of N2 in the packing vial at 22°C. The 
vial was then cooled to O"C, and 5 flg IL-3 or 5 flg GM-CSF in 20 fll borate buffer (0.1 
mol/L, pH 8.2) was applied. The reaction was permitted to proceed for 45 minutes at 
O"C, while the vials were agitated every 5 minutes. Labeling was quenched by 
adding 100 rtl of glycine (0.2 mol/Lin borate buffer). After 5 minutes on ice, 100 fll of 
0.25 % gelatin was added to facilitate recovery of the reactant from the vial. The 
labeled proteins were separated from the unreacted BHR and the iodinated glycine 
by chromatography on sepharose columns (GF-5, Pierce Chemical Co., Rockford, IL), 
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Table 1. Biological activity of radioiodinated IL-3 and GM-CSF 
No. of colonies and clusters 
CSF concentration {pmoi/L) 
IL-3 
GM-CSF 
0.3 
3 
30 
300 
2 
20 
200 
2000 
Non labeled 
100% 
017 
6/21 
14/39 
11/30 
217 
12/34 
31/31 
52/41 
Mixture 125 1-labeled 
50/50% 100% 
0/6 0/2 
5/28 311 8 
15/41 5118 
010 0/0 
3/5 0/6 
22/38 36/35 
37/43 29/40 
20/47 0/8 
Dose response of titrated concentrations native IL-3, radiolabeled IL-3 and a mixture of native or 
radiolabeled IL-3 and the same dose response data for GM-CSF. Colonies and dusters induced from 0.5 x 
105 Ficoll separated marrow cells in 1 ml cultures were scored at day 14. Values indicate average 
numbers of colonies (before the"!") and clusters (after the"/") of duplicate cultures. 
equilibrated with phosphate buffered saline (PBS) containing 0.1% gelatin and 0.01% 
Tween20. 
Samples taken from the void volume were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and subsequent autoradiography 
showing a single band for IL-3 at 15 kD and a broader band for GM-CSF at 20-30 kD 
(Fig. 1). Radiolabeling of IL-3 and GM-CSF using the Bolton and Hunter protocol 
resulted in preparations that retained their ability to stimulate colony formation by 
normal BM cells in methyl cellulose (Table 1). The reduced effectiveness in 
stimulating colony formation by higher concentrations of radiolabeled IL-3 and GM-
CSF is most likely attributed to the continuous irradiation by iodine 125 throughout 
culturing time (14 days). TCA precipitation showed less than 5% nonprecipitable 
radioactivity for both factors. Tl1e maximum binding capacity was estimated at 35-
50% for IL-3 and 40-70% for GM-CSF. This given has been used to correct the "Free" 
cpm in the Scatchard calculations. Specific activity of labeled IL-3 and GM-CSF was 
determined by self displacement analysis (22) or calculated from the TCA 
precipitable radioactivity measured in a small sample taken from the reactant 
(similar results were obtained with both methods, although the selfdisplacement for 
IL-3 was somewhat more inaccurate as compared with the TCA method). The 
specific radioactivity was estimated at 8 to 10 x 104 cpm/ng for IL-3 and 4 to 6 x 104 
cpm/ng for GM-CSF. The fractions containing the radiolabeled protein were stored 
at 4°C in 20% glycerol and 0.2% sodium azide and used within four weeks of 
preparation. 
Colony culture assay. The biological activity of radio labeled IL-3 and GM-CSF 
was determined in normal bone marrow: 0.5 x 105 cells were cultured in a 1 mL 
mixture of Iscove's modified Dulbecco's medium (IMDM), 0.8% methyl cellulose, 
30% FCS, BSA, transferrin, lecithin, sodium-selenite and beta-mercaptoethanol (23). 
Nonlabeled and radiolabeled IL-3 and GM-CSF were added to the cultures in tenfold 
increasing concentrations. The experiment also included cultures containing a 
50/50% mixture of nonlabeled and radiolabeled CSF in order to establish the 
negative effects of gamma radiation on colony formation. Clusters > 15 cells and 
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Figure 2. Binding of 125 1 labeled ll-3 (a) and GM-CSF (b) to normal WBCs in relation to time. 
WBCs 4 x 106 were incubated with 100 pmol!L and 950 pmoi/L IL-3 or 600 and 3000 pmol/l 
GM-CSF at 0°( and 37°C. Binding was assessed as a function of time of incubation. 
colonies > 50 cells were scored at day 14. Duplicate cultures were established for 
each point. 
Binding of radio labeled IL-3 and GM-CSF to AML cells. After thawing, AML cells 
were washed two times in Hanks' balanced salt solution (HBSS). Usually, 2 to 4 x 106 
cells were incubated for 1 hour at 37'C in 100 fLL a-Minimal Essential Medium (o:-
MEM)/10% FCS with 10 to 2000 pmol/L radiolabeled IL-3 or GM-CSF with or 
without 100 nmol/L nonlabeled factor. The cells were then cooled to O'C, layered 
over 500 fLL calf serum in Eppendorf tubes on ice and centrifuged for 5 minutes at 
1000 g. The tubes were frozen in liquid nitrogen, and the tips were cut off for 
counting in a Packard gamma-counter. Specific binding was defined as the difference 
between the amount of radioactivity bound in the without unlabeled factor added, 
and the amount of radioactivity bound with excess unlabeled factor added. 
Experiments were conducted in duplicate. Receptor numbers and binding affinities 
were derived by Scatchard analysis (24). 
3H-11zymidine incorporation into AML cells. DNA synthesis of AML cells was 
Table 2. Binding of 125 1-IL-3 and 125 1-GM-CSF to WBCs and eosinophils 
IL-3 Receptors GM-CSF Receptors 
Cell type Sites/cell Kd (pmoi/L) Sites/cell Kd (pmoi/L) 
WBC donor1 137 86 1,579 230 
donor2 60 53 1,789 392 
donor 3 74 82 1,515 497 
donor 4 134 113 2,091 493 
Eosinophils 1,950 494 1,991 636 
Receptor numbers (mean per cell) and Kd were derived from binding experiments and subsequent 
analysis according to Scatchard (described in legend to Fig. 3). WBCs were obtained from different 
donors. 
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Figure 3. Binding of radio labeled IL-3 (a) and GM-CSF (c) to WBCs and Scatchard plots of these 
data (b and d). Two to 5 X 106 cells and were incubated with increasing amounts of 
radiolabeled IL-3 or GM-CSF for l hour at 37°C. Nonspecific binding was determined in the 
presence of excess unlabeled factor. Specific binding {open circles) as well as nonspecific 
binding (closed circles) data are plotted in the left panels. Each point is the mean of two 
estimates. 
measured as described (25). Two x 104 cells were cultured for 3 days in 96-well 
round-bottom microtiter trays in 100 ~L serum-free mediumr with or without 
addition of IL-3 or GM-CSF. Four hours before harvesting, 0.1 11Ci tritiated 
thymidine (Amersham) was added. Cells were harvested on nitrocellulose paper 
using a Titertek Harvester 550 (Flow Laboratories, Isrike, UK). Radioactivity was 
determined with a scintillation counter (Beckman LS 3800, Fullerton, CA). All 
experiments were performed in triplicate and data expressed as mean dpm. In each 
experiment preirradiated cells were used in control cultures to measure background 
thymidine uptake. 
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Table 3. Binding of human radioiodinated ll-3 and GM-CSF to their receptors on AML cells 
IL-3 receptors GM-CSF receptors 
FAB Case Blasts+(%) Sites/cell Kd (pmoi/L) Sites/cell Kd (pmoi/L) 
M1 98 56 91 23 64 
2 100 25 467 <Det. 
M2 3 100 21 326 <Det. 
4 ND <Det. 40 157 
5 97 55 176 84 123 
M4 6 83 17 183 236 157 
7 89 33 414 561 293 
8 82 21 137 191 162 
9 64 <Det. 843 404 
10 85 60 61 245 155 
11 ND 51 65 792 258 
12 ND 38 26 550 197 
13 ND 98 39 783 169 
M5 14 67 113 163 949 169 
15 50 145 88 1263 274 
Binding assays were performed in duplicate following incubation of 2 to 5 x 106 AML cells for 1 hr at 
37°C with 8 different concentrations of radiolabeled IL-3 or GM-CSF. Mean receptor numbers per cell 
and Kd were derived from Scatchard plots (Fig. 4). < Det.: below detection level; NO: not determined; 
+Blast percentage of AML cells used in binding experiments. 
RESULTS 
Binding of 125I-IL-3 and 125I-GM-CSF to human WBCs and eosinophils. The 
binding kinetics of 1251-IL-3 and 1251-GM-CSF to human WBCs reveal that binding is 
more effective at 37°C than at ooc (Fig. 2). After 1 hour of exposure at 37°C the 
amount of cell associated radioactivity began to decline. Specific binding of IL-3 and 
GM-CSF at 37°C was then determined for WBCs (Fig. 3a and 3b). Scatchard plots 
indicate relatively low numbers of IL-3 receptors (134 sites per cell) of single class 
affinity (Kd 113 pmol/L) on WBCs. Eosinophils expressed more receptors (1950 sites 
per cell) with a Kd of 494 pmol/L. Comparative IL-3 and GM-CSF receptor data for 
human WBCs of four donors and the patient with eosinophilia are shown in Table 2. 
Binding of 125I-IL-3 and 125I-GM-CSF to AML cells. In 13/15 cases, receptors for 
IL-3 could be demonstrated on AML cells (Fig. 4a and Table 3). The average density 
of IL-3 receptors varied between 21 and 145 receptors per celL The Kd ranged from 
26 to 414 pmol/L, which is in the same order of magnitude as the Kd of IL-3 
receptors of normal WBCs (68 to 113 pmol/L). In 11/15 cases both IL-3 receptors and 
GM-CSF receptors were found to be expressed on the cells (Table 3). The mean 
numbers of GM-CSF receptors ranged from 23 to 1263 receptors per cell (Kd 64 to 404 
pmol/L). Thus the average numbers of GM-CSF receptors per cell were 
approximately 10 times greater than those of IL-3 receptors. GM-CSF receptor 
number on cells of patients with AML of FAB classification M1 or M2 tended to be 
less than those of patients of the M4 and MS categories. In contrast IL-3 receptor 
expression on the cells was not different between AML cases of different FAB 
subtypes. 
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Figure 4. Scatchard plots of IL-3 (a) and GM-CSF (b) binding experiments on AML cells {case 
13). For explanation see the legend to Fig. 3. 
Proliferation of AML cells in vitro: Comparison with IL-3 and GM-CSF receptor 
expression. The stimulative effects of human IL-3 and GM-CSF on DNA synthesis of 
AML cells in vitro were determined and compared with the growth factor receptor 
data (Tables 4 and 5). IL-3 was able to increase tritiated thymidine uptake of AML 
cells in ten of 15 cases (Table 4). In nine of the ten IL-3 responders, receptors for IL-3 
could be demonstrated, whereas in one IL-3 responder (case 4) no specific binding of 
IL-3 was measurable. Probably in the latter case, the cells expressed IL-3 receptors 
below the sensitivity of the assay. Of the five nonresponders, in four instances IL-3 
receptors were demonstrated. In all GM-CSF-responsive cases (9 of 15), GM-CSF 
receptors were demonstrable on the cells (Table 4). Among the six nonresponders, 
GM-CSF receptors were not detectable in two cases, whereas significant numbers of 
GM-CSF receptors were demonstrated on the cells of the four remaining 
nonresponsive patients. 
DISCUSSION 
GM-CSF receptors have been demonstrated on AML cells at 44 to 1,074 sites per 
cell with a Kd of 17 to 290 pmol/L using glycosylated GM-CSF (15) and up to 40 sites 
per cell (Kd 10 to 68 pmol/L) using nonglycosylated GM-CSF (26). The expression of 
IL-3 receptors on AML cells has not yet been investigated. The present studies of 15 
patients with AML were undertaken to assess IL-3 receptors on AML cells as well as 
the proliferative response of the cells to IL-3 and to relate these data to GM-CSF 
receptor expression and stimulability. 
High affinity IL-3 receptors are apparent on the cells of most cases of AML (13 of 
15). The density of the IL-3 receptors is relatively low (23 to 145 sites per cell). In one 
of the two IL-3 receptor negative cases (case 9) a proliferative response could be 
evoked by IL-3, which suggested that these cells carried IL-3 receptors at a density 
below the sensitivity of the assay. Apparently the number of receptors necessary to 
elicit a proliferative response in AML cells may be minimal. IL-3 and GM-CSF 
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Table 4. Relationship between IL-3/GM-CSF induced 3H-TdR uptake and IL-3/GM-CSF receptor 
positivity of AML cells 
3H-TdR uptake 3H-TdR uptake 
(dpm x 10-2) (dpm x 10-2) 
No IL-3 ll-3 IL-3 IL-3 No GM-CSF GM-CSF GM-CSF 
FAB Case 200 U/ml responder receptor GM-CSF 200 U/ml responder receptor 
M1 4.5 15.1 + + 4.5 10.2 + + 
2 1.2 1.6 + 1.2 1.1 
M2 3 0.7 0.8 + 0.7 0.5 
4 3.6 8.8 3.6 6.4 + 
5 31.0 90.0 + + 31.0 91.0 + 
M4 6 19.1 57.5 + + 19.1 38.9 + 
7 11.1 20.2 + 11.1 23.3 + + 
8 39.2 88.9 + 39.2 78.4 + + 
9 14.5 41.5 + 14.5 26.3 + + 
10 11.9 92.0 + + 11.9 32.2 + + 
11 53.6 54.6 + 53.6 55.2 + 
12 90.0 89.4 + 90.0 91.3 + 
13 80.8 122.4 + + 80.8 89.0 + + 
M5 14 11.4 26.9 + + 11 .4 13.0 + + 
15 3.3 17.4 + + 3.3 6.8 + 
3H-TdR incorporation by AML cells was determined in triplicate cultures with or without IL-3/GM-CSF. 
When mean dpm of stimulated cultures were significantly greater than the values of unstimulated control 
cultures, IL-3 or GM-CSF responses were considered positive (+). IL-3 or GM-CSF receptor positivity 
based upon data of Table 3. 
receptors were often coexpressed on the cells of the same cases of AML. This 
observation is of interest since apparent similarities exist between the spectrum of 
stimulative abilities of these two growth factors (27). 
Notably, density as well as affinity of the IL-3 receptors of AML cells are in the 
same order as those of normal human WBC; Kd and mean numbers of IL-3 receptors 
per cell did not vary as a function of the cytological classification of the AML cells. In 
contrast, the more immature AML types expressed fewer GM-CSF receptors than 
those of M4 and MS cases as well as those of WBCs. Although the limited number of 
cases do not permit firm conclusions regarding the relationship of receptor density 
and FAB subtype of AML, GM-CSF receptor density may increases as a function of 
progressive maturation, a phenomenon previously reported by others as well (15). In 
the one case with hypereosinophilia, IL-3 receptors were expressed at higher levels 
(2208 sites per cell). This observation is compatible with autoradiography data in 
mice indicating that eosinophils express high numbers of IL-3 receptors (28). 
Demonstration of IL-3 receptors did not always appear to be predictive of the 
proliferative response of the cells to IL-3 (Table 4). In five patients, DNA synthesis 
could not be induced with IL-3. Because in one nonresponder IL-3 receptors were not 
demonstrated, a true absence of IL-3 receptors may have determined the lack of 
response. The cells of the other four nonresponders however, expressed average 
18 CHAPTER TWO 
numbers of IL-3 receptors, comparable to those of the responding cases of AML. 
Thus in those 4 patients IL-3 was unable of inducing DNA synthesis although IL-3 
receptors were available on the cells at normal values. The same phenomenon was 
observed for GM-CSF, i.e., in four of the six patients whose cells did not respond to 
GM-CSF (cases 4, 11, 12 and 15), we could demonstrate GM-CSF receptors on the 
cells. The explanation for this discrepancy between positive growth factor receptor 
expression and negative response is elusive. These cells may already have been 
activated by autocrine CSF production, obscuring a measurable IL-3 or GM-CSF 
response. Indeed, in two nonresponders expressing IL-3 as well as GM-CSF receptors 
(cases 11 and 12) the cells showed high spontaneous activity. In neither case could 
the spontaneous proliferation be blocked by neutralizing anti-IL-3 or anti-GM-CSF 
antibodies. Therefore, these experiments did not provide evidence for endogenous 
IL-3 or GM-CSF stimulation, although we cannot exclude that growth of these cells 
due to autocrine stimulation by IL-3/GM-CSF inside the cells had masked 
exogenous stimulation by IL-3 or GM-CSF. However, in certain other cases IL-3 
(cases 2 and 3) and GM-CSF nonresponders (cases 4 and 15) with positive IL-3/GM-
CSF receptor expression, the cells did not proliferate spontaneously. Why AML cells 
of those patients expressed IL-3 or GM-CSF receptors but were unable of responding 
to these factors is thus unclear. The cells of these patients may have been deficient 
beyond the level of receptor binding, which would not allow them to elicit a normal 
proliferative response. Investigations focusing on signal transduction after 
stimulation with CSFs may be necessary to clarify this question. 
CHAPTER3 
GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTORS IN HUMAN 
ACUTE MYELOID LEUKEMIA 
L.M. Budel, J.P. Touw, R. Delwel, S.C. Clark, B. Lowenberg 
Blood, Vol 74: pp 2668-2673, 1989 
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SUMMARY 
The binding of granulocyte colony-stimulating factor (G-CSF) to normal and human 
acute myeloid leukemia (AML) cells was investigated using radiolabeled 
recombinant human G-CSF. In all14 cases of primary AML specific receptors for G-
CSF were demonstrated on purified blast cells. The average numbers of G-CSF 
receptors ranged from very low to 428 receptors per cell (mean). Normal 
granulocytes showed G-CSF binding sites on their surface at higher densities (703 to 
1296 sites per cell). G-CSF receptors appeared of a single affinity type with a 
dissociation constant (Kct) ranging between 214 to 378 pmol/L for AML blasts and 
405 to 648 pmol/L for granulocytes. In 12 of 14 cases including those with relatively 
low specific binding, G-CSF was a potent inducer of DNA synthesis of blasts in vitro; 
therefore, apparently relatively few receptors are required to permit activation of 
AML cell growth. However, in two cases cell cycling was not activated in response to 
G-CSF despite G-CSF receptor availability. The results show that G-CSF receptors of 
high affinity are frequently expressed on the blasts of human AML, but their 
presence may not be a strict indicator of the proliferative responsiveness of the cells 
to G-CSF. 
INTRODUCTION 
Colony stimulating factors (CSFs) are essential for the proliferation, differentiation 
and survival of hematopoietic cells (1,2,3,4). Growth of human acute myeloblastic 
leukemia (AML) cells in vitro depends also on CSFs but a great variability in 
response to IL-3, GM-CSF, M-CSF and G-CSF has been observed among different 
cases (5,6,7,8,9). A major function of G-CSF is its ability to induce neutrophil colonies 
from normal bone marrow (BM) progenitors (10). G-CSF may also induce maturation 
of myeloid leukemia (8,10,11). Radiolabeled murine G-CSF binds specifically to 
receptors on normal and leukemic human myeloid cells and also stimulates 
functional activities in such cells (12,13,14). Analysis of extended series of AML cases 
showed that the blasts from a significant proportion of patients are nonresponsive to 
stimulation by G-CSF (8,9). The inability of the cells to respond to stimulation might 
be caused by lack of receptors on the membrane or inability of the receptors to 
transduce a secondary signal into the cells. To gain insight into the action of G-CSF 
and the mechanisms that lead to proliferation of AML cells in response to this factor, 
we determined numbers and affinity of G-CSF receptors on blast cells of patients 
with AML as well as on peripheral blood (PB) granulocytes of healthy individuals 
and compared these data with the proliferative reactivity of the AML cells to G-CSF 
in vitro. 
MATERIALS AND METHODS 
Patients and preparation of AML cells, normal BM cells and granulocytes. AML 
was diagnosed according to the criteria of the French-American-British (FAB) 
committee (15,16) (Table 3). BM (all cases except cases 4 and 9) or PB (4 and 9) was 
taken from the patients at diagnosis before any treatment was administered in all14 
cases. The percentage of blasts in BM specimens before purification is given in Table 
3. The leukemic cells were separated from BM or PB after bovine serum albumin 
G-CSF RECEPTORS AND AML 21 
0.20 -,-------------, 
a 
10 
b 
'?0 8 
0.15 ~ 
~ 
• 
• 
~ 0.10 \ 0.05 E 6 0. ~ , ~ 4 , , ~ u. 
"' 
2 y 
"' 0.00 +--.----.-::----r:--.:---,------1 
10° 101 102 103 104 105 106 
0 
0 10 20 30 40 50 
G-CSF added ( ofmol; • cpm) G-CSF added (!mol) 
Figure 1. Measurement of specific radioactivity of radio labeled G-CSF by self displacement. (a) 
Bound/free (8/F) ratio's were determined for titrated concentrations of radiolabeled G-CSF 
(triangles) versus titration of nonlabeled G-CSF in the presence of 350 pmoi/L 125 1-G-CSF 
(circles). Binding of radiolabeled G-CSF paralleled that of radiolabeled G-CSF displaced by 
non labeled G-CSF. (b) Total radioactivity added was plotted against the corresponding quantity 
of unlabeled G-CSF to derive the specific radioactivity. The slope indicates the specific 
radioactivity of the labeled G-CSF. 
density gradient (BSA) or Ficoll-Isopaque centrifugation and subsequent removal of 
E-rosette forming cells (17,18). In addition, AML cell preparations used in the 
binding experiments, the proliferative assays, and the colony assay were also 
depleted from monocytic cells after plastic adherence (19). This resulted in cell 
preparations with a purity of blasts determined by morphology that was always 
more than 98%. The viability of the cells after thawing was always more than 95%. 
Normal BM was obtained by posterior iliac crest puncture from hernatologically 
normal adults and subsequently separated over Ficoll-Isopaque density gradient (20) 
to isolate the mononuclear cell fraction. White blood cells (WBCs) were separated 
from the blood of healthy subjects following sedimentation in 0.1% methyl cellulose. 
Granulocytes were obtained as the sedimented cell fraction following Ficoll-Isopaque 
centrifugation of WBCs and consisted of 90 to 95% neutrophils, 2 to 6% eosinophils 
and 3 to 5% monocytes/lymphocytes. 
G-CSF and radioiodination. Recombinant human G-CSF (rhG-CSF)(E. Coli 
derived, MW 18,800 Da) was prepared and purified at Amgen (Thousand Oaks, CA) 
(10). Purified rhG-CSF was radiolabeled according to the method described by 
Bolton and Hunter (21). Five hundred )lCi of Bolton-Hunter reagent (Amersham 
laboratories, Arnersham, UK) dissolved in benzene was dried down under a stream 
of N2 in the packing vial at 22"C. The vial was then cooled down to O"C and 3 )lg 
rhG-CSF in 15 )ll borate buffer (0.1 mol/L, pH 8.2) was applied. The reaction was 
permitted to proceed for 60 minutes on ice and was quenched by adding 100 )ll of 
glycine (0.2 mol/Lin borate buffer). After 5 minutes on ice 100 )ll gelatin (0.25 %) 
was added to aid recovery of the reactant from the viaL The labeled rhG-CSF was 
separated from the reactant by chromatography on a sepharose column (PIERCE 
GF5) equilibrated with phosphate buffered saline (PBS) containing 0.1% gelatine and 
0.01% Tween 20. Radiolabeling of rhG-CSF resulted in a protein that retained 
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Table 1. Colony stimulating activity of iodinated G~CSF 
No. of Colonies and Clusters 
G-CSF concentration G-CSF Mixture 1231-G-CSF 
(pmoi/L) 100% 50150% 100% 
3 010 010 010 
30 5/25 6/39 1 1/53 
300 51/41 78/55 70/48 
Colonies and clusters induced by titrated concentrations (3, 30, 300 pmoi/L) of native G-CSF, radio-
labeled G-CSF and a 50/50% (wt/wt) mixture of G-CSF/125 1-G-CSF from 0.5 x 10 5 Ficoll-separated BM 
cells. Values are the average number of colonies (before the"/") and clusters (after the"/") of duplicate 
cultures. 
biological activity (Table 1), had a specific binding capacity of 50 to 60% and was 85 
to 90% trichloroacetic acid insoluble. 1251-G-CSF was stored at 4°C in 20% glycerol 
and 0.2% sodium azide and used within four weeks of preparation. 
Specific radioactivity of 125I-G-CSF. Self displacement (22) was applied to 
determine the specific activity of G-CSF following labeling (Fig. 1). The parallel 
displacement curves that were obtained (Fig. 1a) show that the affinities of the 
radiolabeled and native molecules for the G-CSF receptors of granulocytes were 
similar and confirm that labeling had not altered the binding characteristics of G-
CSF. From the slope of the line (Fig. 1b) the specific radioactivity was estimated at 9-5 
x 104 cpm/ng. This specific activity was used to determine the concentration of 
labeled G-CSF used in the binding experiments. 
Binding of labeled G-CSF to AML blasts and granulocytes_ To remove any G-CSF 
that might have remained present on the membrane, the blasts were washed in 
sodium citrate (pH 4) (23)- Before and after this acid wash the cells were washed 
twice in Hanks' Balanced Salt Solution (HBSS). Two to 4 x 106 cells were incubated 
for 1 hour at 37°( in 100 [!l a-Minimal Essential Medium with 10% FCS in the 
presence of 10 to 1,200 pmol/L radiolabeled G-CSF with or without excess (i.e., 100 
nmol/L) nonlabeled G-CSF. The cells were then cooled down to 0°(, layered over 
500 [ll calf serum in Eppendorf tubes on ice, and centrifuged for 5 minutes at 1,000 g. 
The tubes were snapfrozen in liquid nitrogen, and the pellet cut off for counting in a 
gamma-counter (Packard, Downers Grove, USA). Specific binding was determined 
as the difference between the amount of radioactivity bound without unlabeled G-
CSF and the amount of radioactivity bound with excess unlabeled G-CSF. 
Experiments were conducted in duplicate. Receptor numbers and binding affinity 
were derived after analysis according to Scatchard (24). In calculations the maximal 
binding capacity was used to correct for the free counts. 
Colony cultures. To estimate whether the biological activity of radiolabeled G-CSF 
had been retained normal BM cells (0.5 x 105) were cultured in ca 1 mL mixture of 
Iscove's modified Dulbecco's medium (IMDM), 0_8% methyl cellulose, 30% FCS, 
BSA, transferrin, lecithin, sodium-selenite and beta-mercaptoethanol (20)-
Nonlabeled, labeled and a 50/50% mixture of nonlabeled and labeled G-CSF were 
added to the cultures in titrated concentrations. Clusters of more than 15 cells and 
colonies of more than 50 cells were scored at day 14. Each estimate is based on the 
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Figure 2. Binding of radioiodinated G-CSF to normal granulocytes. (a) Displacement of bound 
radio iodinated G-CSF (1 00 pmoi/L; 100 J!l per tube) by increasing amounts of unlabeled G-CSF. 
(b) relationship between cell number and binding of radioiodinated G-CSF (SO pmoi/L; 500 ~-tl 
per tube} to granulocytes. Increasing numbers of cells were incubated with labeled G-CSF with 
(closed circles) or without (open circles) excess unlabeled G-CSF. (c) Binding of radiolabeled G-
CSF to granulocytes as a function of time: 4 X 106 granulocytes were incubated with 300 pmoi/L 
radiolabeled G-CSF at 0 °( (circles) and 37 oC (squares). Total binding (open symbols) as well 
as nonspecific binding (solid symbols) were assessed at various times of incubation. Values are 
means of duplicate estimations. 
data of duplicate cultures. The effect of G-CSF on AML colony formation was also 
determined. In these experiments 1 x 105 blasts were plated per dish containing 1 mL 
of serum-free medium in 0.9% methyl cellulose with and without addition of G-CSF 
(9). After 14 days clusters of more than 15 cells and colonies of more than 50 cells 
were scored (Table 3). Each estimate is based on the data of duplicate cultures. 
3H-thymidine incorporation into AML blasts. Two x 104 blasts were cultured for 
72 hours in serum-free medium with or without the G-CSF (9). DNA synthesis of 
AML blasts was measured as described (9). All experiments were performed in 
triplicate, data were expressed as mean dpm, and differences of DNA synthesis 
between stimulated and nonstimulated cultures analyzed for significance (P>0.95; 
Student's t test). 
RESULTS 
Radioiodination of G-CSF. Radiolabeled G-CSF had retained the ability to 
stimulate colony formation from normal BM cells in methyl cellulose (Table 1). Fig. 
2a shows that competition of nonlabeled G-CSF with binding of radiolabeled G-CSF 
to granulocytes was dose dependent. Both specific and nonspecific binding of 
radiolabeled G-CSF to granulocytes using excess ligand appeared linear with cell 
numbers up to 5 X 106 cells and the linear functions extrapolated through zero (Fig. 
2b). This was indicative that binding of radiolabeled G-CSF as measured was cell-
associated and independent of cell number. Self displacement analysis demonstrated 
similar affinities of labeled and unlabeled G-CSF for granulocytes (Fig. 1). From these 
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Table 2. Binding of 125 1-G-CSF to granulocytes 
G-CSF receptors 
Donor Sites per cell Kd (pmoi/L) 
1 703 648 
2 1,019 405 
3 955 492 
4 1,066 481 
5 1,296 586 
Receptor numbers (mean per cell) and Kd were derived from binding experiments and subsequent 
analysis according to Scatchard (described in legend to Fig. 3). Granulocytes were obtained from 5 
different normal donors. 
data it was apparent that the 1251-G-CSF preparation permitted quantitative receptor 
binding studies. 
Binding of radio labeled G-CSF to granulocytes. Binding of 125I-G-CSF to human 
granulocytes appeared time and temperature dependent (Fig. 2c). G-CSF was more 
efficiently bound at 37'C than at O'C. After 1 hour of exposure of the cells to G-CSF 
at 37°C, the amount of cell associated radioactivity began to decrease. Nonspecific 
binding (radioactivity bound in the presence of excess unlabeled competitor) was 
virtually independent of time or temperature. When granulocytes were incubated 
with increasing concentrations of 125I-G-CSF (20 to 1,250 pmol/L), binding appeared 
saturable, while nonspecific binding increased linearly with increasing 
concentrations of labeled rhG-CSF and varied with cell type and cell number from 
0.4 to 1.8 % of total input cpm (Fig. 3a). The Scatchard plot of the binding data 
revealed an average of 1,019 G-CSF sites per cell of high affinity (Kct 405 pmol/L) 
(Fig. 3a). G-CSF receptor analysis of granulocytes obtained from the blood of 5 
different donors showed limited variations as regards receptor densities (703 to 1296 
sites per cell) and receptor affinity for G-CSF (Kct 405 to 648 pmol/L) (Table 2). 
Binding of radio labeled G-CSF to AML blasts. Binding of 125!-G-CSF to AML 
blasts was examined in 14 cases of AML. In all cases specific binding of 125I-G-CSF 
was measurable (Fig. 3b, Table 3). In five of these cases, binding was too low to 
permit complete Scatchard analysis. In the other 9 cases Scatchard analysis revealed 
comparatively low numbers of G-CSF receptors (49 to 428 sites per cell). The 
apparent dissociation constant ranged between 214 and 373 pmol/L (mean 299 ±53 
pmol/L ±SO), which is similar to the Kct of G-CSF receptors on granulocytes (mean 
522 ± 95 pmol/L ±SO). On the average, the cases of M4 cytology expressed greater 
numbers of G-CSF receptors (mean 274 ± 129 sites per cell± SO) than did M1 and M2 
cases (positive receptor expression but no Scatchard analysis possible in cases 2, 4, 5 
and 7; mean 84 ± 31 sites per cell± SD in the remaining three cases). However, the 
small number of cases tested do not allow any conclusions regarding the relationship 
between cytology and receptor expression. 
Proliferation of AML blasts in vitro: comparison with receptor data. Although 
thymidine uptake generally provides a more sensitive assay of proliferative activity 
of AML cells than the colony assay(9), we also determined the in vitro response of 
the cells in colony culture. In five cases (cases 7, 10, 11, 12 and 14), a significant 
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Table 3. Relationship between G-CSF receptor positivity of AML blasts and G-CSF stimulability 
of 3H-TdR uptake by AML cells 
3H-TdR uptake 
G-CSF receptors Colonies and clusters (dpm x 1 o·1} 
Case no. Blast No With No With resp. 
(%)* Sites/cell Kd (pM) G-CSF G-CSF G-CSF G-CSF 
M1 96 108 263 010 010 9.9 23.5 + 
2 87 § NO 010 010 6.9 15.7 + 
M2 3 93 94 309 010 010 1.8 15.7 + 
4 91 § NO 010 010 3.6 14.9 + 
5 58 § NO 0/5 0/20 0.9 4.6 
6 87 49 214 010 010 0.7 1.8 
7 86 § NO 89/NO 399/NO 7.1 25.2 + 
M4 8 78 406 284 0/46 0/392 73.2 260.2 + 
9 69 192 373 010 0/25 6.7 61.0 + 
10 49 203 378 195/500 296/500 53.7 118.3 + 
11 75 102 276 01112 436/500 67.4 124.2 + 
12 76 428 274 74/500 500/500 31.0 221.0 + 
13 47 310 324 175/500 1 95/500 86.4 162.1 + 
MS 14 28 § NO 0/5 511 9 4.5 9.4 + 
G-CSF receptor numbers per cell and Kd were derived from Scatchard plot analysis (see Fig. 3). Colony 
and cluster formation was scored after 2 weeks. Values are the average number of colonies (before "/") 
and clusters (after "/") per 105 cells from duplicate experiments; Colony or cluster numbers higher than 
500 are marked 500. Stimulation of 3 H-TdR incorporation by AML blasts was determined in cultures with 
300 pmol!L G-CSF. When mean dpm of stimulated cultures were significantly greater than the values of 
unstimulated control cultures, G-CSF responses (last column) were considered positive(+). *percentage of 
blasts in marrow at diagnosis (see materials and methods). §: specific binding detectable (total binding 
exceeds nonspecific binding) but complete Scatchard analysis was not performed; in these instances the 
Kd was not determined (ND). 
increase in colony numbers was seen when G-CSF had been added (Table 3). The 
stimulative effects of rhG-CSF on DNA synthesis of AML cells was determined in 
serum-free culture and the response of the cells compared with growth factor 
receptor expression (Table 3). A significant increase of tritiated thymidine uptake 
was seen in most cases (12 of 14). In 2 cases (cases 5 and 6), DNA synthesis could not 
be activated although G-CSF receptors were clearly identified on the cells. Receptor 
density and affinity of the cells from the two nonresponders (case 5, positive specific 
binding; case 6, 49 sites per cell, Kct 214 pmol/L) were comparable to those of the 
responding cases. 
DISCUSSION 
G-CSF receptors were demonstrated on the blast cells of all14 patients with AML 
included in this study. In 5 of 14 cases, estimation of G-CSF receptor numbers was 
not possible owing to low binding, although significant specific binding was evident. 
In the other nine cases the estimated receptor density ranged between 49 and 428 
sites per cell. That the cells from most cases, including 3 of the five patients with low 
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Figure 3. Binding of radiolabeled G-CSF to granulocytes (a) and AML blasts (c) and Scatchard 
plots of these data {b and d). Four x 106 granulocytes (donor 2, Table 2) or blasts (AML case 8, 
Table 3) were incubated with increasing amounts of radiolabeled G-CSF for 1 hour at 37°C. 
Nonspecific binding was determined in the presence of excess unlabeled G-CSF. Specific 
binding (open circles) and nonspecific binding (closed circles) data are plotted in the left panels. 
Each point represents the mean of two estimates. B/F indicates bound/free ratio. 
specific binding, showed increased DNA synthesis upon stimulation with G-CSF 
established that only minimal numbers of receptors per cell are required to evoke a 
proliferative response to G-CSF. G-CSF receptors demonstrated on the (immature) 
AML blasts were all of high affinity with a dissociation constant (Kd 212 to 378 
pmol/L) which was slightly less than that of G-CSF receptors on granulocytes (Kct 
405 to 648 pmol/L). How these properties compare to those of normal immature 
progenitor cells remains unresolved as long as it is impossible to analyze great 
numbers of purified marrow precursors. On the other hand, the density of G-CSF 
receptors on granulocytes (703 to 1296 sites per cell) appeared greater than that on 
AML blasts. A similar phenomenon (ie, more receptors on granulocytes than on 
AML blasts), has previously been reported for the GM-CSF receptor (25,26). 
We have shown here as well as in a previous study (9) that 3H-TdR uptake 
provides a more sensitive assay for the mitogenic response of AML cells than the 
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colony assay. Indeed, in several cases, a significant increase in DNA synthesis was 
observed, whereas no effect could be demonstrated in the colony assay. Therefore, 
we have related the receptor data to 3H-TdR uptake as parameter of response (Table 
3, last column). G-CSF was able to stimulate DNA synthesis of the blasts from most 
cases (Table 3). The expression of G-CSF receptors did not unequivocally predict 
whether these cells would enter active cell cycling in response to G-CSF. In cases 5 
and 6, G-CSF was incapable of inducing DNA synthesis, although the blasts of these 
patients clearly expressed G-CSF receptors on their membranes. The 
unresponsiveness of AML cells to CSF in spite of receptor availability has also been 
reported for IL-3 and GM-CSF (26). Why AML cells of some patients express G-CSF 
receptors, but cannot respond to stimulation by the ligand is unclear. Although in 12 
of 14 cases the 72 hour period proved sufficient to detect an increase of DNA 
synthesis, in the remaining two cases an undetectable response of only a small 
subpopulation of cells may have occurred. The receptors of the cells of these patients 
similar to those of granulocytes may be functional for other purposes so that they 
cannot elicit proliferation. Investigations along the lines of signal transduction may 
clarify mechanisms that determine the inability of the cells of cases of AML to 
proliferate in reaction to G-CSF stimulation. 

CHAPTER4 
EFFECTS OF KIT LIGAND ON ACUTE MYELOID LEUKEMIA CELLS IN 
VITRO: EFFECTS OF COMBINATIONS WITH OTHER CYTOKINES. 
L.M. Budel, R. Delwel, C. v Buitenen, H. Hoogerbrugge and B. Lowenberg 
Leukemia, Vol77: pp 426-434,1993 
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SUMMARY 
We have investigated the stimulative effects of kit ligand (KL) in primary AML in 
vitro. KL stimulated DNA synthesis of purified leukemic blasts in 8 of 10 cases and 
colony formation in 4 cases in serum-free (SF) culture. KL synergized with 
Interleukin-3 (IL-3; 4 of 10 cases), Granulocyte-Macrophage Colony Stimulating 
Factor (GM-CSF; 3 of 10 cases), Granulocyte-Colony Stimulating Factor (G-CSF; 6 of 
10 cases), Macrophage-Colony Stimulating Factor (M-CSF; 1 of 10 cases) and 
Erythropoietin (EPO; 1 of 10 cases) in its effects on AML cell proliferation when 
added to culture in combination. Synergistic effects of KL in combination with other 
CSFs were also seen in the colony assay. Antibodies against GM-CSF, M-CSF, G-CSF 
and IL-6 did not inhibit the KL response, suggesting that the stimulative effect of KL 
was not mediated through autocrine release of those cytokines. In contrast, the 
proliferative response to KL was abrogated in the presence of Tumor Necrosis Factor 
(TNF; 4 of 10 cases) and Interleukin-4 (IL-4; 2 of 10 cases). FACS analysis with antic-
kit antibodies revealed KL receptor expression in 8 of 9 cases, often in a 
subpopulation of the cells. Scatchard analysis of KL receptors in two cases indicated 
the presence of (mean) 1,460 and 41,500 binding sites respectively. In comparison the 
leukemia cell line M07e expressed more than 120,000 KL binding sites per cell. AML 
cells as well as the M07e cell, expressed one class of high affinity KL receptors (Kd 40 
to 160 pmol/L). The KL dose-response curve in the presence of IL-3 or GM-CSF 
resulted in a higher plateau of DNA synthesis, however no shift in the dose response 
was apparent. The respective reciprocal dose response relations to GM-CSF, IL-3 or 
G-CSF were similarly elevated when KL was added. KL did not alter IL-3 and GM-
CSF receptor expression, nor did IL-3, GM-CSF, G-CSF, TNF or IL-4 influence KL 
binding to AML cells. Hence, we conclude that (a) KL directly stimulates AML blast 
cell proliferation, (b) KL has profound enhancing effects on AML blast cell growth 
induced by other cytokines, (c) costimulation by dual factors may trigger additional 
subsets of AML cells that do not respond to the individual factors, (d) synergy 
between KL and IL-3, GM-CSF or G-CSF and antagonism between KL and TNF or 
IL-4 are not the consequence of altered sensitivity to HGF stimulation nor changes of 
the status of membrane receptors. 
INTRODUCTION 
A variety of hematopoietic growth factors (HGF) are involved in the regulation of 
normal steady state hematopoiesis (1,2,3,4). The proto-oncogene c-kit, which encodes 
a membrane receptor in hematopoietic cells, plays an important role in stem cell 
development (5-10). Kit ligand (KL), steel factor (SLF), mast cell growth factor 
(MGF), or stem cell factor (SCF) has recently been cloned and identified as the ligand 
for c-kit (5-10). KL stimulates mast cell growth, but also stimulates proliferation of 
normal and leukemic progenitor cells (11-14). In addition, enhancing effects of KL 
have been observed in myelopoiesis, lymphopoiesis and erythropoiesis in 
combination with other cytokines (15-18). 
Like in normal hematopoiesis, the regulation of AML cell growth is under the 
control of multiple GFs (19-23). In almost all cases the blast cells have retained their 
ability to respond to HGFs, while in some cases AML cells have become factor 
independent through autocrine or paracrine mechanisms involving CSFs (24-27). IL-
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3, GM-CSF and G-CSF are the most important hematopoietins for in vitro growth of 
primary AML (19-23). To a lesser extent are M-CSF, IL-6 and EPO active as 
exogenous stimulators of AML blast cell DNA synthesis (22,23,28). IL-l and also TNF 
are able to stimulate AML growth via induction of endogenous HGF release through 
activation of transcription or stabilization of HGF mRNA in AML cells (29,30). 
In order to establish the role of KL in the regulation of AML growth in vitro, we 
have conducted studies to determine the effects of KL on AML cell proliferation 
alone and in combination with other cytokines. We have investigated whether 
synergistic or inhibitory effects of individual cytokines in combination with KL were 
achieved at the level of KL, IL-3 or GM-CSF receptor modulation. 
MATERIALS AND METHODS 
Patients and preparation of AML cells. Cells obtained from 10 cases of primary 
AML were diagnosed according to the criteria of the French-American-British 
Committee (FAB) (31,32) as Ml (cases 1 to 3), M2 (cases 8 and 10), M4 (cases 4 and 7) 
and MS (cases 6 and 9). Bone marrow was obtained after permission. The cells were 
recovered from the interface following Ficoll-Hypaque density gradient 
centrifugation, depleted from T cells by E-rosetting and cryopreserved (33,34). After 
thawing, monocytes were depleted by plastic adherence (23). Cells were cultured in 
suspension or colony assay in serum-free (SF) medium (23). 
Growth factors and neutralizing antibodies. The following purified recombinant 
growth factor preparations were used: IL-3 (100 U/mL; Gist Brocades, Delft, The 
Netherlands), GM-CSF and IL-4 (200 U /mL & 100 U /mL; Genetics Institute, 
Cambridge, MA), M-CSF (2000 U /mL; Cetus Corporation, Emmeryville, CA), G-CSF 
and KL (10 ng/mL & 25 ng/mL; Immunex Seattle, WA), TNFa (1000 U/mL; 
Boehringer Institute, Vienna, Austria) and used at the indicated concentrations 
unless specified otherwise. Polyclonal rabbit anti IL-3, sheep anti GM-CSF (both from 
Genetics Institute), rabbit anti G-CSF (from Immunex), rabbit anti IL-6 (Central 
Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam, 
The Netherlands) and monoclonal anti M-CSF (Cetus) were used in dilutions that 
completely blocked the effects of optimal concentrations of the corresponding 
growth factors (35). 
3H-Thymidine ('H-TdR) incorporation. DNA synthesis of AML cells was 
measured in 96 well microliter plates as described (19,23). The results of triplicate 
experiments of 2 x 104 cells per well are expressed as means ± standard deviation 
(SO). Preirradiated (30 Gy) AML cells were always run in parallel to assess 
background thymidine incorporation. Statistical analysis to determine significant 
differences (P<0.05) to identify additive or synergistic effects, was performed with 
the Student's t test (StatWorks, Cricket Software, Philadelphia, PA). 
AML clonogenic assay. AML colony forming units (CFU) were measured in 8 of 
the 10 cases. In these experiments 1 x 105 cells were plated in 1 mL SF medium that 
contained 0.9% methyl cellulose, and cultured in humidified 5% C02 atmosphere at 
37°C in the presence of indicated cytokines (19). All CFUs that contained more than 
15 cells were scored. Presented data refer to myeloid colony formation, unless stated 
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Figure 1. KL receptors on AML cells. AML cells (5 x 105 cells/tube; case 8) were incubated with 
radiolabeled KL (50-3200 pmol/L) in the absence (closed circles) or presence of excess Kl (1 00 
nmoi/L; open circles). Inset shows Scatchard transformation of binding data after correction for 
nonspecific binding. All data represent means of duplicate estimations. 
other wise. The values indicate means of duplicate cultures at day 10-14. Colony 
growth from 1 x 105 cells from AML suspension cultures was assessed in the 
presence of IL-3, GM-CSF, G-CSF and EPO at day 14. 
Fluorescence labeling of the cells. Cells were labeled with the monoclonal 
antibodies (CD14, CD15, CD33, CD34, CDw65 and anti-c-kit, a kind gift from Dr. H-J 
Biihring, Univ. of Tiibingen, Germany (36)) and with a second step reagent GAM-
FITC (Nordic, Tilburg, The Netherlands) as described (37). Fluorescence was 
measured on a FACS 440 (Becton Dickinson, Mountain View, CA). Cell labeling 
studies were performed after thawing of the cells and after 7 days of cui ture in the 
presence of no factor, KL, IL-3 and G-CSF. 
Radiolabeling of cytokines and binding experiments. Purified recombinant GM-
CSF, IL-3 and KL were labeled with iodine 125 using the Bolton and Hunter 
technique as described (38). In brief 0.25 x 1CJ6 cells were incubated for 1 hour at 22" C 
in 100 ~L a-Minimal Essential Medium with 1% BSA in the presence of titrated 
concentrations of radiolabeled KL with or without excess (i.e., 100 nmol/L) 
nonlabeled KL. GM-CSF and IL-3 receptors were measured in the presence of 400 
pmol/L labeled factor. Specific binding was defined as the difference between the 
amount of radioactivity bound in the absence of nonlabeled factor, and the amount 
of radioactivity bound in the presence of excess nonlabeled factor. Binding 
experiments were conducted in triplicate or duplicate (KL Scatchard analysis). 
Receptor numbers and binding affinities were derived following Scatchard analysis 
(39), using the ENZfitter computer program (Sigma Chemical co, st. Louis, MO). 
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Table 1. c-kit expression in AML cells and MO 7e cells 
c-kit expression 125 1-KL binding 
case FAB (FACS analysis) R {sites/cell) Kd (pmoi/L) 
M1 15% 
2 M1 20% 
3 M2 5% 
4 M4 1% 1,460 " 30 160 ± 11 
5 M4 25 ch. 
6 Ms negative 
7 M4 NO 
8 M2 30 ch. 41,500 ± 1,320 98 ± 3.2 
9 Ms 2% 
10 M2 15 ch. 
M07e 122,000 ± 4,800 41 :!:: 4.5 
c-kit expression on AML cells was determined by FACS analysis and by KL radiolabeling studies. Values 
indicate the percentage of AML cells contained in the c-kit positive subpopulation, or the peak shift 
(expressed as the numbers of channels, 17 channels peakshift is equivalent to one log more fluorescence) 
after c-kit/GAM-FITC labeling. Mean numbers of binding sites per cell and affinity for KL were derived 
from Scatchard analysis. NO: not determined. 
RESULTS 
Expression of c-kit on AML cells. KL receptors were studied with anti c-kit 
antibodies and radiolabeled KL. FACS analysis revealed variable positive expression 
of c-kit in eight of 9 cases (Table 1). Case 6 did not express detectable levels of c-kit. 
This case showed a clear response to KL in combination with G-CSF or M-CSF in the 
clonogenic assay, indicating that this case also expressed c-kit, but below the level of 
fluorescence detection. The fluorescence histograms revealed in 5 cases a c-kit 
positive subpopulation of 1-20% of AML cells. In the three remaining cases a peak 
shift indicated expression of c-kit on the majority of cells. Scatchard analysis of KL 
binding data of two cases with relatively low c-kit fluorescence (case 4) and high c-
kit fluorescence (case 8) revealed the presence of 1,460 and 41,500 binding sites 
respectively (Table 1, Fig. 1). In comparison, the leukemia cell line M07e expressed 
more than 120,000 KL binding sites per cell. The low mean number of KL binding 
sites on AML cells, as compared to M07e, probably reflects the fact that only a 
subpopulation of cells were positive for c-kit. AML cells from cases 4 and 8, as well 
as the M07e cell, expressed a single class of high affinity KL receptors (Kd 40-160 
pmol/L). 
Response of AML blast cells: effect of KL in 3H-TdR and colony assay. The 
optimal concentration of KL to induce DNA synthesis was tested in two cases. Half 
maximal effects were reached at 5-6 ng/mL KL and a plateau was reached at 20 
ng/mL. Based on these data further experiments were performed with 25 ng/mL. 
The stimulative effects of KL on the DNA synthesis of ten AML cases were assessed 
in comparison with nonsupplemented cultures (Table 2). In most cases AML cells 
show some baseline DNA synthesis as compared to preirradiated controls. In 8 cases, 
a significant increase of DNA synthesis was observed in culture following 
stimulation 
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Figure 2. The effects of KL in combination with other cytokines on 3H-TdR uptake by AML cells. 
3H-TdR uptake by AML cells from 10 cases was determined in cultures with the individual 
recombinant factors (ll-3, GM-CSF, M-CSF, EPO, IL-4 and TNFa) or KL in combination with 
these factors as a measure of proliferation. Values plotted represent the mean of triplicate 
estimations. * indicates additive action of GFs; ** indicates synergistic action of GFs; <> 
indicates inhibition of KL response. Student 1S t test was used to determine significance of 
additive, synergistic or inhibitory effects (P<O.OS). 
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Figure 3. The effects of KL in combination with other cytokines on colony formation from AML 
blast cells. AML colony formation in culture with KL in the presence of IL-3, GM-CSF, G-CSF, 
M-CSF or EPO*. Values indicate mean numbers ofCFUs (>15 cells) per 1 x 105 cells.* CFU in 
the presence of EPO indicate erythroid colony growth only; in the absence of EPO, no erythroid 
colony formation was observed; EPO had no effect on spontaneous or KL induced myeloid 
colony growth. 
with KL. In two cases that exhibited already high spontaneous proliferation (cases 5 
and 6), KL did not augment proliferation. Variable spontaneous colony growth (1 to 
780 CPU) was measured in 6 cases (Table 2). In the two other cases (2 and 3), 
spontaneous colony growth was absent. Following the addition of KL to culture in 
four cases (3, 6, 8 and 9) the numbers of CFU increased. 
Effects of anti HGF neutralizing antibodies. KL is a synergistic factor that 
stimulates AML growth when used as a single factor. Since HGFs are frequently 
produced by AML cells we have examined the possibility that the effects of KL were 
36 CHAPTER FOUR 
Table 2. Effect of KL in 3H-TdR uptake and colony assay of AML blasts 
3H-TdR uptake (dpm x 10"2} AML-CFU per 105 cells 
case control Kl irr. control KL 
1 1.3 2.5 0.2 
2 0.7 29 0.3 0 0 
3 2.7 40 0.4 0 11 
4 60 75 0.5 nd nd 
5 138 160 1.4 780 710 
6 25 30 0.2 210 330 
7 16.8 35 0.2 nd nd 
8 7.7 198 0.7 2 117 
9 2.1 6.9 0.4 2 54 
10 3.3 28 0.3 15 17 
3H-TdR uptake and colony formation was determined in the absence (control) or presence of KL. For 
further explanation see materials and methods. irr. "' cultures of preirradiated cells (30 Gy). nd = not 
determ'1ned. 
the result of synergy with autocrine HGFs or were obtained through induction of 
HGFs. A cocktail of blocking antibodies against GM-CSF, G-CSF, M-CSF and IL-6 
supplemented to the cultures did not inhibit KL dependent DNA synthesis in six of 8 
cases (Table 3). In two cases (3 and 9), moderate suppression (22% and 24%) of KL 
stimulated proliferation was noted. In case 3 the inhibitory effect was also produced 
with the selected neutralizing antibodies against GM-CSF and G-CSF and in case 9, 
with anti GM-CSF and anti IL-6 antibodies. 
Response of AML blasts cells: effect of KL in combination with other cytokines. 
In order to assess the cooperative relationship between KL and other regulatory 
cytokines, induction of DNA synthesis of AML cells in response to IL-3, GM-CSF, G-
CSF, M-CSF, EPO, IL-4 and TNFcx was evaluated in the presence and absence of KL 
(Fig. 2). KL combined with IL-3 or GM-CSF increased the rate of DNA synthesis in 
most cases as compared to the effects of the single factors alone. In some cases the 
effect was additive, whereas in others synergy was identified. G-CSF in combination 
with KL appeared a highly potent mitogenic stimulus of AML cells. Clear synergy 
was observed in 6 cases. In 5 of these cases (cases 1, 2, 8, 9 and 10), G-CSF plus KL 
resulted in the highest levels of DNA synthesis as compared to the other KL-cytokine 
Table 3. KL stimulated DNA synthesis: effect of anti HGF neutralizing antibodies 
no antibodies added anti-HGF cocktail 
Case control KL control KL 
1 1.1 ± 0.2 3.3 ± 0.4 0.7 ± 0.2 3.9 ± 1 .5 
2 2.0 ± 0.1 56 ± 2.3 3.1 ± 0.2 64 ± 3.7 
3 0.7 ± 0.1 37.7 ± 0.6 0.7 ± 0.1 29.0 ± 0.2 
4 43 ± 2.8 45 ± 1.9 38 ± 3.3 50 ± 4.3 
7 18.2 ± 0.7 50 ± 2.8 16 ± 1.4 61.0 ± 0.7 
8 4.3 ± 0.4 150 :t 1 5.0 2.4 ± 0.1 114 ± 4.0 
9 1.9 ± 0.4 32 ± 1.3 1.2 ± 0.3 25 ± 1.5 
10 1.4 ± 0.2 9.5 ± 1.1 1.5 ± 0.2 9.8 ± 1.0 
Values indicate dpm x 10-2 :t SO. Significant inhibition of KL stimulated thymidine uptake is indicated in 
bold print. control cultures in were performed in the absence of KL anti-HGF cocktail includes: anti-GM-
CSF, -G-CSF, -M-CSF and -IL-6 antibodies. 
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Table 4. Kl binding to AML cells after incubation with ll-3, GM-CSF, G-CSF, ll-4 and TNFcx 
non- incubated 
Case incubated without factor IL-3 GM-C5F G-C5F IL-4 TNF 
2 1810 ± 27 1480 ± 11 1330 ± 31 1220 ± 40 1240 ± 37 1236 ± 9 1270 ± 14 
3 1480 ± 14 5300 ± 140 3800 ± 190 3790 ± 46 5000 ± 120 3720 ± 14 3430 ± 36 
4 148 ± 14 176 ± 2 155 ± 10 180 ± 7 161 ± 7 200 ± 28 100 ± 43 
8 2800 ± 73 2110 ± 66 1260 ± 29 1480 ± 21 3100 ± 180 2210 ± 40 2810 ± 48 
9 770 ± 15 2680 ± 12 2170 ± 34 2400 ± 30 2030 ± 75 2030 ± 54 850 ± 95 
10 1630 ± 36 1160 ± 39 880 ± 49 920 ± 31 845 ± 8 1830 ± 30 1140 ± 99 
Cells from 6 AML cases were incubated with no factor IL-3, GM-CSF, G-CSF, IL-4 or TN Fa for 18 hours 
prior to 125 1-Kl binding studies. Parallel 125 1-KL binding experiments were also performed for 
nonincubated cells. Values refer to mean specific binding ± S.D. of triplicate estimations and are 
expressed as cpm per 0.25 x 106 cells. 
combinations. KL infrequently enhanced proliferative responses to M-CSF and EPO 
(synergistic effects in cases 2 and 3 respectively). 
IL-4 and KL were additive to each other in 3 cases (cases 2, 3 and 7). In contrast, 
IL-4 inhibited the proliferative response to KL in two cases (cases 8 and 10) to 
varying degrees. In one other case (case 4), IL-4 inhibited the KL response almost 
completely, however in this case the spontaneous proliferation was also inhibited by 
IL-4 alone. TNF suppressed the KL response in 4 cases (cases 2, 3, 8 and 10). In case 4 
IL-4 and TNF each inhibited both spontaneous and KL induced proliferative activity. 
KL as a single stimulus was not a very efficient inducer of colony growth from 
AML blast cells (Table 2). However, in combination with IL-3, GM-CSF and G-CSF, 
KL augmented colony formation essentially in the same cases that also showed 
synergy in the thymidine uptake assay (cases 1, 2, 3, 8, 9 and case 10 for G-CSF) (Fig. 
3). M-CSF in combination with KL enhanced colony formation in 3 cases (cases 3, 8 
and 9). 
Sensitivity of AML blasts to KL in the presence or absence of IL-3/GM-CSF; 
sensitivity to IL-3 and GM-CSF in the presence or absence of KL. To investigate the 
possibility that the sensitivity of the cells to KL or IL-3/GM-CSF/G-CSF was 
enhanced in the presence of other factors, as an explanation for synergy, KL titration 
experiments were conducted in the presence or absence of IL-3/GM-CSF/G-CSF, 
and vice versa IL-3/GM-CSF/G-CSF was titrated in the presence and absence of KL. 
The KL dose response curves in the absence and presence of IL-3 (Fig. 4a) both reach 
half maximal effects at identical KL concentrations (i.e. -6 ng/mL). Identical results 
were obtained when GM-CSF (Fig. 4c) or G-CSF (data not shown) was supplemented 
to titrated KL concentrations. The result of the reciprocal experiment indicated that 
the sensitivity of AML cells to IL-3 did not alter in the presence of KL (1050s 2-3 
U/mL IL-3; Fig. 4b). Similarly, no changes of AML cell sensitivity to stimulation by 
GM-CSF (Fig. 4d) or G-CSF (data not shown) were seen when both cytokines were 
titrated in the presence of KL. 
Modulation of c-kit by other cytokines and modulation of IL-3 and GM-CSF 
receptors by KL. In order to verify whether upregulation of receptors for KL, IL-3 or 
GM-CSF could explain the observed synergistic effects of combined HGFs, we 
measured the effects of various cytokines on KL receptor expression and vice versa 
the effect of KL on IL-3 and GM-CSF receptor expression. KL receptors were not 
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Table 5. IL-3 and GM-CSF binding to AML cells after incubation with Kl 
GM~CSF IL~3 
upregulated in six of 6 cases, following incubation of the AML cells with IL-3, GM-
CSF or G-CSF (Table 4). In fact, IL-3 and GM-CSF slightly suppressed KL receptor 
expression in three cases (cases 3, 8 and 9). In the AML cases with suppressed 
responses to KL in the presence of IL-4 or TNFa (Fig. 2), KL receptor expression was 
not downregulated by the inhibitory cytokines (Table 4). On the other hand GM-CSF 
or IL-3 binding to AML cells was not influenced by KL in three of 3 cases (Table 5). 
Surface markers on AML blast cells before and after culture. Immunophenotyping 
experiments performed after 7 days of culture in the presence of no factor, MGF, IL-3 
or G-CSF, only revealed small differences of maturation. A strongly CD15 positive 
minor subpopulation appears among the cells from 4 cases after culture in the 
presence of MGF as compared to nonsupplemented cultures. In two of these cases 
the shift of CD15 expression was also seen in IL-3 or G-CSF supplemented cultures 
although less clearly. In two cases MGF induced a minor increase of CDw65 
fluorescence as compared to nonsupplemented cultures. In one case the average 
level of CD33 expression increased after culture with MGF, as a result of the 
disappearance of a subpopulation with weakly positive CD33 binding. 
DISCUSSION 
The present study was conducted to gain insight into the role of KL in AML 
growth. It was found that in eight of 9 cases the AML cells expressed c-kit at 
sufficiently high levels, for detection with immunofluorescence. Radiobinding 
experiments revealed that KL receptors on AML cells were all of high affinity, which 
is in agreement with the KL concentrations required to reach half maximal 
stimulation of DNA synthesis. The high prevalence of c-kit expression in AML is in 
agreement with recent work of other groups (13,14) and suggests that KL may play 
an important role in AML. Indeed the results of activation of DNA synthesis and 
colony formation demonstrate that KL in addition to IL-3, GM-CSF and G-CSF (19-
23), is an important cytokine in regulating AML cell proliferation. KL stimulated 
DNA synthesis of AML cells in nine of 10 cases. Blocking experiments with 
antibodies against several HGFs make unlikely that the response to KL resulted from 
induction of HGF production or is the result of synergy between KL and (minimal) 
amounts of secreted autocrine HGFs. This suggests that KL is a direct stimulus for 
AML cells. 
Furthermore, the KL induced proliferation of AML cells was significantly 
augmented by other cytokines. In a number of cases, combination of KL with other 
factors resulted in clearly additive effects of proliferation, suggesting independence 
of action due to reactivity of different subsets. In 3 to 6 cases KL acted as a potent 
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Figure 4. Synergy between KL and IL-3 or GM-CSF. Effects of titrated concentrations of KL in the 
absence (open circles) or presence (closed circles) of IL-3 (a) or GM-CSF (c) on AML cell 
thymidine uptake (case 2). The reverse experiments are concerned with the effects of titrated 
concentrations of IL-3 (b) or GM-CSF (d) in the absence (open circles) or presence (closed 
circles) of KL on AML cell thymidine uptake (case 2). 
synergistic factor in association with IL-3, GM-CSF and G-CSF. The latter 
observation could be of relevance in AML. KL, which has been described as a 
stromal factor in vivo (40-43), may promote the outgrowth of leukemic cells in the 
bone marrow due to its synergistic abilities in combination with other autocrine 
mechanisms involving CSFs. 
The mechanism of synergy between KL and other cytokines remains uncertain. 
The sensitivity of AML cells to KL stimulation in the presence of IL-3, GM-CSF or G-
CSF did not change. Conversely KL did not alter the dose response to GM-CSF, G-
CSF or IL-3 either. In addition, radioreceptor studies did not provide any indication 
for upregulation of KL receptors following incubation with IL-3, GM-CSF or G-CSF. 
Additionally, the level of GM-CSF or IL-3 receptor expression on the AML cells 
remained unaltered as well in the presence of KL. Hence, these data demonstrate 
that synergy between KL and IL-3, GM-CSF or G-CSF is not the result of receptor 
modulation or the appearance of cells that become receptor positive. Possibly, certain 
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cells which are a priori KL and IL-3 receptor positive but insensitive to stimulation 
by one factor, are stimulated by the combination of KL and IL-3. Thus we assume the 
existence AML cell populations able of responding to optimal concentrations of KL 
alone and IL-3/GM-CSF/G-CSF alone and subsets that are induced to enter DNA 
synthesis when IL-3, GM-CSF or G-CSF is combined with KL. 
IL-4 exerted enhancing as well as inhibitory effects on KL induced proliferation. 
Additive effects of KL and IL-4 are probably explained by subpopulations with 
distinct factor responsiveness and are consistent with the cellular heterogeneity of 
AML (23). The mechanism responsible for the inhibitory effects of IL-4 remains 
unexplained. IL-4 has been characterized as T-cell and mast cell derived cytokine 
that acts on B-cells, T-cells, NK-cells and monocytes (44). Inhibitory effects of IL-4 on 
the IL-2 response in human B-cells have been related to down regulation of the IL-2 
receptor (45,46). However, our receptor data do not suggest a regulatory role for IL-4 
of KL receptor expression in AML. The mechanism responsible for TNF inhibition of 
KL stimulated AML growth also remains unresolved. The inhibitory effects of TNF 
did not result from downregulation of the KL receptors as was demonstrated to be a 
possible mechanism for the inhibitory effects of TNF on the G-CSF response in AML 
(47). 
Immunophenotyping did not indicate a clear role of MGF in the regulation of 
maturation or commitment of AML in vitro. Only minor changes in the pattern of 
immature and more mature granulocytic/monocytic membrane markers were 
observed in the presence of MGF. Thus these data do not disclose whether MGF 
stimulates the survival or self renewal of AML blast cells in vitro 
In conclusion, these results indicate that KL, in addition to IL-3, GM-CSF and G-
CSF, is an important GF in controlling AML cell proliferation in vitro. Although its 
synergistic capacities in combination with other CSFs suggest that KL may 
contribute to the outgrowth of AML cells in vivo, further investigations will be 
required to provide insight in the role of KL in leukemic cell growth. 
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SUMMARY 
Tumor necrosis factor (TNF) acts as a potent enhancer of granulocyte-macrophage 
colony-stimulating factor (GM-CSF)- and interleukin-3 (IL-3)-induced human acute 
myeloid leukemia (AML) growth in vitro. We have analyzed the effects of TNFa on 
the expression of GM-CSF and IL-3 receptors on AML cells. Incubation of blasts from 
seven patients with AML in serum-free medium with TNF (103 U /mL) and 
subsequent binding studies using 125I-GM-CSF and 125I-IL-3 show that TNF increases 
the specific binding of GM-CSF (30% to 280%) and IL-3 (40% to 600%) in all cases. 
From Scatchard plot analysis it appears that TNF upregulates (1) low-affinity GM-
CSF binding sites, (2) common high-affinity IL-3/GM-CSF binding sites, and (3) 
unique (non-GM-CSF binding) IL-3 binding sites. The effect of TNF is dose 
dependent and is half maximal at a concentration of 100 U/mL, and becomes evident 
at 18 hours of incubation with TNF at 37"c, but not at O"C. The GM-CSF dose-
response curve of AML-colony-forming units plateaus at a higher level in the 
presence of TNF, which indicates that additional numbers of cells become responsive 
to GM-CSF. Incubation of AML blasts with the phorbol ester 12-0-
tetradecanoylphorbol-13-acetate or formyl-Met-Leu-Phe (protein kinase C activators) 
does not influence GM-CSF receptor expression, suggesting that receptor 
upregulation by TNF is not mediated through activation of protein kinase C. On the 
other hand, the protein synthesis inhibitor cycloheximide abrogates receptor 
upregulation induced by TNF. In contrast to these findings in AML, TNF does not 
upregulate GM-CSF receptor numbers on blood granulocytes or monocytes. We 
conclude that TNF exerts positive effects on growth factor receptor expression of 
hematopoietic cells. 
INTRODUCTION 
Tumor necrosis factor a (TNFa) is a polypeptide with multiple biologic activities, 
including effects on hematopoiesis (1). Macrophages are the major cellular sources of 
TNFa (2,3). TNFa may inhibit proliferation of hematopoietic progenitor cells from 
normal subjects and influence the efficiency of growth of human leukemia (4-7). 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 
(IL-3) belong to the group of CSFs that regulate proliferation and differentiation of 
relatively primitive hematopoietic precursor cells (8-11). GM-CSF and !L-3 are potent 
stimulators of proliferation of human acute myeloid leukemia (AML) in vitro (12-15). 
TNF acts synergistically with the stimulative effects of GM-CSF (16,17) and !L-3 (17) 
on AML proliferation in vitro, but may depress G-CSF-mediated AML growth in 
vitro (17). The mechanism of enhancement of GM-CSF-or !L-3-induced AML cell 
growth by TNF is unknown. 
Here we present studies that were concerned with the question as to whether the 
TNF effects might be accomplished at the level of membrane receptors. The results of 
these experiments indicate that TNF upregulates the expression of GM-CSF and IL-3 
receptors on AML blasts. These observations may provide a plausible explanation 
for the synergistic relationship between TNFa and GM-CSF /IL-3 with regard to 
stimulation of growth in vitro. 
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MATERIALS AND METHODS 
Patients and purification of AML blasts, normal granulocytes, and monocytes. 
AML blasts were isolated from the peripheral blood and the bone marrow of seven 
adult untreated AML cases that were classified as M1 (n=3), M4 (n=2), and M5 (n=2) 
(18,19). Approval was obtained from the Institutional Review Board for these 
studies. Patients were informed that blood samples were obtained for research 
purposes, and that their privacy will be protected. AML blasts were separated after 
Ficoll-Isopaque centrifugation and subsequent removal of E-rosette-forming cells, 
and then cryopreserved (20). Monocytes were removed from the AML cell 
preparation by plastic adherence. Morphologic examination of cytospin slides of the 
final cell suspension showed that more than 98% of the cells were blasts. 
Granulocytes were obtained from the blood of healthy volunteers after 
sedimentation in 0.1% methyl cellulose, and subsequent Ficoll-Isopaque 
centrifugation. The resulting cell fractions consisted of neutrophils (92% to 96%), 
eosinophils (2% to 5%), and mononuclear cells (3% to 5%). Monocytes (more than 
80%) were obtained from the Ficoll-Isopaque interphase of mononuclear cells with 
subsequent removal of E-rosetting cells. 
Incubation of the cells with TNF. Before the binding experiments, AML cells, 
granulocytes, or monocytes were washed twice in Hank's balanced salt solution 
(HBSS), then incubated with TNF (10.3 U /mL) in serum-free medium (21) at 37°C for 
1, 2, 4, 8, and 18 hours (for AML cells), 18 hours (for monocytes), or 10 to 60 minutes 
(for granulocytes). The cells were then washed in sodium citrate (pH 4) to remove 
cell-bound TNF (22). Before and after the latter acid wash, the cells were washed 
twice in HBSS. 
Treatment of AML blasts withfMLP, TPA, and cycloheximide. AML cells (case 7) 
were incubated in serum-free medium for 18 hours at 37°C without or with TNF (see 
above). In parallel, blasts were also exposed to protein kinase C (PKC) activators. The 
phorbol ester 12-0-tetradecanoylphorbol-13-acetate (TPA; Sigma Co, StLouis, MO) 
was applied at 10 nmol/L, and formyl-Met-Leu-Phe (fMLP; Sigma) was added at 1 
Jlmol/L. Analog incubations were performed with varying concentrations of 
cycloheximide (0.25, 0.5, and 1 f!g/mL). After incubation, the cells were washed in 
sodium citrate (pH 4). Before and after the acid wash, the cells were washed twice in 
HBSS and subsequently used in radiolabeling studies. 
Radioiodination of GM-CSF and IL-3. Recombinant human GM-CSF (rhGM-CSF, 
CHO-cell derived; glycosylated, molecular weight (mol wt} 25 Kd) was prepared and 
purified at Genetics Institute (Cambridge, MA). rhiL-3 (Yersinia derived; 
nonglycosylated, mol wt 15 Kd) was prepared and purified at Gist Brocades (Delft, 
The Netherlands). Both proteins were radiolabeled with Bolton and Hunter reagent 
(Amersham Laboratory, Amersham, UK) (23) as described (24). Specific activities as 
determined by selfdisplacement analysis (25) were 5 to 7 x 10 4 cpm/ng for 
radioiodinated GM-CSF [1 25I-GM-CSF) and 3 to 6 x 10 4 cpm/ng for 125I-IL-3. 
Trichloroacetic acid precipitation showed less than 5% nonprecipitable radioactivity 
for both factors. The maximum binding capacity was estimated at 90% to 95% for 
GM-CSF and 55% to 60% for IL-3. In Scatchard calculations the free cpm were 
corrected for the maximum binding capacity (26). 
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Table 1. Effect of TNF on Specific Binding of 125 1~GM-CSF or 125 1-IL-3 to AML Blasts 
1251-GM-CSF binding 125 1-IL-3 binding 
case non incubated incubated cells incubated cells non incubated incubated cells incubated cells 
no. cells without TNF with TNF cells without TNF with TNF 
1 242 :!: 37 286 :t 85 1,090 ± 85 14 ± 10 11 ± 8 88 ± 23 
2 649 ' 72 737 ± 101 1,400 ± 274 283 ± 47 321 ± 55 719 ± 127 
3 162 :t 44 237 :t 63 736 ± 245 65 :t 24 82 ± 13 597 ± 62 
4 2,876 ::t 416 3,816 ± 133 5,864 ± 356 ND 1,577 ± 250 1,752 ± 249 
5 2,414 ± 286 3,240 ± 116 4,425 ::!:: 236 1,127 :t 264 1,750 ± 206 3,924 ± 113 
6 2, 11 6 :t 235 3,784 :t 135 4,941 
' 
100 479 ± 68 518 ± 127 1,054 :t 186 
7 817 ± 39 1,586 :t 38 2,714 :t 39 296 ± 149 383 ::t 46 551 ::!:: 64 
Cells from seven AML cases were incubated with or without TNF for 18 hours before the radiolabeling 
studies using single concentrations of 125 1-GM-CSF or 125 1-IL~3. Parallel experiments were performed also 
for non incubated cells. Values refer to the mean specific binding± SO (in cpm} of triplicate estimations. 
Values were corrected for nonspecific binding. The specific activities for 125 !-GM~CSF and 125 1~1L-3 were 
6.1 x 104 and 4.4 x 104 cpm/ng, respectively. NO: not done. 
Binding of radio labeled GM-CSF and IL-3 to AML blasts, granulocytes, and 
manacytes. GM-CSF and IL-3 binding to the cells was assessed as described (24). 
Equilibrium binding conditions for both GM-CSF and IL-3 at 37°C were reached after 
1 hour (27). Cells, 1 to 8 x 106, were incubated for 1 hour at 37°C in 100 f!L a-minimal 
essential medium with 1% bovine serum albumin. Initial binding experiments were 
performed using two concentrations (1 or 2 nmol/L) of 125!-GM-CSF or !25!-IL-3. To 
allow estimation of both high- and low-affinity GM-CSF receptor numbers and 
affinities on AML cells, complete binding assays with titrated concentrations of 1251-
GM-CSF (20 to 5,000 pmol/L) were performed. Binding experiments with 125!-GM-
CSF were also performed in the presence of excess concentrations of non!abeled IL-3 
(see Table 3). Results from these experiments represent low-affinity binding of GM-
CSF alone, because IL-3 selectively competes for the high-affinity binding of GM-CSF 
(28) (the common IL-3/GM-CSF binding site). For a complete IL-3 binding assay, 20 
to 2,000 pmol/L 125!-IL-3 was used. Nonspecific binding was determined in parallel 
incubations in the presence of excess (i.e., 200 nmol/L) unlabeled GM-CSF or IL-3. 
Specific binding was defined as the difference between the amount of radioactivity 
bound in the absence of nonlabeled factor and the amount of radioactivity bound in 
the presence of nonlabeled factor. To distinguish the two different IL-3 binding sites 
that have been described, (28) excess concentrations of nonlabeled GM-CSF were 
used in binding experiments performed with 125!-IL-3. The common IL-3/GM-CSF 
binding sites were defined as sites that bind 125!-IL-3 which are competed for by 
unlabeled GM-CSF. The unique IL-3 binding sites are those that remain detectable 
with 125!-IL-3 after competition with GM-CSF (28). All experiments were conducted 
in duplicate. Samples were counted in a gamma-counter (Packard, Downers Grove, 
IL). The counting efficiency for 125! was 80%. Receptor numbers and binding 
affinities were estimated by Scatchard analysis (26). Two affinity receptor analyses 
were performed with the ENZfitter computer program (Sigma). 
AML clanagenic assay. The dose-response curve of GM-CSF was established in 
the presence and absence of TNF for the clonogenic cells of two AML cases (nos. 4 
and 6). In these experiments, 105 AML cells were plated in serum-free colony culture 
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Figure 1. (a) Upregulation of 125 1-GM-CSF specific binding to AML cells by TNF. Cells (3.8 x 
1 06 ) of AML case 7 were incubated with (closed circles) or without (open circles) TNF (1 03 
U/ml) for 18 hours in serum-free medium and then subjected to radiolabeling studies with 
titrated concentrations of 125 1-GM-CSF. An identical binding assay was performed with non-
incubated cells (2.1 xl 0 6) of the same AML case (open squares). Data have been corrected of 
nonspecific binding. (b) Scatchard plots of the data shown in (a). 
(1 mL) with 0.9% methyl cellulose (17) supplemented with variable concentrations of 
GM-CSF (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30,100,300, and 1,000 U/mL). All aggregates of 
10 cells or more were scored after 14 days. 
RESULTS 
TNF upregulates high- and low-affinity sites of GM-CSF on AML blasts. The 
AML blasts from seven cases were cultured for 18 hours with TNF (103 U/mL). 
Subsequent incubation of the cells with 1 nmol/L 125I-GM-CSF demonstrated that 
TNF had augmented specific GM-CSF binding to cells from all seven cases (Table 1) 
as compared with the cells incubated without TNF or preculture cells. The increase 
of specific binding ranged from 31% (case 6) to 281% (case 1). In four cases (nos. 4 
through 7), AML blasts that were cultured for 18 hours without TNF also expressed 
greater GM-CSF binding as compared with precultured cells (Table 1). Binding 
assays with titrated concentrations of 125I-GM-CSF showed that, after TNF exposure, 
both high-and low-affinity GM-CSF binding sites increased considerably (Table 2, 
Fig. 1). The TNF-dependent increase of low-affinity GM-CSF receptor numbers on 
AML blasts was also apparent in separate binding experiments performed after the 
blockade of high-affinity GM-CSF binding in the presence of an overdose of 
nonlabeled IL-3 (200 nmol/L) (Table 3) (28). Upregulation of GM-CSF receptors 
appeared TNF dose dependent with a maximal effect at approximately 300 U/mL 
(Fig. 2). In separate experiments, AML cells were incubated with TNF for varying 
time intervals (1, 2, 4, 8 and 18 hours). The increase of GM-CSF binding induced by 
TNF became expressed after 18 hours (not shown). In control experiments, the effects 
of TNF on the expression of GM-CSF binding to granulocytes as well as monocytes 
were investigated. As observed previously, (29) TNF was found to downregulate 
GM-CSF receptor expression on granulocytes (Table 2). On the other hand, TNF 
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Figure 2. GM-CSF receptor upregulation on 
AML blasts: Relationship to TNF 
concentration. Cells (2.2 x 1 06) of AML case 
7 were incubated for 18 hours with varying 
concentrations of TNF (0, 10, 30,100, 300, 
1 ,000, 3,000 U/ml) in serum-free medium. 
Subsequently, the specific binding of 125 1-
GM-CSF {using 2 nmol/l 125 1-GM-CSF) was 
determined. Values represent the means of 
triplicate estimations in cpm ±SO and were 
corrected for nonspecific binding. The 
specific activity of 125 1-GM-CSF was 5.4 x 
104 cpm/ng. 
Table 2. Effect of TNF on GM-CSF Receptor Expression (Scatchard analysis) 
Without TNF With TNF 
Cell type Sites/cell Kd (pmol/LI Sites/cell Kd (pmol/LI 
AML Case 1 + + 38 (H) 57 
1200 (l) 13000 
Case 7 190 IHI 18 410 (H) 23 
8100 (l) 4100 16000 Ill 6500 
Neutro. Donor 1 2800 680 1020 580 
Donor 1 1776 520 760 410 
Mono Donor 1 230 IHI 63 200 IHI 46 
Donor 2 165 IHI 87 190 (H) 118 
Cells were incubated with or without TNF for 18 hours (AML blasts and monocvtes) or for 1 hour 
(granulocytes), and then subjected to GM-CSF radioreceptor analysis. Receptor numbers (mean per cell) 
and Kd were derived from Scatchard plot analysis. (+) Indicates that specific binding was detectable but 
values were too low to permit complete Scatchard analysis. Abbreviations: H, high-affinity binding; L, 
low-affinity binding. 
under identical conditions did not affect GM-CSF receptor expression on monocytes 
(Table 2). 
TNF upregulates high-affinity binding sites of IL-3 on AML blasts. Preliminary 
binding studies showed that TNF also increased the specific binding of 125!-IL-3 to 
AML cells in six of seven cases (Table 1). The increase of specific binding of 125!-IL-3 
ranged from 44% to 628%. From a complete binding assay with titrated 
concentrations of 1251-IL-3 with cells from AML cases 1, 3 and 5 (Table 4, Fig. 3), it 
was evident that IL-3 receptor numbers had increased as compared with the values 
following the control incubation in the absence of TNF. Cross-competition with 
excess nonlabeled GM-CSF showed that both the unique IL-3 binding sites as well as 
the common IL-3/GM-CSF binding sites (28) were upregulated by TNF (Fig. 3). The 
average numbers of unique IL-3 binding sites increased from 90 sites per cell to 262 
sites per cell (Kd 261 pmol/L). The numbers of common IL-3/GM-CSF binding sites 
calculated by subtraction of unique IL-3 receptor numbers from total IL-3 binding 
sites increased from 175 sites per cell toward 340 sites per celL 
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Figure 3. (a) Upregulation of 125 1-ll-3 specific binding to AML blasts by TNF. Cells (2.2 x 1 06 ) of 
AML case 5 were incubated with (triangles) or without (circles) TNF (1 03 U/ml) and then 
subjected to radioreceptor studies using titrated concentrations of 125 1-IL-3 in the presence (solid 
symbols) or absence (open symbols) of 200 nmoi/L GM-CSF to discriminate between the 
common ll-3/GM-CSF and unique high-affinity IL-3 receptors, as outlined in Materials and 
Methods. (b) Scatchard plots of these binding data. Each point represents the means of duplicate 
estimations. All data represent specific binding after correction for nonspecific binding. 
Table 3. Effect of TNF on Low-Affinity Binding of 1251-GM-CSF to AML Blasts 
No competitor• Competition with IL-3"" 
Case non incubated incubated cells incubated cells non incubated incubated cells incubated cells 
no. cells without TNF with TNF cells without TNF with TNF 
4 4,000 ± 500 5,600 ± 340 8,700 ± 440 14 ± 10 11 ± 8 88 ± 23 
5 1,540 ± 100 1,900 ± 340 3,200 ± 620 1,100 ± 130 1,400 ± 140 2,500 ± 120 
6 1,900 ± 170 2,900 ± 190 4,100 ± 170 1,400 ± 130 2,000 ± 240 2,900 ± 320 
Cells from AML cases 4, 5, and 6 were incubated without or with TNF for 18 hours before radiolabeling 
studies using 115 !-GM-CSF (1 nmoi/L). Comparative experiments were performed with non incubated cells. 
Values refer to the means of triplicate estimates of specific binding ± SO (in cpm} in the presence or 
absence of excess nonlabeled !l-3 (200 nmol/l). Values were corrected for nonspecific binding (20% to 
30% of the total binding). The specific activity of 125 !-GM-CSF was 5.2 x 104 cpm/ng. •indicates the sum 
of high- and low-affinity binding of 125 1-GM-CSF (without ll-3 competition). ""Indicates low-affinity 
binding of 125 1-GM-CSF (with ll-3 competition}. 
Upregulation of GM-CSF receptor expression by TNF is not dependent on PKC 
activation. Downregulation of the expression of GM-CSF receptors on neutrophils 
by TNF, as was recently shown (29) is probably mediated through activation of PKC 
(30). To investigate whether the upregulation of GM-CSF receptors on AML cells is 
also mediated via activation of PKC, the blasts were exposed to the PKC activators 
TPA or fMLP. Neither TPA nor fMLP, at concentrations that downregulate GM-CSF 
receptors on neutrophils, elevated the numbers of GM-CSF receptors on AML blasts 
(Fig. 4a). 
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Figure 4. (a) GM-CSF receptor upregulation by TNF: Effect of PKC activators. Cells (1. 1 x 1 06) 
from AML case 7 were incubated in serum-free medium for 18 hours with no supplement(-), 
TNF (103 U/ml), TPA (10 nmoi/L), or fMLP (1 ~moi/L). Specific binding of "'1-GM-CSF using (1 
nmo!/L) was subsequently determined. Values represent the means of triplicate estimations in 
cpm ± SO and were corrected for nonspecific binding. A control experiment was also 
performed with blasts before incubation (nonincubated). (b) GM-CSF receptor upregulation by 
TNF: Effect of cycloheximide. Cells (7.8 x 106 ) from AML case 7 were incubated in serum-free 
medium for 18 hours with increasing concentrations of cycloheximide (0.25, 0.5, 1 Jlg/ml) in 
the presence or absence of TNF. Specific binding of 125 1-GM-CSF (l nmoi/L) was subsequently 
determined. Values represent the means of triplicate estimations in cpm ± SO. A control 
experiment was also performed with non incubated cells. 
GM-CSF receptor upregulation is blocked by cycloheximide. We further examined 
whether the increase in GM-CSF receptor numbers after incubation of the AML cells 
with TNF required active protein synthesis. The addition of the protein-synthesis 
inhibitor cycloheximide at concentrations of 0.25 to 1 (.lg/mL did not affect GM-CSF 
binding in the absence of TNF (Fig. 4b). However, at these concentrations, 
cycloheximide prevented the increase of GM-CSF binding induced by TNF. The 
spontaneous increase in GM-CSF binding after 18 hours of incubation, which was 
seen in four cases of AML, was not suppressed by cycloheximide (Fig. 4b ). 
Altered GM-CSF dose-response relationship of AML colony forming cells as the 
consequence of TNF addition. Using titrated GM-CSF concentrations, we established 
the effect of TNF on AML colony formation. The results (Fig. 5) show that there was 
no change in the sensitivity to GM-CSF as a result of the addition of TNF. TNF did 
not shift the dose-response curve to the left. Instead, TNF was found to increase the 
plateau of GM-CSF stimulation, indicating the recruitment of greater cell numbers 
into proliferation at maximal GM-CSF concentrations. 
DISCUSSION 
TNF is a regulator of surface expression of hematopoietic growth factor receptors. 
It downregulates the expression of GM-CSF receptors (29) and G-CSF receptors on 
granulocytes (30), as well as M-CSF receptors on macrophages (31). In this study, we 
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Figure 5. Effect of TNF on GM-CSF-induced 
colony formation of AML cells: GM-CSF dose 
response in the presence (closed circles) or 
absence of TNF (open circles). The data 
represent colony numbers per 105 AML cells 
(case 4) of duplicate cultures. 
investigated the effects of TNF on GM-CSF and IL-3 receptors on AML blasts. It is 
evident from the results of these experiments (Tables I and 2, and Fig. 1) that TNF 
augments the average level of GM-CSF receptors on AML blasts by approximately 
twofold. The increase of receptor numbers after TNF exposure is accomplished 
within approximately 18 hours. Both the high-affinity and low-affinity binding sites 
of GM-CSF increase on these cells (Tables 2 and 3, Fig. 1). In a recent study, high-
affinity IL-3/GM-CSF binding sites, which can bind both IL-3 and GM-CSF, and IL-
3-specific high-affinity binding sites have been distinguished on human AML blasts 
(28). It appears from the results presented here that TNF upregulates both high-
affinity receptors, ie, GM-CSF /IL-3 and IL-3 binding sites (Fig. 3 and Table 4). 
Upregulation of GM-CSF, IL-3, and common GM-CSF/IL-3 receptors is not 
associated with an apparent change in receptor affinities. 
Receptor upregulation by TNF might result in a positive effect of TNF on IL-3- or 
GM-CSF-mediated AML cell growth. Recent findings have shown that TNF 
enhances DNA synthesis and colony formation of AML blasts after stimulation with 
GM-CSF or IL-3 (17). Cells that initially express no or subliminal levels of growth 
factor receptors may become responsive to IL-3 and GM-CSF after TNF exposure. 
This would imply that additional subpopulations are triggered to proliferate and 
that the sensitivity of the cells to GM-CSF or IL-3 has remained constant. The change 
of the GM-CSF dose-response curve of proliferating AML cells as the consequence of 
TNF supplementation is in accordance with this conclusion. GM-CSF dose 
Table 4. Effect of TNF on ll-3 Receptor Expression 
Without TNF With TNF 
AML cells Sites/cell Kd (pmoi/L} Sites/cell Kd (pmoi/L) 
Case 1 + + 76 157 
Case 2 + + 278 63 
Case 3 265 259 602 192 
AML cells were incubated with or without TNF for 18 hours. This was followed by IL-3 radioreceptor 
analysis. Receptor numbers {mean per cell) and Kd were derived from Scatchard plot analysis. {+) 
Indicates that specific binding was detectable but values were too low to permit complete Scatchard 
analysis. 
50 CHAPTER FIVE 
dependence of AML-colony-forming units (Fig. 5) or actively DNA synthesizing cells 
(data not shown) is not shifted to the left in the presence of TNF, being indicative of 
the same sensitivity of stimulation. In fact the maximal level of stimulation is 
elevated to a higher plateau. Recently, analogous with the results in human AML, it 
was observed that IL-3 and TNF or GM-CSF and TNF synergize in stimulating the 
colony formation of purified normal bone marrow blast cells as well (32). Receptor 
upregulation could also provide a plausible explanation for IL-3/TNF or GM-
CSF/TNF synergistic growth activation of normal hematopoietic progenitors. We 
assume that in vitro IL-3 and GM-CSF receptor upregulation by TNF may be a 
feature of leukemic as well as normal hematopoiesis. 
The exact mechanism of receptor upregulation by TNF presently remains 
unresolved. However, the observations that increase of GM-CSF and IL-3 receptors 
requires an incubation of approximately 18 hours and is inhibited by cycloheximide 
suggest that the effect of TNF depends on active protein synthesis (Fig. 4b). The 
negative effects of TNF on the expression of GM-CSF and G-CSF receptors on 
neutrophils and M-CSF receptors on monocytes appear to be mediated through 
activation of PKC (29-31). The studies presented here do not support the idea that 
PKC is similarly involved in receptor upregulation. The PKC activators TPA and 
fMLP did not influence GM-CSF receptor values (Fig. 4a). The spontaneous increase 
of GM-CSF receptor numbers in some AML cases in this study is unlikely caused by 
endogenous TNF production by AML cells (33 ,34) and subsequent activation of new 
protein synthesis. 
The indirect growth-promoting effects of TNF in hematopoiesis have, until 
recently, been attributed to the pleiotropic capacity of TNF to induce the release of 
certain hematopoietic growth factors from endothelial cells, monocytes, or 
fibroblasts. Based on the investigations presented here, it is evident that the role of 
TNF in blood cell formation also includes potentially important effects on the 
expression of growth factor receptors, ie, upregulation of GM-CSF and IL-3 
receptors, which may explain the recruitment of cells into the proliferative 
compartment. These findings, in association with observations indicating G-CSF 
receptor downregulation by TNF on AML cells and granulocytes (30), demonstrate 
that TNF acts as a differential regulator of hematopoietic growth factor receptors and 
expresses the capacity to stimulate versus suppress distinct subsets of proliferating 
target cells selectively. 
CHAPTER6 
TUMOR NECROSIS FACTOR DOWNREGULATES G-CSF RECEPTOR 
EXPRESSION ON HUMAN AML CELLS AND GRANULOCYTES 
0. Elbaz, L. M. Budel, H. Hoogerbrugge, I. P. Touw, R. Delwel, L.A. Mahmoud and 
B. Lowenberg 
Journal of Clinical Investigation, Vol87: pp 838-841, 1991 
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SUMMARY 
Tumor necrosis factor (TNF) inhibits granulocyte-colony-stimulating factor (G-CSF)-
induced human acute myeloid leukemia (AML) growth in vitro. Incubation of blasts 
from three patients with AMLin serum-free medium with TNF (103 U/mL) and 
subsequent binding studies using 125I-G-CSF reveal that TNF downregulates the 
numbers of G-CSF receptors by -70 %. G-CSF receptor numbers on purified blood 
granulocytes are also downmodulated by TNF. Downregulation of G-CSF receptor 
expression becomes evident within 10 min after incubation of the cells with TNF at 
37'C and is not associated with an apparent change of the dissociation constant (Kd). 
The TNF effect does not occur at O'C and cannot be induced by IL-2, IL-6, or GM-
CSF. TNF probably exerts its effect through activation of protein kinase C (PKC) as 
the TNF effect on G-CSF receptor levels can be mimicked by 12-0-
tetradecanoylphorbol-13-acetate. The PKC inhibitor Straurosporine (Sigma Chemical 
Co., St. Louis, MO) as well as protease inhibitors can completely prevent G-CSF 
receptor downmodulation. Thus, it appears TNF may act as a regulator of G-CSF 
receptor expression in myeloid cells and shut off G-CSF dependent hematopoiesis. 
The regulatory ability of TNF may explain the antagonism between TNF and G-CSF 
stimulation. 
INTRODUCTION 
Tumor necrosis factor a (TNFa) is a nonglycosylated protein with a mol wt of 
17,350 (1) synthesized by activated mononuclear phagocytes (2). It has an important 
role in regulating hematopoiesis. It may induce the release of certain hematopoietic 
growth factors from diverse cells, e.g., granulocyte macrophage-colony-stimulating 
factor (GM-CSF) (3) and granulocyte-colony-stimulating factor (G-CSF) (4) from 
human lung fibroblasts, monocyte colony-stimulating factor (M-CSF) from human 
monocytes (5), and interleukin-1 from endothelial cells (6). 
The role of G-CSF in controlling the survival, proliferation, differentiation, and 
functional activation of granulocytes and their precursors has been established (7). 
Further, G-CSF stimulates the proliferation of acute myeloid leukemia (AML) in 
culture (8-10) and it may also induce maturation of myeloid leukemia (11-13). In 
previous reports, it has been shown that TNF acts antagonistically with the 
proliferative effects of G-CSF on AML blasts in vitro (14, 15), and thus appears to be 
a negative regulator of the G-CSF-induced proliferation of AML cells. 
In this study we have addressed the question whether the mechanism of TNF 
suppression of G-CSF-mediated growth may occur at the level of G-CSF membrane 
receptors. The results of the experiments reported here show that TNFa 
downregulates G-CSF receptor expression on AML blasts, suggesting that the 
antagonistic effect of TNF is accomplished through G-CSF receptor 
downmodulation. A similar downregulation of G-CSF receptor expression is also 
evident when blood granulocytes are incubated with TNF. Additional experiments 
suggest that activation of protein kinase C (PKC) and release of proteases that cleave 
off the receptors are crucial events in the rapid downregulation of G-CSF receptors. 
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METHODS 
Purification of AML blasts and normal granulocytes. AML cells were isolated 
from the peripheral blood and the bone marrow of eight adult untreated AML cases 
that were classified as M1 (n =2), M2 (n =1), M4 (n =2), and M5 (n =3) (16, 17). The 
AML cells were separated by Ficoll-Isopaque centrifugation and subsequent removal 
of E-rosette-forming cells (18), and then cryopreserved in 7.5% DMSO and 20% 
inactivated FCS. The cell preparations were also depleted from monocytic cells by 
plastic adherence. The viability of the cells after thawing was always >90%. 
Morphological examination of cytospin slides of the thawed cells after depleting the 
monocytic fraction revealed that ~98% of the cells were blasts. Normal peripheral 
blood granulocytes were obtained from the heparinized blood of healthy volunteers 
following sedimentation in 0.1% methyl cellulose, and subsequent Ficoll-Isopaque 
centrifugation. The resultant cell fractions consisted of 92%-96% neutrophils, 2%-5% 
eosinophils, and 3%-5% monocytes/lymphocytes. The latter cell preparations were 
used fresh. 
Hematopoietic growth factors. Recombinant human GM-CSF (a gift from Dr. S. 
Clark from Genetics Institute, Cambridge, MA) at 200 U /mL, IL-2 (Cetus Corp., 
Emeryville, CA) at 50 U /mL, IL-6 (Central Laboratory of the Netherlands Red Cross 
Blood Transfusion Service, Amsterdam) at 103 U /mL, and TNFa (Dr. Adolf, 
Boehringer Institute, Vienna, Austria) at 103 U/mL were applied for incubation of 
cells prior to binding studies. These concentrations supported optimal AML cell 
proliferation under serum-free conditions (10,11,15,19). Recombinant human G-CSF 
(Amgen Biologicals, Thousand Oaks, CA) was used for radiolabeling purposes. 
Treatment of the cells with 12-0-tetradecanoylphorbol-13-acetate (TPA), 
Staurosporine, and protease inhibitors. To study the mechanism of action of TNF, 
granulocytes were incubated in serum-free medium (SFM) for 60 min. at 37"C with 
TPA (Sigma Chemical Co., St. Louis, MO) at 50 ng/mL. The cells were pretreated 
with the protein kinase C (PKC) inhibitor Staurosporine (Sigma) at 0.1 ~M. The cells 
(1 mL end volume) were also pretreated with 20 ~L mixture of protease inhibitors 
(mixture: 2% gelatine in 0.15 M NaCl, 1 mg/mL Aprotinin, 1 mg/mL Leupeptin, 1 
mg/mL Iodoacetamide, 1 mg/mL Bacitracin, and 1 mM PMSF). This pretreatment 
was applied 30 min before the direct addition of TNF or TP A. 
Preincubation of the cells with TNF. Before the binding experiments, the AML 
cells or granulocytes were washed twice in HBSS, then incubated in SFM (20) for 10 
to 60 minutes at 37'C without or with TNF (103 U/mL). Finally, the cells were 
washed twice in HBSS to remove residual TNF. 
Binding of radiolabeled G-CSF to AML blasts and granulocytes. Purified rhG-CSF 
was radiolabeled according to the method of Bolton and Hunter (21) as described 
(22). Radiolabeling of rhG-CSF resulted in a protein that had a maximal binding 
capacity of 50 to 60 %, and a specific activity of 20,000 cpm/ng. The cells (4 to 8 x 106 
per point) were incubated for 1 hr at 37°C in 100 f!L a-minimal essential medium 
with 10% FCS and with 1 and 2 nmol/L 1251-G-CSF (for preliminary binding 
estimations) or 20 to 4,000 pmol/L 125]-G-CSF (for the complete binding assay) in the 
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Figure 1. Downregulation of G-CSF receptors by TNF. (a) Scatchard plots of 125 1-G-CSF binding 
to AML cells: cells (4.9 x 106) of AML case 1 were pre incubated with (closed circles) or 
without (open circles) TNF (103 U/ml) in serum-free medium for 1 hour, and then subjected to 
radioreceptor studies with titrated concentrations of 125 1-G-CSF as described in Methods. {b) 
Scatchard plots of 125 1-G-CSF binding to AML cells: granulocytes (8.8 x 1 06) were incubated 
with (closed circles) or without (open circles) TNF (1 03 U/ml) for 1 hour. Data have been 
corrected for nonspecific binding. Each point represents the mean of duplicate estimations. 
presence or absence of excess nonlabeled G-CSF (i.e., 200 nmol/L) exactly as 
described (22). Specific binding was determined as the difference between the 
amount of radioactivity bound in the absence, and the amount of radioactivity 
bound in the presence of nonlabeled G-CSF. Experiments were conducted in 
duplicate. Receptor numbers and binding affinity were derived following Scatchard 
analysis (23). In calculations, the maximal binding capacity was used to correct for 
the free counts. 
RESULTS 
TNF downregulates the number of high affinity G-CSF receptors on AML blasts. 
In previous experiments (22) we have demonstrated that AML blasts frequently 
show low levels of specific binding of 125!-G-CSF, so that in practice it is difficult to 
assess a suppressive TNF effect on G-CSF receptor expression. The cells from cases 1, 
2, and 3 were selected for the complete binding studies because of relatively high G-
CSF specific binding as became evident from preliminary 125!-G-CSF binding 
Table 1. Effects of TNF on Binding of 125 1-G-CSF to AML Blasts 
~ithQ!Jt TNF with TNF 
Case no. Sites/cell Kd (pmoi/L) Sites/cell Kd (pmoi/L) 
577 ± 48 546 ± 106 123 ± 37 357 ± 64 
2 357 ± 65 472 ± 83 114 ± 18 302 ± 46 
3 243 ± 18 386 ± 129 96 ± 21 317 ± 93 
Receptor numbers (mean per cell ±SO) and Kd (mean± SO) were derived from binding experiments and 
subsequent analysis according to Scatchard. Aspirated bone marrow cells (2 to 5 x 106 ) were obtained 
from three cases with AML and used, in duplicate, for each point of analysis. 
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Figure 2. (a) Downregulation of G-CSF receptors by TNF as a function of time. Granulocytes (3 
x 106) were incubated with (closed circles) or without (open circles) TNF {10 3 U/ml) for 0, 10, 
30, or 60 minutes. Specific binding of 125 1-G-CSF (using 1 nmoi/L 125 1-G-CSF) was subsequently 
determined as described in Methods. Values have been corrected for nonspecific binding and 
represent the means of triplicate estimations in cpm :±: SO. (b) Downregulation of G-CSF 
receptors: specific ability of TNF. Granulocytes (2 x 106) were incubated with TNF and 
comparative cytokines, i.e., GM-CSF, ll-2, and IL-6, for 1 hour at 37°( and specific G-CSF 
binding was assessed (see a). 
experiments (data not shown). 
Complete binding assays with titrated concentrations of 1251-G-CSF and 
subsequent Scatchard analysis for cases 1, 2, and 3 revealed that TNF reduced the 
average numbers of G-CSF receptors on the cells of the three cases by -70% (Fig. 1a, 
Table 1). To exclude the possibility that these effect were caused by direct 
competition between TNF and G-CSF, specific binding of 1251-G-CSF to AML blasts 
(case 1) was determined in the presence of excess TNF (400 nmol/L) at ooc for 6 
hours. Under these conditions, TNF did not inhibit specific binding of 125!-G-CSF. 
TNF down regulates the number of high affinity G-CSF receptors on blood 
granulocytes. In comparison, we have also determined the effect of TNF on G-CSF 
receptor expression on granulocytes. Preliminary 125!-G-CSF binding experiments 
using granulocytes from the blood of four donors demonstrated that preincubation 
with TNF reduced specific binding of 125!-G-CSF by 70 to 90%. Complete binding 
experiments (Fig. lb) revealed that TNF reduced the number of G-CSF receptors on 
granulocytes from 1,969 ± 186 per cell (Kct 667 ± 109 pmol/L) to 342 ± 47 per cell (Kct 
638 ± 76 pmol/L). The downregulatory effect of TNF was already apparent within 10 
minutes after addition of TNF to granulocytes (Fig. 2a). This inhibitory effect did not 
become apparent when the cells were incubated under identical conditions with 
other recombinant cytokines, i.e., IL-2, IL-6, GM-CSF (Fig. 2b). 
G-CSF receptor downregulation dependent on protein kinase C. G-CSF receptor 
downregulation could also be achieved following exposure of granulocyte to the 
PKC activator TPA (Fig. 3a). Complete binding experiments (Fig. 3b) using titrated 
concentrations of 125]-G-CSF revealed that TPA reduced the numbers of G-CSF 
receptors on granulocytes from 1,332 ± 124 per cell (Kct 614 ± 98 pmol/L) to 487 ±53 
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figure 3. Downregulation of G-CSF receptors: (a) effect of TPA, Staurosporine, and protease 
inhibitors. Granulocytes (5 x 1 06) were incubated with no supplement(-), Staurosporine (STSP) 
(0. 1 f-tM), or protease inhibitors (PI) for 30 minutes at 37°C. Then, TN F (1 03 U/ml) or TPA (50 
ng/ml) was added for 60 minutes at 37°C. The specific binding of 125 1-G-CSF was assessed (see 
Fi?,. 2a). A control experiment was also done with non incubated cells. (b) down regulation of 
12 1-G-CSF specific binding to granulocytes by TPA. Granulocytes (8.3 x 106 ) were incubated 
with (closed circles) or without (open circles) TPA (SO ng/ml) for 1 hour, and then subjected to 
radioreceptor studies (see legend to Fig. 1 ). 
per cell (Kct 645 ± 132 pmol/L). To further investigate whether the mechanism of 
action of TNF might depend on activation of PKC, we have determined the effect of 
TNF or TPA (PKC activator) on specific binding of 125!-G·CSF to granulocyte 
following pretreatment with Staurosporine (PKC inhibitor). Staurosporine reversed 
the inhibitory effect of both TNF and TPA (Fig. 3a). A cocktail of protease inhibitors 
could also abolish the effect of TNF under the same conditions (Fig. 3a). 
DISCUSSION 
This study was carried out to investigate the possibility that antagonistic effects 
between TNF and G-CSF on AML cell proliferation are accomplished at the level of 
G-CSF membrane receptors. The results reveal that incubation of the cells with TNF 
decreases G-CSF receptor numbers both on AML blasts and blood granulocytes 
considerably, i.e., by ~70% of the initial mean receptor number. Suppression of G-
CSF receptor binding by TNF could not be attributed to direct cross competition 
between G-CSF binding and TNF binding because this phenomenon does not occur 
at ooc. It is likely that the negative effect of TNF on the level of G-CSF receptor 
expression may contribute to the antagonistic relationship between the two factors. 
A reduction of the mean receptor density on the cells may reflect the loss of receptors 
of a proportion of G·CSF reactive cells and thus these cells may become 
nonresponsive to G-CSF. The loss of G-CSF stimulability of AML blasts and 
granulocytes as controlled by TNF may represent an important regulatory function 
in hematopoiesis (24,25). 
G·CSF receptor downregulation by TNF can be characterized by the following 
features: G·CSF surface receptors disappear relatively rapidly (within 10 minutes), 
suppression occurs at 37°C, but not at 0°C, maximal suppression is attained at 60 
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minutes (data not shown), and finally it involves a loss of G-CSF binding sites 
without an apparent change in receptor affinity. The fact that reduction in G-CSF 
receptor density by TNF in AML cells and granulocytes is not complete (70%), raises 
the possibility of functionally different subsets of G-CSF receptors. We have found 
that TPA can also downregulate G-CSF receptors under the same conditions (Fig. 3a) 
and that the G-CSF receptors inhibitory effect due to TNF or TPA can be reversed by 
Staurosporine (PKC inhibitor) or protease inhibitors (Fig. 3a). It is possible that the 
analogy with the observation of Downing et al (26), who showed that the M-CSF 
receptor is downmodulated by its ligand as well as by TPA, TNF acts through 
activation of PKC. PKC, in turn, activates the release of proteases that specifically 
cleave off the ligand-binding domain from the receptor. 
It remains unclear what the physiological significance of receptor downregulation 
by TNF in AML cells is. However, it is conceivable that a higher concentration of G-
CSF is required to excite the same number of receptors after TNF exposure, and 
thereby rendering the cells less susceptible to G-CSF. The fact that TNF upregulates 
on the same cell type, receptor for IL-3 and GM-CSF (both early acting factors) (27) 
suggests that TNF acts as a response modulator. By increasing the susceptibility for 
IL-3 and GM-CSF and at the same time decreasing the susceptibility for G-CSF, TNF 
elicits a more immature response pattern to these three CSFs. 
The observation that the survival of neutrophils in vitro can be increased by G-
CSF (28) is interesting in view of the downregulation of G-CSF receptors on 
neutrophils by TNF. Possibly TNF acts as a shut-off signal for granulocytes in 
circulation. However, more research needs to be done to elucidate the biological 
meaning of this phenomenon. 
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COMMON BINDING STRUCTURE FOR GM-CSF AND IL-3 ON HUMAN 
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SUMMARY 
Granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-
3) control the proliferation of human acute myeloid leukemia (AML) cells in vitro. 
Previously, we have shown that receptors for GM-CSF and IL-3 are often 
coexpressed on AML cells. Here we present experiments with purified AML blasts, 
normal monocytes and granulocytes, that were conducted to analyze the properties 
of GM-CSF and IL-3 binding proteins in more detail. On AML cells from 8 cases we 
demonstrate two types of GM-CSF receptors: one with low affinity (dissociation 
constant {Kct)5.1 to 24.8 nmol/L) and one with a high affinity (Kct 31 to 104 pmol/L). 
These AML cells also expressed high affinity receptors for IL-3 (Kct 24 to 104 
pmol/L). Cross competition experiments showed that an excess concentration of 
nonlabeled IL-3 completely prevented the high affinity binding of radiolabeled GM-
CSF. This competition occurred at 37°C as well as 4"C. Low affinity GM-CSF binding 
was not affected by IL-3. Binding of radiolabeled IL-3 could be prevented by 
nonlabeled GM-CSF. In certain cases, this competition was complete, whereas in 
others only partial (49 to 77%) reduction of the radiolabeled IL-3 binding was seen. 
On the basis of these ligand binding features, we propose the existence of three 
receptor types on AML cells: (i) low affinity GM-CSF receptors that do not bind IL-3, 
(ii) dual high affinity GM-CSF/IL-3 receptors, and (iii) high affinity IL-3 receptors 
that do not bind GM-CSF. We could also demonstrate these receptor types on normal 
rnonocytes. In addition, a fourth type of receptor was apparent on normal 
granulocytes (iv), incapable of binding IL-3 and with an intermediate affinity for 
GM-CSF ( -400 pmol/L). Chemical cross-linking showed that GM-CSF and IL-3 both 
bind to proteins with molecular weight values of 130, 105 and 75, which provides 
additional evidence for the existence of a common GM-CSF /IL-3 receptor complex. 
INTRODUCTION 
GM-CSF and IL-3 are hematopoietic growth factors (GF) with multilineage 
stimulative abilities (1-4) that exert their effects on the cells through specific 
membrane receptors (5). These factors also induce proliferation of acute myeloid 
leukemia (AML) cells (6-10). GM-CSF and IL-3 receptors are frequently coexpressed 
on AML cells (11), and the mitogenic responses among the different cases of AML to 
GM-CSF and IL-3 often coincide (10). Parallel effects of GM-CSF and IL-3 on colony 
formation from purified normal human marrow progenitors have also been 
demonstrated (12,13). These studies suggest that the control of growth and 
differentiation of hematopoietic cells by IL-3 and GM- CSF is closely interrelated. 
Recently, evidence has been obtained for the existence of a receptor structure on 
AML blasts and leukemia cell lines with a high affinity for both GM-CSF and IL-3 
(14-16).ln the present study, we compared the abilities of AML cells, monocytes and 
granulocytes to bind GM-CSF and IL-3. We confirm that AML blasts, as well as 
monocytes express membrane structures that can bind GM-CSF and IL-3 both with 
an equally high affinity (Kct - 60 pmol/L). Preliminary crosslinking experiments 
indicate that both GM-CSF and IL-3 bind to proteins with Mrs of 130, 105 and 75 
kDa, the latter probably being a product of proteolytic cleavage. In addition to this 
common GM- CSF /IL-3 binding site, three selective GM-CSF or IL-3 binding sites are 
distinguished, i.e., a low affinity GM-CSF receptor with no affinity for IL-3 (AML 
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cells and monocytes), a high affinity IL-3 receptor that does not bind GM-CSF 
(monocytes and some cases of AML) and a receptor with intermediate affinity for 
GM-CSF that does not bind IL-3 (neutrophils). 
MATERIALS AND METHODS 
Patients and purification of AML cells and normal cells. Bone marrow (all cases 
except case 6) or peripheral blood (case 6) was taken from eight patients with AML 
diagnosed according to the French-American-British (FAB) classification (17,18) 
(AML case 8: FAB M1; case 2: FAB M2; case 6 FAB M3; cases 1, 3, 4 and 7: FAB M4; 
case 5: FAB M5). The leukemic cells were separated after bovine serum albumin 
density gradient (BSA) or Ficoll-lsopaque centrifugation and subsequent removal of 
E-rosette forming cells (19) and cryopreserved (6). The viability of the cells after 
thawing was always more than 95%. White blood cells (WBC) were separated from 
the blood of healthy subjects following sedimentation in 0.1% methyl cellulose. 
Granulocytes were obtained as the sedimented cell fraction following Ficoll-Isopaque 
centrifugation of WBC and consisted of 90-95% neutrophils, 2-6% eosinophils and 3-
5% monocytes/lymphocytes. Monocytes were obtained from the Ficoll-Isopaque 
interface of WBC and subsequent removal of E-rosette forming cells and consisted of 
70-80% monocytes, 20-30% non E-rosetting lymphocytes and less than 2% 
granulocytes. 
Growth factors and radioiodination. Recombinant human GM-CSF (CHO cell-
derived; glycosylated, MW 20-30 kDa) (20) was prepared and purified at Genetics 
Institute (Cambridge, MA). Recombinant human IL-3 (Yersinia derived; 
nonglycosylated, MW 15 kDa) was prepared and purified at Gist Brocades (Delft, 
The Netherlands) (21). Both proteins were radiolabeled with Bolton and Hunter 
reagent (Amersham Laboratories, Amersham, UK) (22) as described (11). Specific 
activity of radiolabeled GM-CSF and IL-3 as determined by self displacement 
analysis (23), was 5-7 x 104 cpm/ng for GM-CSF and 8-10 x 104 cpm/ng for IL-3. The 
iodinated preparations retained their ability to stimulate colony formation by normal 
bone marrow cells in methyl cellulose (11). TCA precipitation showed less than 5% 
nonprecipitable radioactivity for both factors. The maximum binding capacity was 
estimated at 40 to 65% for IL-3 and 50 to 95% for GM- CSF. In Scatchard calculations 
the "free" cpm were corrected for the maximum binding capacity (23). 
Binding of labeled GM-CSF and IL-3 to AML blasts, monocytes and granulocytes. 
GM-CSF and IL-3 binding to the cells was assessed as described (11). Equilibrium 
binding conditions for both GM-CSF and IL-3 at 37'C and O'C were reached in 1 and 
17 hours respectively (11,15,24). Two to 7 x 106 cells were incubated for 1 hour at 
37'C or 18 hours at 4'C in 100 ~L a-Minimal Essential Medium with 1% BSA in the 
presence of 20 to 6,000 pmol/L radiolabeled IL-3 or GM-CSF with or without excess 
(i.e., 200 nmol/L) nonlabeled factor. Specific binding was defined as the difference 
between the amount of radioactivity bound in the absence of nonlabeled factor, and 
the amount of radioactivity bound in the presence of excess nonlabeled factor. 
Experiments were conducted in duplicate. Receptor numbers and binding affinities 
were derived following Scatchard analysis and two affinity receptor analysis was 
performed by the R-Binding program (25,26). Binding characteristics of low affinity 
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Table 1. Summary of cross competition data in AML and monocytes 
High affinity High affinity 
125 1-GM-CSF binding 125 1-IL-3 binding 
IL-3 GM-CSF 
case no com12etitor comeetition no comeetitor com12etition 
AML cells 217 131 I 0 135 (52) 31 (20) 
2 53 (104) 0 14 (58) 0 
3 61 (57) 0 60 (60) 20 (30) 
4 120 (46) 0 124 (103) 0 
s 275 (70) 0 226 (86) 0 
6 95 (56) 0 121 (36) 0 
7 122 (42) 0 147 (37) 76 (1 s 1) 
8 112 163) 0 234 (24) 0 
Monocytes 56 (42) 0 ND 
2 348 (106) 0 ND 
3 218 (34) 0 115 (82) 
4 ND 143 (40) 86 (31) 
Values represent mean numbers of binding sites pe:- cell determined from radiolabeling experiments with 
AML cells (see materials and methods; Fig. 2}. Kd values (pmoi/L) are indicated in brackets. Low affinity 
GM-CSF binding was not competed for by non labeled IL-3 (see Fig. 2). NO, not determined. , Indicates 
specific binding detectable but too low for complete Scatchard analysis. 
GM-CSF binding sites were assessed by self displacement of 1 nmol/L 125!-GM-CSF, 
essentially as has been described by Robb et.al. for the low affinity IL-2 receptor (27). 
Cross linking of receptors. Two to 5 X 10 7 AML cells were incubated with 
radiolabeled IL-3 or GM-CSF (2 nmol/L) both with and without excess (200 nmol/L) 
nonlabeled !L-3 or GM-CSF. After 1 hour, the cells were chilled on ice and layered on 
top of 1 mL fetal calf serum (FCS). After centrifugation for 5 minutes, the cell pellet 
was rinsed twice in ice-cold HBSS and resuspended in 300 ~L PBS. Ethylene 
glycolbisuccinimidyl succinate (EGS, PIERCE chemical company, Rockford, IL) was 
then added at a final concentration of 1 mmol/L and incubated at 4"C for 30 
minutes. After two acid washes with sodium citrate (pH 4) to remove noncrosslinked 
but receptor bound ligand (27), the cells were fragmented by repeatedly freezing and 
thawing in hypotonic phosphate buffered solution (50 mmol/L sodium chloride, 2 
mmol/L potassium chloride and 5 mmol/L phosphate buffer). Membrane fragments 
were isolated after spinning down the nuclei by high speed centrifugation (90 
minutes, 60,000 g). In all steps the protease inhibitors, phenyl methylsulphonyl 
fluoride (PMSF; 2 mmol/L), leupeptin (10 ~mol/L), iodoacetamide (2 mmol/L), 
pepstatin (10 ~mol/L) and aprotinin 1 mg/mL were present. Pelleted membrane 
fragments were boiled in SDS buffer (0.2 mol/L Tris HCl, pH 6.8, 6% SDS. 1% beta-
mercaptoethanol, 40% glycerol and bromophenol blue) for 10 minutes and 
membrane preparations were then analyzed by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS PAGE, 7.5%) under reducing conditions 
and subsequent autoradiography. 
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Figure 1. High and low affinity GM-CSF receptors on AML cells. (a) Cells (4 x 1 06) of AML case 
7 were incubated with 125 1-GM-CSF (30 to 4000 pmo\/l) for 18 hours at 4°(. The biphasic 
Scatchard plot indicates distinct high and low affinity type GM-CSF receptors. (b) Binding of 
GM-CSF to low affinity receptors (AML case 5) was measured in the presence of 1000 pmoi/L 
1251-GM-CSF and titrated concentrations of non labeled GM-CSF (0 to 300 nmoi/L). Total binding 
of GM-CSF was calculated from the ratio labeled/nonlabeled GM-CSF and specific binding of 
radio labeled GM-CSF. Subsequent Scatchard analysis of those data revealed 9503 sites per cell, 
Kd 15.8 nmoi/L. Each point represents the mean of two estimations. Nonspecific binding was 
determined in the presence of excess non labeled GM-CSF and was subtracted prior to plotting 
data. 
RESULTS 
Binding of radio labeled GM-CSF and IL-3 to leukemic cells. Binding of titrated 
concentrations of radiolabeled GM-CSF to AML cells (from 40 to 7,000 pmol/L) 
consistently produced biphasic Scatchard plots indicating high and low affinity 
components (Fig. 1a). The average numbers of high affinity GM-CSF receptors 
among 8 cases was estimated at 132 per cell (distribution 53-275 sites per cell; Kd ± 
S.D.: 59 ± 22 pmol/L)(Table 1). Estimations of the numbers and affinity of the low 
affinity GM-CSF receptors derived from binding experiments with concentrations of 
radiolabeled GM-CSF up to 7,000 pmol/L showed considerable standard variations, 
since the estimation of the binding maximum in these calculations could only be 
reached by extrapolation. In order to assess the low affinity binding component more 
accurately, titrated concentrations of nonlabeled GM-CSF were added to the cells in 
the presence of 1 nmol/L radiolabeled GM-CSF. From these experiments total 
binding of GM-CSF (labeled plus nonlabeled) to the cells could be calculated (27) 
(Fig. 1b). Subsequent calculations showed saturable binding at GM-CSF 
concentrations of 33 to 100 nmol/L with a Kd of 5.1 to 24.6 nmol/L (mean± S.D.: 13.2 
± 6.2 nmol/L). The average numbers of low affinity GM-CSF receptors was 4,688 per 
cell (range 1,099 to 11,900 sites per cell). In all 8 cases, also receptors for IL-3 could be 
demonstrated on the AML cells (Table 1). The average density of IL-3 binding sites 
was estimated at 117 per cell (range 14 to 234) and the average Kd (± S.D.) was 
estimated at 57± 26 pmol/L. 
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Figure 2. Inhibition of High affinity GM-CSF binding by IL-3 (a) AML cells {2 x 1 06; case 5) were 
incubated with increasing concentrations of 125 1-GM-CSF for 1 hour at 37°( in the absence 
(open circles) or presence (closed circles) of 200 nM IL-3. The upper curve represents high and 
low affinity GM-CSF binding, the lower represents low affinity binding of GM-CSF alone. Both 
curves have been corrected for nonspecific binding. (b) The central panel shows in detail 
(abscissa 0 to 0.8 nM) the same data. Nonspecific binding, determined in the presence of 200 
nM non labeled GM-CSF ( --x--) and high affinity binding (diamonds) determined as the result of 
GM-CSF binding in the absence of ll-3 minus binding in the presence of IL-3 are shown in 
addition. The latter curve reaches a plateau at a GM-CSF concentration of 200 pM. {c) 
Scatchard plots of these data showing that ll-3 select'1vely competes for high affinity GM-CSF 
binding. 
Competition of 1251-GM-CSF binding to AML cells by IL-3. Binding of 
radiolabeled GM-CSF to AML cells was reduced by an excess concentration of 
nonlabeled IL-3 (Fig. 2a). The difference between 1251-GM-CSF binding in the absence 
and presence of nonlabeled IL-3 appeared as a readily saturable component of total 
binding (Fig. 2b). The Scatchard plot of these data shows that in the presence of IL-3 
the steep segment of the biphasic curve disappeared, indicating that IL-3 prevented 
high affinity l25J-GM-CSF binding, but not low affinity 125!-GM-CSF binding (Fig. 
2c). Data from 8 cases of AML are summarized in Table 1. Tumor necrosis factor 
(TNF) or G-CSF in concentrations up to 100 nmol/L did not affect binding of 
radiolabeled GM·CSF to AML cells. 
Competition of 1251-IL-3 binding to AML cells by GM-CSF. Binding of 
radio labeled IL-3 was prevented in the presence of 200 nmol/L GM-CSF in 5 cases 
Table 2. GM-CSF receptors on granulocytes 
GM-CSF binding 
no competitor after IL-3 competition 
Donor no. sites/cell Kd (pmoi/L) sites/cell Kd (pmoi/L) 
1 1,949 405 2,090 422 
2 2,720 363 2,673 332 
3 2,343 469 2,393 444 
4 2,155 469 2,393 403 
Receptor numbers (mean per cell) and Kd were derived from Scatchard plot analysis (see materials and 
methods). Granulocytes were obtained from 4 different normal donors. 
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Figure 3. Inhibition of 125 1-IL-3 binding to AML by GM-CSF. (a) Binding (AML case 4} of 125 1-IL-3 
was determined in the absence (open circles) or presence (closed circles) of 200 nmol!L GM-
CSF at 4'C. Specific binding of JL-3 was completely blocked by GM-CSF. (b) The same 
experiment with cells from case 3 showing that GM-CSF reduced IL-3 binding only partially 
(68%). All data represent specific binding after subtraction of nonspecific binding. 
(cases 2, 4, 5, 6 and 8; Fig. 3a, Table 1). In the remaining 3 cases this inhibition was 
partial (Fig. 3b, Table 1). Scatchard analysis of the IL-3 receptors of the latter three 
cases revealed that only 23-51% of the initially established numbers of receptors had 
remained detectable in the presence of excess GM-CSF (Table 1). The affinity of the 
latter receptors was comparable to the affinity of those that had been estimated in the 
absence of GM-CSF (Table 1). These results suggest that there are two different high 
affinity IL-3 binding sites in AML. The first one appears as a dual binding site that 
can interact with GM-CSF and IL-3, and is detectable in all 8 cases of AML. The 
second type of IL-3 binding site demonstrated in 3 of the 8 cases does not bind GM-
CSF. 
Cross competition of 125I-GM-CSF and 125!-IL-3 at 4"C. Cross competition of 125!-
IL-3 binding with GM-CSF and, reciprocally, 125!-GM-CSF binding by IL-3 was 
apparent within 1 hour of incubation at 37'C and 18 hours at 4'C (Fig. 4). The 
amount of acid resistant radioactivity after 18 hours incubation at 4°C was 
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Figure 4. Temperature independence of cross competition of 125 1-GM-CSF binding. Scatchard 
plots derived from binding experiments with radiolabe!ed GM-CSF performed at 37"C (left 
panel: AML case 5; 2 x 106 cells per tube; 1 hour incubation time) and at 4"( (right panel: AML 
case 4, 6 x 106 cells per tube, 18 hours incubation time) in the absence (open circles) or 
presence (closed circles) of 200 nM IL-3. 
approximately 8%/ indicating that 92% of the radioactive ligand had remained 
surface bound under these conditions (results not shown). These data suggest that 
the cross inhibition of binding for both factors does not require active cell 
metabolism and therefore resulted from direct interference at the receptor level 
(rather than down modulation). 
Dose dependence of GM-CSF and IL-3 cross inhibition. We then determined the 
comparative efficiency of GM-CSF and IL-3 as competitors for radiolabeled GM-CSF 
binding to AML cells, first of patient no. 5 (Fig. Sa). A fixed concentration of 
radiolabeled GM-CSF (450 pmol/L), deducted from binding curves with and 
without excess nonlabeled IL-3 to give approximately equal of 1251-GM-CSF binding 
to high and low affinity binding sites, was displaced by titrated concentrations of 
nonlabeled GM-CSF or IL-3. Displacement of radiolabeled GM-CSF by IL-3 was dose 
dependent, but leveled off at a higher plateau than GM-CSF, in accordance with the 
fact that!L-3 competes for the high affinity GM-CSF binding sites only. From this 
experiment it was also evident that200 nmol/L IL-3 (as used in the cross competition 
experiments) was sufficient to occupy all high affinity dual GM-CSF /IL-3 binding 
sites. Displacement of radiolabeled IL-3 from AML cells of patient no. 7 by GM-CSF 
did not equal the displacement by IL-3 (Fig. Sb). illustrating that on these cells the 
two types of IL-3 receptors were present; i.e., one competed and one not competed 
for by GM-CSF. The same experiment was performed with AML cells from another 
patient (case 4) showing complete inhibition of 125!-IL-3 binding by excess GM-CSF 
(Fig. Sc). As expected, binding of radiolabeled IL-3 was displaced to the same extent 
by both IL-3 and GM-CSF, confirming that the cells from this AML case indeed only 
carried the dual GM-CSF /IL-3 binding sites. From the observation that the 
displacement curves attained by nonlabeled GM-CSF and IL-3 are identical in this 
experiment, it appears that the common GM-CSF /IL-3 binding structure has equal 
affinity for both ligands (Fig. Sc). 
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Figure 5. Displacement of radiolabeled GM-CSF or IL-3 from AML cells by homologous and 
heterologous ligand. (a) Cells (4 x 106 , AML case 5) were incubated with 450 pmoi/L 125 1-GM-
CSF plus titrated concentrations of either nonlabeled GM-CSF or IL-3 (0 to 300 nmoi/L) as 
competitors for 45 minutes at 37°C. The upper curve shows that ll-3 competed for GM-CSF 
binding in a dose dependent way. The maximal competition was reached at IL-3 concentration 
of approximately 5 nmoi/L. (b) The reciprocal displacement experiment (AML case 7; 7 x 106 
cells per tube) using 250 pmoi/L 125 1-IL-3 showing that IL-3 was displaced by 55% of total 
specific binding in a dose-dependent manner by GM-CSF. Maximal displacement was reached 
at a concentration of approximately 5-10 nmoi/L for both GM-CSF and IL-3. (c) Like (b) (AML 
case 4; 4 X 106 cells per tube), both competitors displaced IL-3 from the cells equally well. 
Binding of radio labeled GM-CSF to normal cells. Binding of radiolabeled GM-
CSF to monocytes did not appear saturable at GM-CSF concentrations up to 5 
nmol/L and the Scatchard plot was curvilinear (not shown) indicating that, similar 
to AML, high and low affinity GM-CSF binding was involved. Cross competition 
with IL-3 showed that the high affinity component of 1251-GM-CSF binding could be 
inhibited by IL-3. Calculations from three experiments revealed an average number 
of 207 high affinity binding sites (range 56 to 348) (Table 1) and 4,320 low affinity 
sites (range 1,087 to 7,892) for GM-CSF on monocytes. Binding of radiolabeled GM-
CSF to normal granulocytes was saturable at a GM-CSF concentration of 
approximately 2 nmol/L and was not affected by the addition of 200 nmol/L IL-3 
(Table 2). Thus, the GM-CSF receptor on normal granulocytes appears not capable of 
binding IL-3. Scatchard analysis of 1251-GM-CSF binding to granulocytes from 4 
different donors showed an average of 2,292 binding sites per cell (range 1,949 to 
2,729) of single affinity with a Kd of 400 ±50 pmol/L, which is intermediate between 
the high and low affinity GM-CSF receptors in AML. 
Binding of radio labeled IL-3 to normal cells. Monocytes expressed 115 to 143 high 
affinity IL-3 binding sites per cell (Kd ± SD: 61 ± 30 pmol/L), which were also 
partially inhibited by excess nonlabeled GM-CSF (Table 1). Scatchard analysis 
revealed 38 to 112 high affinity IL-3 receptors per cell (Kd ± SD: 147 ± 79 pmol/L) on 
granulocyte samples from three different donors. These samples contained 90-95% 
neutrophils, 2-6% eosinophils and 3-5% monocytes/lymphocytes. Because 
eosinophils have been reported to express up to 2,000 IL-3 binding sites per cell (11), 
it is most likely that the eosinophils in these cell samples had been responsible for IL-
3 binding. 
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Figure 6. Affinity labeling of the IL-3 and 
GM-CSF receptors on intact AML cells by 
chemical crosslinking. 125 1-GM-CSF (lane 
1-3) or 125 1-IL-3 (lane 4-6) were crosslinked 
to 4 x 107 cells (AML case 5) as described 
in materials and methods either without 
non labeled factor (lane 1 and 5) or in the 
presence of excess nonlabeled GM-CSF 
(lane 2 and 6) or IL-3 (lane 3 and 4) in the 
initial binding reaction. The crosslinked 
species were resolved by SDS PAGE. The 
autoradiograph was obtained by exposing 
the gel to Kodak X-Omat AR film at -70°( 
for 4 weeks. 
Cross linking of receptors. Chemical crosslinking was performed to estimate the 
molecular weights of the GM-CSF and IL-3 binding proteins. Affinity crosslinking 
using radiolabeled IL-3 and GM-CSF and AML cells is shown in Fig. 6. The 
autoradiograph demonstrates the migration of three conjugates with apparent MW 
of 100. 130 and 155 kDa for 125I-GM-CSF (Fig. 6, lane 1). Also, three different 
conjugates for 125I-IL-3 with MW of 90, 120 and 145 kDa appeared (Fig. 6, lane 5). In 6 
separate experiments using cells from different patients the same three bands for 
GM-CSF as well as IL-3 were observed. In the presence of 100 fold overdose 
nonlabeled GM-CSF or IL-3 in the initial binding reaction, no bands appeared on the 
autoradiograph (Fig. 6, lanes 2 and 4). After subtraction of the molecular weights of 
the ligands (GM-CSF: 25 kDa; IL-3: 15 kDa), GM- CSF and IL-3 binding membrane 
proteins are estimated to have equal MW of 75, 105 and 130 kDa. 
DISCUSSION 
In this study we provide evidence for the presence of a binding structure on AML 
cells and monocytes with high affinity for both IL-3 and GM-CSF. This conclusion 
has been based upon two sets of experimental findings: (i) Radiolabeled ligand 
binding showed bidirectional cross competition between GM-CSF and IL-3 binding 
to AML cells and monocytes. This competition occurred equally well at 37"C and 
4°C, indicating that receptor down-modulation was not involved in the observed 
GM-CSF /IL-3 receptor interaction. (ii) Chemical cross linking of GM-CSF and IL-3 to 
AML cells revealed that both factors bind to proteins with similar electrophoretic 
mobility on SDS polyacrylamide gels with MWs estimated at 70, 105, and 130 kDa. 
These findings are in agreement with observations recently made by other 
investigators (14-16) who postulated three subtypes of IL-3 and GM-CSF receptors 
on human leukemia cell lines and AML cells, one being capable of binding both 
ligands. We have at present no experimental data that could explain the mechanism 
of IL-3 and GM-CSF cross competition. The fact that no sequence homology between 
GM-CSF and IL-3 has been found (28) would be remarkable although not impossible 
in view of a shared single binding domain on the receptor. Alternatively, the 
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common GM-CSF /IL-3 binding structure may consist of two separate binding 
domains which each have high affinity for their respective ligands. Cross 
competition between the two ligands could then occur through conformational 
changes upon binding of either ligand preventing binding of the other. It is also 
possible that the binding domains are located in such proximity that binding of one 
ligand will preclude binding of the other due to steric hindrance. 
We have obtained evidence for the presence of two types of GM-CSF receptors on 
AML cells and monocytes. In our experiments on human AML with concentrations 
of radiolabeled GM-CSF up to 6-7 nmol/L, Scatchard plots were in favor of two 
affinities. When comparable concentrations of radiolabeled GM-CSF were applied to 
granulocytes, complete saturation was evident (Table 2 and references 11, 24, 29, 30), 
indicating that the low affinity component that was observed in AML was not 
inherent to an artifact of the experimental procedure or the result of impaired 
binding of the ligand due to the labeling procedure. Further evidence for the 
existence of low affinity receptors for GM-CSF was derived from displacement of 
radiolabeled GM-CSF by its nonlabeled homologue (Fig. 1b and Sa) and from 
crosslinking experiments with radiolabeled GM-CSF in the presence of IL-3 (Fig. 6). 
In earlier reports this distinction of two affinity GM-CSF receptor types has not been 
made (11,29-31). This discrepancy can be explained by the fact that the initial 
measurements were performed over only a limited range of free ligand 
concentrations. Consequently it becomes difficult to distinguish between single 
affinity versus multiple affinities because of failure to detect a curvature in the 
Scatchard plot, and one may inadvertently select the wrong model of data fitting. 
Indeed the existence of high and low affinity GM-CSF receptors is in agreement with 
later reports on human cell lines, monocytes and AML cells (14,32,33). 
Crosslinking of GM-CSF binding membrane proteins revealed three bands of 
which the lower was markedly broader than the upper two. The fact that omission of 
protease inhibitors produced an even broader lower band at the expense of the 
upper two (results not shown) suggested that this band is at least partially the 
product of proteolysis as has been demonstrated for the IL-3 receptor in mice (34). 
Since the addition of excess IL-3 in the initial binding reaction with radiolabeled GM-
CSF equally reduced the intensity of all three bands, these bands appear all related to 
the common GM-CSF /IL-3 binding structure (Fig. 6, lane 3). Cross linking of IL-3 
binding proteins revealed components of equal mass. 
Granulocytes express GM-CSF receptors that do not bind IL-3 and show an 
intermediate affinity as compared to the high and low affinity GM-CSF binding sites 
on AML cells and monocytes. The observation of intermediate affinity GM-CSF 
binding to granulocytes adds a third distinct GM-CSF receptor type. IL-3 
competition experiments did not provide evidence for the presence of this receptor 
type on AML (Table 2). The physiological relevance of an intermediate affinity GM-
CSF receptor could be that neutrophils will be functionally activated by GM-CSF 
only at relatively high tissue concentrations of GM-CSF; e.g., induced by bacterial 
infection. 
The potential biological role of low affinity GM-CSF binding to AML cells and 
monocytes remains elusive. Thus far no biological effects have been reported in 
response to GM-CSF at the nmolar concentration range. Possibly this low affinity 
GM-CSF binding site represents a precursor of the functional GM-CSF receptor. 
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The fact that IL-3 and GM-CSF bind to common or closely related structures, 
raises the possibility that alternative factors trigger the same target cells through a 
common receptor and perhaps activate the cells via identical intracellular signal 
pathways. This would explain the marked parallelism of stimulative abilities in 
normal precursor cells and AML of the two hematopoietins. 
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SUMMARY 
AML blasts express dual affinity (high and low) GM-CSF binding, and the high 
affinity GM-CSF binding is counteracted by excess IL-3. Neutrophils express a single 
class of GM-CSF-R with intermediate affinity that lack IL-3 cross reactivity. Here we 
demonstrate the differentiation associated changes of GM-CSF binding 
characteristics in three models representative of different stages of myeloid 
maturation. We find that high affinity GM-CSF binding is converted into 
intermediate affinity binding, which still cross reacts with IL-3, beyond the stage of 
prornyelocytes. During terminal maturation towards neutrophils, IL-3 cross 
reactivity is gradually lost. We sought to determine the mechanism underlying the 
affinity conversion of the GM-CSF-R. Northern and reverse transcriptase-polymerase 
chain reaction (RT-PCR) analysis of GM-CSF-Ra and ~c (KH97) transcripts did not 
provide indications for the involvement of GM-CSF-R splice variants in the 
formation of the intermediate affinity GM-CSF-R complex. In COS-cell transfectants 
with increasing amounts of ~c in the presence of a fixed number of GM-CSF-Ra: 
chains, the high affinity GM-CSF binding converted into intermediate affinity GM-
CSF binding. These results are discussed in view of the concept that increasing 
expression of ~c subunits may cause alternative oligomerization of the GM-CSF-Ra 
and ~c subunits resulting in the formation of intermediate rather than high affinity 
GM-CSF-Ra/~c complexes. 
INTRODUCTION 
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is a hematopoietic 
growth factor (GF) with multilineage stimulative abilities (1-4), that exerts its effects 
on hematopoietic cells through specific membrane receptors (5). At the immature 
stages of myeloid development, GM-CSF regulates proliferation and commitment. In 
mature neutrophils GM-CSF has a role in functional activation. In immature myeloid 
cells there is a considerable degree of functional overlap between GM-CSF and 
interleukin-3 (IL-3) and to some extent also interleukin-5 (IL-5) (6-9). 
A common feature of GM-CSF, IL-3 and IL-5 receptors is that the high affinity 
interaction of these growth factors with their receptors requires the presence of two 
different receptor subunits, an a and a f3 subunit. The a subunits are specific for GM-
CSF, IL-3 and !L-5 and bind to their respective ligands with low affinity. The affinity 
converting ~ subunit, alternatively referred to as ~cor KH97 (10), is shared by the a 
chains of GM-CSF-R, IL-3-R and !L-5-R in the formation of the respective high 
affinity receptor complexes (9,11). This explains why GM-CSF can compete with IL-3 
and IL-5 in high affinity binding to various human cell types (12-19). 
Acute myeloid leukemia (AML) blast cells express both high affinity receptors (Kd 
-50 pmol/L) which cross reacts with IL-3 and low affinity GM-CSF binding sites (Kd 
5-20 nmol/L) (12-15). In contrast, peripheral blood neutrophils express GM-CSF 
receptors with a single, intermediate affinity (12-15,18) (Kd -400 pmol/L), that 
cannot be competed for by !L-3. No explanation has yet been given for the 
differences in ligand binding characteristics of GM-CSF-R between AML blasts and 
neutrophils. Moreover, it has not previously been investigated whether the GM-CSF 
binding characteristics progressively change during maturation from myeloblasts 
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towards neutrophils, or whether these alterations occur at the terminal stage of 
neutrophilic differentiation. 
In the present study, we first determined at which stages of maturation the GM-
CSF binding features change. For this purpose we used three leukemia models: 1) 
primary AML cells that mature spontaneously in culture towards myelocytes, 2) 
chronic phase CML cell samples containing myelocytes, rnetamyelocytes and band 
forms and 3) the promyelocytic cell line HL-60 in which retinoic acid (RA) induces 
neutrophilic differentiation. We subsequently performed a series of experiments to 
analyze which mechanisms can be held responsible for the GM-CSF-R affinity 
changes that take place during myeloid maturation. 
MATERIALS AND METHODS. 
Cells. AML cells from 2 cases of AML, cytologically classified as FAB M1 (22,23) 
and light density CML chronic phase cells of 3 patients were recovered from the 
interface of Ficoll-Isopaque centrifugation of WBC from peripheral blood. The 
cellular composition of these samples is shown in Table 1. None of the patients had 
received treatment before cell samples were drawn. Normal peripheral blood 
granulocytes (90-95% pure) were obtained after sedimentation of the blood of 
healthy subjects in 0.1% methyl cellulose and Ficoll-Isopaque centrifugation (24) as 
previously described (25). The HL-60 cell line was obtained at passage level 28 (26) 
from Dr Farzaneh, King Cross College, London UK. 
In vitro cultnre. The HL-60 cells were maintained in RPMI/10% FCS at a density 
of maximally 5-6 x 105 cells/mL. Granulocytic maturation in HL-60 was induced by 
incubating exponentially growing cells (6 x 105 /mL) in RPMI/10% FCS with 1~M all 
trans retinoic acid (RA, Sigma Chemical CO, St Louis, MO) for 5 or 6 days. After 
culture with RA the percentage of cells with polymorphic nuclei exceeded 90% 
(Table 1). The AML cells were cultured in RPMI/10% FCS with 100 pmol/L IL-3 and 
after 8-20 days harvested for receptor assays. Examination of cytospin smears of 
cultured AML cells showed that the cells had lost their blastic appearance and had 
proceeded towards promyelocytic/myelocytic stages of maturation (Table 1). 
Radioiodination of growth factors and binding experiments. Recombinant human 
GM-CSF (glycosylated, chinese hamster ovarium (CHO) cell derived; MW 20-30 
kDa) (27) and IL-3 (Escherichia coli derived; MW 15 kDa) (28) were prepared and 
purified at Genetics Institute (Cambridge, MA). GM-CSF and IL-3 were radiolabeled 
with Bolton and Hunter reagent (Amersham Laboratories, Amersham, UK) (29) as 
described (30). Specific activities of radiolabeled GFs as determined by self 
displacement analysis (31), were 5-7 x 104 cpm/ng for GM-CSF and 4-6 x 104 
cpm/ng for IL-3. Trichloroacetic acid precipitation showed less than 5% 
nonprecipitable radioactivity for both factors. The maximum binding capacity was 
estimated at 90% to 95% for GM-CSF and 55% to 60% for IL-3. In Scatchard 
calculations the "free" cpm were corrected for the maximum binding capacity (31). 
GM-CSF and IL-3 receptor analysis were performed as previously described (30). 
Cross competition experiments were performed with 200 nmol/L heterologous GF 
(12). Experiments were carried out in duplicate or triplicate. Receptor numbers and 
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Table 1. Morphology of AML, CML and HL60 cell samples 
myeloblasts promyelo- myelocytes metamyelo- band forms segmented other* 
Cells cytes cytes 
AML#l dO 67 12 12 9 
d8 12 36 30 7 15 
AML#2 dO 58 29 9 
d10 6 28 57 9 
CML#l 10 16 16 31 27 
CML #2 8 12 17 32 28 3 
CML #3 9 31 30 30 
HL-60 100 
HL-60 + RA 45 33 22 
Numbers indicate percentages of total cells scored. '· indicates other morphologies, i.e., of megakaryo-
cytic, monocytic, and eosinophilic lineages. 
binding affinities were derived from Scatchard plot analysis, using the ENZfitter 
program (Sigma Chemical CO, StLouis, MO). 
PCR analysis of GM-CSF-Ra and f3 transcripts. Total RNA was isolated from the 
cells after lysis in guanidium thiocyanate containing buffer (32) followed by cesium 
chloride gradient centrifugation (32). eDNA prepared from these RNAs using 
reverse transcriptase (MMLV-RT superscript, GIBCO BRL, Gaithersburg MD) were 
used as templates in the PCR analysis. Primers spanning the extracellular plus 
transmembrane domain were: 5' TCAGATCTGCACCATGCTTCTCCTG 3' and 5' 
CCTTTTAAAGAGGAAGCCG 3' corresponding to bp 137 to bp 1193 of the 
published GM-CSF-Ro: sequence (33) and 5' CAGAGCTGACCAGGGAGATGG-
TGCT 3' and 5'GTAGATGCCACAGAAGCG 3' corresponding to bp 12 to bp 1426 of 
the published ~c sequence (10). 
Construction of GM-CSF-Ra and f3 deletion mutants and expression in COS cells. 
Deletion mutants of both GM-CSF-R subunits, that lacked the complete cytoplasmic 
part (GM-CSF-Ro:Myt, GM-CSF-R~I'.cyt) were obtained by PCR from complete 
cDNAs, using the primers indicated above. Both truncated receptor eDNA fragments 
were cloned into the pCMV4 expression plasmid (pCMV4-GM-CSF-Ro:t.cyt, pCMV4-
GM-CSF-R~t.cyt) (34). GM-CSF-Ro: eDNA, provided by Dr. N. Gough (33) was 
cloned into the pCMV 4 expression plasmid. The ~c expression plasmid (pSVhu!L-5-
R~ (9)) was provided by Drs. G Plaetinck and J. Tavernier (Roche Research, Gent, 
Belgium). COS-1 cells were transfected with (complete or truncated) o: and ~ 
subunits by CaP04 precipitation (32). The expression of ~c was varied by changing 
the amount of ~c expression plasmid in the CaP04 precipitate. Forty-eight hrs post 
transfection the COS-1 cells were detached and harvested with 1 nmol/L EDTA, 
gently forced through a 22 gauge needle to obtain a single-cell suspension and used 
in binding studies. 
(3 H)-hymidine incorporation into AML cells. DNA synthesis of AML cells was 
measured as described (6). Two x 104 cells were cultured for 3 days in 96-well round-
bottom microtiter trays in 100 JlL serum-free medium, with or without addition of 
IL-3 or GM-CSF. Four hours before harvesting, 0.1 ~Ci titrated thymidine 
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Figure 1. Scatchard plot of GM-CSF receptor-binding in AML cells (case 1) before and after 
culture. (a) AML cells: fresh (6.4 X 106 cells per tube) and (b) after 20 days of culture (.95 x 106 
cells per tube) were incubated with 125 1-GM-CSF (40-5000 pmoi/L). Binding of GM-CSF was 
determined as described in Materials and Methods. Scatchard plots of parallel GM-CSF binding 
experiments that were performed in the absence (open circles) or presence of excess IL-3 
(dosed circles). Data were corrected for nonspecific binding and normalized for cell numbers 
(data are expressed as binding per 106 cells). Each point represents the mean of two estimations. 
(Amersham) was added. Cells were harvested on nitrocellulose paper using a 
Titertek Harvester 550 (Flow Laboratories, Isrike, UK). Radioactivity was determined 
with a scintillation counter (Beckman LS 3800, Fullerton, CA). All experiments were 
performed in triplicate and data expressed as mean dpm. 
RESULTS 
Comparison of GM-CSF receptor numbers and affinity in noncultured versus 
cultured AML cells. Binding characteristics of GM-CSF receptors on AML blasts (case 
1) before and after culture are shown in Fig. 1 and Table 2. In line with previous 
observations (12-15,18), the noncultured cells expressed few high affinity GM-CSF 
receptors (60 sites per cell; Kd 50 pmol/L) and ~30 fold more low affinity GM-CSF 
receptors (1,900 sites per cell; Kd 20 nmol/L). In the presence of excess (200 nmol/L) 
nonlabeled IL-3, GM-CSF binding to the high affinity GM-CSF receptors was 
completely prevented (Fig. 1A). In contrast, after 8-20 days of culture, the cells, then 
predominantly showing a promyelocytic/myelocytic morphology, had lost the 
characteristic high affinity GM-CSF binding. In return, intermediate affinity GM-CSF 
binding sites appeared (Fig. 1B) (Kct=350 pmol/L; R=2,700 sites per cell). Low affinity 
binding was markedly reduced. Excess IL-3 (200 nmol/L) virtually prevented all 
GM-CSF binding (81-93 %; Fig. 1B). The remainder of the GM-CSF bound with a low 
affinity. Theoretically, the presence of low affinity GM-CSF binding after cross 
competition with IL-3 could be explained by the residual presence of AML blast cells 
after culture (Table 1), which express excess GM-CSF-Ra chains. However, because 
the presence of low affinity binding was not evident from the Scatchard analysis 
without IL-3 competition, it is more likely that the residual low affinity GM-CSF 
binding is caused by the GM-CSF-Ra subunits dissociated from the intermediate 
affinity GM-CSF-R complex after IL-3 competition. Comparable GM-CSF binding 
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Figure 2. Sensitivity to GM-CSF on fresh and cultured AML cells. DNA synthesis of AML cells (a 
case 2, b case 1) that had been cultured for 10 days {closed circles) as well as freshly thawed 
AML cells (open circles) was determined in the presence of titrated concentrations of GM-CSF. 
EDSO values for each dose response curve are annotated. 
results before and after in vitro culture were obtained in the other AML case (Table 
2). 
GM-CSF binding to CML cells. The CML chronic phase cells from all three cases 
exclusively expressed GM-CSF receptors of intermediate affinity type (Kct 330-390 
pmol/L), at densities that were somewhat lower than those on normal granulocytes 
(Table 2). Excess IL-3 competed 20-60% of labeled GM-CSF binding (Table 2). In 
cases 1 and 2, some low affinity binding appeared to be present after cross 
competition with IL-3 (Table 2). However in all cases the major portion of IL-3 
resistant GM-CSF binding sites expressed the characteristic intermediate affinity. 
GM-CSF binding to HL-60 cells before and after treatment with all trans retinoic 
acid. HL-60 cells expressed 380-470 GM-CSF binding sites per cell of intermediate 
affinity (Kct 200-370 pmol/L, Table 2). Excess nonlabeled IL-3 competed 30-40% of 
125!-GM-CSF binding to HL-60 cells. The Kct value of the GM-CSF binding that 
remained detectable after IL-3 competition was lower than in the absence of IL-3, 
suggesting the presence of low affinity binding. After exposure of the HL-60 cells to 
RA (5-6 days), IL-3 cross reactive GM-CSF binding was completely lost (Table 2). 
Parallel experiments with radiolabeled IL-3 showed that upon RA treatment the HL-
60 cells lost IL-3 binding sites (data not shown). 
GM-CSF induces a proliferative response in AML cells expressing intermediate 
affinity GM-CSF receptors. We measured DNA synthesis in response to GM-CSF in 
AML cells before (expressing high and low affinity GM-CSF receptors) and after 10 
days of culture (when the cells had acquired intermediate affinity GM-CSF 
receptors). In both cases the cells were still able to respond to GM-CSF after 10 days 
of culture, indicating that the intermediate affinity GM-CSF receptor is still capable 
of conducting a mitogenic signal (Fig. 2). The plateau levels of GM-CSF induced 
DNA synthesis before and after culture did not differ significantly. However, the 
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Table 2. GM-CSF binding characteristics of AML, CML, HL60 cells and neutrophils 
without IL-3 with IL-3 (200 nmol!L) 
Cells R Kd (pmoi/L) R Kd (pmoi/L) 
AML#l dO 60 
' 
45 50 
' 
16 0 
1,900 
' 
950 20,000 
' 
13,000 1,900 
' 
780 18,000 
' 
7,900 
dB 2,600 
' 
82 390 
' 
38 NO 
d20 2,700 
' 
50 350 
' 
17 720 
' 
150 3,000 
' 
1,100 
AML#2 dO 59 
' 
3 44 
' 
7 NO 
1,600 
' 
570 30,000 
' 
14,000 
d10 430 
' 
14 360 
' 
39 • 
CML#1 610 
' 
10 330 
' 
20 450 
' 
25 610 
' 
93 
CML #2 540 
' 
18 340 
' 
30 220 
' 
23 980 
' 
250 
CML #3 520 
' 
8 390 
' 
16 360 
' 
8 410 
' 
25 
HL60 exp. 380 
' 
8 370 
' 
16 240 
' 
9 1,100 
' 
71 
exp. 2 470 
' 
9 200 
' 
9 310 
' 
9 120 
' 
10 
HL60+RA d5 530 
' 
28 250 
' 
35 515 
' 
59 250 
' 
74 
d6 1,230 
' 
36 450 
' 
33 1,220 
' 
46 490 
' 
48 
Neutrophils {n= 3) 2,100 
' 
180 410 
' 
53 2,200 
' 
160 420 + 21 
Mean numbers of binding sites (R} (mean ±50) and dissociation constant (Kd}(± SO) were derived from 
radiolabeling studies with noncultured cells or cells that were cultured during indicated periods {AML and 
HL-60 cells). Data were analyzed with the program ENZfitter (Elsevier Biosoft). : Binding data were in 
favor of dual binding characteristics. +:Specific binding detectable, but too low for Scatchard analysis_ 
NO: not determined. 
dose response curves are indicative of a slight loss of sensitivity to GM-CSF after 
culture (EDSO before culture: ~20 pmol/L; EDSO after culture: ~40 pmol/L), possibly 
as a result of the lowered affinity GM-CSF receptor on the cultured cells. 
RT-PCR analysis of the extracellular domains of the GM-CSF-Ra and {3 subunits. 
By Northern analysis, transcripts for GM-CSF-Ra and ~ could be detected in AML 
cells, CML cells, HL-60 cells as well as neutrophils (data not shown). To investigate 
whether splice variants of the GM-CSF-R extracellular domains would be involved in 
the formation of intermediate affinity GM-CSF receptors, we analyzed transcripts of 
the GM-CSF-Ra and~ in cells at different stages of myeloid maturation by RT-PCR 
analysis using PCR primers spanning the extracellular plus transmembrane regions 
of the a and ~ chains. We PCR amplified from all cell samples the fragments of the 
expected lengths of the wild type receptor 1056 nt and 1414 nt respectively, but no 
alternatively sized fragments (Fig. 3). These data rule out alternative RNA splicing as 
a mechanism involved in the formation of the intermediate affinity GM-CSF 
receptors. 
Increasing expression of f3c in COS cells results in the conversion from high 
affinity towards intermediate affinity of the GM-CSF receptor complex. Expression 
of GM-CSF-Ra and ~in principle can reconstitute high affinity GM-CSF receptors in 
COS cells (10). Truncation of the cytoplasmic part of GM-CSF-Ra and/ or ~c does not 
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Figure 3. PCR amplification of extracellular domains of GM-CSF-Ra (a) and ~c (b) from AML 
(lanes a1-a3, b1 and b2); AML day 10 (lane b3); HL-60 (lanes a4 and bS); CML (lane b4) and 
neutrophils (lanes aS, a6 and b6). APst indicates Lambda-Pst I markers. 
affect the formation of the high affinity GM-CSF receptor complex formed in COS 
cell transfectants (Fig. 4A). Because immature myeloblasts express few (50 to 100) 
high affinity GM-CSF receptors, whereas differentiated cells express much higher 
numbers (2000 to 3000) of intermediate affinity receptors and because Northern 
analysis indicated that ~c transcripts but not GM-CSF-Ra transcripts increase with 
progressive maturation, we considered the possibility that increased availability of ~c 
could be held responsible for the affinity changes during myeloid maturation. To 
verify this hypothesis, we performed COS-cell transfections in which the GM-CSF-
Ra chain expression was held at a constant level and the expression of ~c was 
increased (Fig. 4B). Indeed we found that increases in the expression of ~c in relation 
to GM-CSF-Ra affected the affinity of the GM-CSF-Ra/~c complex in a manner 
similar to the affinity changes in the leukemia models. 
DISCUSSION 
The data of this study show that the properties of GM-CSF-R on hematopoietic 
cells alter with progressive myeloid maturation. During the conversion from 
myeloblasts towards (pro)myelocytes, the cells lose the characteristic high and low 
affinity GM-CSF binding to the GM-CSF-Ra/~c complex and the single GM-CSF-Ra 
chain, respectively, and acquire intermediate affinity GM-CSF receptors. At this 
stage of maturation, cross competition by IL-3 for Be affects the intermediate affinity 
GM-CSF binding. In the phase during which the cells mature towards terminally 
differentiated granulocytes, cross competition by IL-3 is gradually lost. This gradual 
loss of cross competition by IL-3 is caused by the disappearance of IL-3-Ra subunits. 
In agreement with this notion, RA treated HL-60 and neutrophils were found to lack 
significant IL-3 binding. 
We have attempted to elucidate the events that take place during the first stage of 
myeloid maturation, leading to the loss of high and low affinity GM-CSF binding 
and the appearance of intermediate affinity receptors. Two mechanisms have 
previously been reported to affect the affinity of hemopoietin receptors. Fukunaga et 
a!. (35) have demonstrated that structural alterations of the extracellular domain of 
the human and murine G-CSF-R, either resulting from naturally occurring 
alternative RNA splicing or caused by experimentally created deletions, may result 
in the decreased affinity of the G-CSF-R. We therefore investigated whether GM-
CSF-Ra and or ~ c splice variants with altered extracellular domains could be 
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Figure 4. Scatchard plots of GM-CSF receptor-binding in COS transfectants (a) GM-CSF-R 
cytoplasmic deletion mutants expressed in COS cells reconstitute high affinity GM-CSF binding. 
Scatchard plot of GM-CSF receptor-binding in COS-1 cells cotransfected with GM-CSF-RaAcyt 
and GM-CSF-RBMyt 1Kct1=79 pmoi/L, R1=2,100 sites/cells, Kd2=18 nmoi/L, R2=2S,OOO 
sites/cell). (b) The affinity of the GM-CSF receptor complex in COS-cells alters as a result of 
increased ~c expression. Scatchard plot of GM-CSF binding to COS-1 cells cotransfected with 
10 1-1-g GM-CSF-RaAcyt expression plasmid and 10 !18 (closed circles; Kd1 =83 pmoi/L, 
R1 =2,600 sites/cells, Kd2=24 nmoi/L, R2=37,000 sites/cell) or 50 [!g (open circles; Kd=680 
pmoi/L, R=12,000 sites/cells) ~c expression plasmid. 
detected in cells expressing the intermediate affinity GM-CSF-R. However, no 
evidence for the presence of such splice variants in cultured AML cells, HL-60 cells, 
CML cells and neutrophils was obtained. 
The second mechanism that has been shown to influence receptor affinity is the 
involvement of additional receptor or receptor linked structures. Recently a third 
receptor chain, involved in the formation and function of the high affinity IL-2 
receptor complex has been identified and molecularly cloned (36). COS-cell 
transfectants expressing human IL-5-Ro: and ~showed intermediate rather than high 
affinity IL-5 binding (9). Similarly, IL-6 binds with intermediate affinity to IL-6-
R/gpl30 COS cell transfectants (37). On this basis, the possible involvement of 
additional receptor structures in the formation of high affinity IL-5-R as well as the 
IL-6-R, LIF-R, OSM-R complex has been postulated (9,37). In contrast it has been 
reported, and here confirmed by us, that COS as well as NIH-3T3 cells (data not 
shown), cotransfected with GM-CSF-Ro: and Be cDNAs can express high affinity GM-
CSF binding (10). Transfection of COS-cells with GM-CSF-Ro: and ~c cytoplasmic 
deletion mutants also resulted in high affinity GM-CSF binding, proving that the 
intracellular domains are not critical for the formation of high affinity GM-CSF 
receptors. Thus, no experimental data have been forwarded to indicate that a 
component additional to the GM-CSF-Ro: and B structures is involved in the 
formation of the high affinity GM-CSF-R complex. On the other hand, our data from 
COS cell transfection experiments established that the level of ~c expression relative 
to GM-CSF-Ra. directly determines the affinity of the GM-CSF-R complex. Therefore, 
it appears most likely that during myeloid maturation, GM-CSF-R binding 
characteristics are altered simply by upregulation of the ~c subunit. 
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The exact configuration of the high and intermediate affinity GM-CSF-R is still 
unknown. Kaushansky et al. and Shanafelt et al. have shown that two regions 
(residues 14-24 and 77-94) in the C-terminus of human GM-CSF are important for 
biological activity (38,39). In addition the involvement of regions 40-77 and 110-127 
in receptor binding has been suggested by Nice et al (40). These results predict that 
GM-CSF can bind to several distinct binding sites of the GM -CSF-R complex and 
open the possibility that alternative oligomerization of GM-CSF-Ra and ~c subunits 
determine the different affinities of the receptor complex. For instance, one could 
hypothesize that in case of low availability of ~c' a high affinity complex is formed by 
one a subunit and one ~ subunit, which could become an intermediate affinity 
receptor when increased availability of ~c permits a~~ complexes. The latter 
alternative of receptor complex formation has recently also been proposed for the IL-
6-R and LIF-R (41). Further investigations of the interactive domains of GM-CSF and 
the GM-CSF-R structures are required to solve this issue. 
So far, no functional differences between high and intermediate affinity GM-CSF-
R have been identified. AML cells expressing the intermediate affinity GM-CSF-R 
after culture were capable of responding to GM-CSF with only slightly decreased 
sensitivity as compared with the fresh cells that expressed the high affinity GM-CSF-
R. Moreover identical tyrosine phosphorylation patterns were observed after GM-
CSF stimulation of M07e cells, which express high affinity GM-CSF-R and 
neutrophils (intermediate affinity GM-CSF-R) (42). What then, could be the 
physiological relevance of alternative oligomerization? Increasing evidence has 
become available that upon ligand induced di- or oligomerization of receptor 
subunits, interaction between the intracellular domains of the receptor structures is 
required for GF receptor activation (35,41,43). Soluble forms of GM-CSF-Ra and IL-5-
Ra: have been reported to antagonize the activation of the membrane receptors. 
These observations indicate that the intracellular domains of the GM-CSF-Ra and IL-
5-Ra: have a role in receptor activation. In contrast, association of a soluble form of 
the IL-6-Ra (lacking the trans membrane and cytoplasmic parts) with the signal 
transducing gp130 molecule results in the formation of a functional IL-6-R. Hence it 
is likely that gpl30 subunit dimerization, rather than IL-6-Ra/ gp130 dimerization 
activates the IL-6 signaling process (41). Based on these observations, we now 
assume that, depending on the availability of ~c subunits, GM-CSF signaling can be 
mediated through a~ or through a~ and ~~ association. Whether these alternative 
ways of receptor activation have qualitative implications for GM-CSF mediated 
responses (other than mitogenic activation and tyrosine phosphorylation) or simply 
represent another example of receptor redundancy (44) remains to be answered. 
Hence, future investigations will focus on the role of the cytoplasmic domains of the 
GM-CSF-Ra and ~c subunits in signal transduction activated by the different 
oligomeric GM-CSF receptor complexes. 
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Introduction 
Based on the nucleotide hmnology of binding domains, several classes of receptors 
have been identified (Chapter 1). Most HGFs bind to receptors that belong to the 
hematopoietin receptor superfamily or Class I cytokine receptors. These receptors 
are integral membrane glycoproteins, with an extracellular N-terminal domain, a 
single hydrophobic membrane spanning domain, and a C-terminal cytoplasmic 
domain. In this chapter, the structural and functional properties of the hematopoietin 
receptor superfamily will be discussed. 
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Figure 1. Linear representation of the conserved receptor homology domain of Class I cytokine 
or hematopoietin receptors. The common motif of these receptors is a ""'21 0 amino acid region 
in the extracellular domain that is conserved among all members of the superfamily. 
Character"rstic features are the two sets of conserved cysteine residues in the N-terminal part of 
the extracellular region, and the WSXWS box in the membrane proximal C-module. TM denotes 
the transmembrane domain. 
9.1 The cytokine receptor homology domain 
The cytokine receptor superfamily is defined by a stretch of ~210 amino acid (aa) 
residues in the extracellular domain that contains numerous conserved residues and 
that is essential for ligand binding. This region, referred to as the cytokine or 
hematopoietin receptor homology (CRH) domain, can be subdivided into two 
modules of ~100 aa each (Fig. 1). The N-terminal module shows distinctive 
conservation of two sets of evenly spaced cysteine residues that form disulfide loops. 
The membrane proximal (C-terminal) domain contains the highly conserved Trp-Ser-
X-Trp-Ser box (WSXWS). Strikingly, both modules express a significant resemblance 
to fibronectin (FN) type III domains. FN III domains are ~90 aa modules that are 
present in adherence molecules expressed at the cell surface (1-3). The similarity of 
these structural characteristics in the conserved domain suggest that the members of 
the cytokine receptor family emerged either from a primitive adhesion molecule or 
from a common ancestral gene. This notion is further stressed by the presence of an 
additional triple repeat of a FN HI domain proximal to the membrane in gp130, the 
LIF receptor and the G-CSF receptor. 
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Table 1 . The hematopoietin receptor family 
Receptor EC domain WSXWS box Cys EC TM IC ref 
hull-2-R~ CRH WSPWS 4 214 25 286 4 
hull-2-Ry CRH WSEWS 4 232 29 86 5 
hull-3-Ra N-CRH LSAWS 4 287 20 53 6 
mull-3-Ra N-CRH LSSWS 4 315 24 41 7 
hull-4-R CRH WSEWS 4 207 24 569 8 
mull-4-R CRH WSEWS 4 208 24 553 9,10 
hull-5-Ra N-CRH WSEWS 4 315 • 11 
mull-5-Ra N-CRH WGEWS 4 322 22 54 12,13 
hull-6-R lg-CRH WSEWS 4 339 28 82 14 
hull-7-R lg-CRH WSEWS 2 219 25 195 15 
hull-9-R CRH WSEWS 4 233 26 231 16 
mull-9-R CRH WSEWS 4 233 26 177 16 
huGM-CSF-Ra N-CRH WSSWS 4 297 27 54 17 
muGM-CSF-Ra N-CRH WGEWS 4 295 25 38 18 
KH97 {hu~d {CRHI2 PSKWS/WSEW5 4/4 422 27 432 19 
AIC2A {mu~IL31 {CRHI2 PSRWS/WSEWS 4/4 417 26 413 20 
AIC2B (mupc) !CRHI2 PSRWS/WSKWS 4/4 418 26 430 21 
huG-CSF-R lg-CRH-{FN-111)3 WSDWS 4 603 26 183 22,23 
muG-CSF-R lg-CRH-(FN-111)3 WSPWS 4 601 24 187 24,25 
huEPO-R CRH WSAWS 4 225 22 240 26 
muEPO-R CRH WSAWS 4 225 23 235 27 
hugp130 lg-CRH-{FN-11113 W5DW5 4 597 22 277 28 
mugpl30 lg-CRH-{FN-11113 WSDWS 4 595 22 278 29 
huLIF-R {CRH)2-IFN-IIII3 WSDWS/WSKWS 4/2 789 26 238 30 
huMPL-R !CRHl2 WSGWS/WSSWS 4/4 463 22 122 31 
huPRL-R CRH WSAWS 4 210 24 364 32 
huGH-R CRH FSEVL 4 246 24 350 33 
huCNTF-R lg-CRH WSDWS 4 352 34 
CRH, cytokine receptor homology domain; lg, immunoglobulin-like fold; N, non conserved "cap-region" 
of ""80-100 residues characteristic for the a-subunits of IL-3, GM-CSF and IL-5 receptors; FN-111, 
fibronectin type Ill domain; Cys denotes the number of conserved cysteines in the CRH domain; EC, TM, 
IC denote the number of amino acids in the extracellular, transmembrane and intracellular domains 
respectively; *indicates the number of amino acid residues of the mature protein, i.e., without the signal 
peptide; hu, human receptor subunit; mu, murine receptor subunit; t, only the soluble ll-5-R was 
cloned , CNTF-R is anchored to the cell membrane by glycosyl phosphatidyl inositol linkage (GPI). 
The class I cytokine receptor family does not exclusively contain receptor 
structures for hematopoietic growth factors and cytokines. Prolactin receptor, 
growth hormone (GH)-R, and ciliary neurotrophic factor (CNTF)-R also belong to 
this family (Table 1), In some members of the family, variations of the common motif 
are apparent, For example LIF receptor, AIC2A, AIC2B, and KH97, have a 
duplication of the CRH domain (Table 1, Fig, 2), In the latter three receptor molecules 
this duplication has been accompanied by a replacement of the first residue of the 
WSXWS motif in the most N-terminally located CRH domain to a tryptophan, 
Furthermore, the G-CSF, IL-6, CNTF, and IL-7 receptors contain an additional 
immunoglobulin-like domain, located N-terminal to the CRH domain. LIP receptor, 
gp130, and G-CSF receptor contain three repeats of a FN type Ill domain between the 
CRH and transmembrane domains. Although in several members of the cytokine 
receptor family the FN-III and Ig domains constitute a substantial part of the 
extracellular domain, they have not proven to serve any known function. Both the Ig 
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Figure 2. Different dimeric or oligomeric forms of high affinity hematopoietin receptor 
complexes: (a) Cytokine receptors that have high affinity ligand binding by homodimerization, 
(b) heterodimeric cytokine receptors that require two distinct subunits to form a high affinity 
receptor, (c) heterotrimeric high affinity receptor complex. Stippled shading represents CRH 
domain; hatched area represents triple fibronectin type Ill domains; crosshatched area 
represents immunoglobulin-like domains (see Table 1 ). The G-CSF, IL-3, and IL-2 receptors are 
shown as examples. IL-2-Rcx is not a member of the hematopoief1n receptor fam'dy. 
and FN-Ill domains in the G-CSF receptor as well as the Ig domain of the IL-6 
receptor are not required for ligand binding or signal transduction (35,36). 
9.2 HGF receptor splice variants 
Splice variants of mRNA have been described for most receptors of the cytokine 
super family including those of G-CSF, GM-CSF and IL-3. Strikingly, alternative 
mRNA splicing most often involves exons encoding the transmembrane or 
intracellular domains. The physiological significance of this phenomenon is still 
unclear, but expression of different receptors may represent a regulatory mechanism 
(see also 9.6). Most of the splice variants give rise to soluble receptor forms. Specific 
transcripts for soluble forms have been identified for the IL-2, IL-4, IL-5, IL-6, IL-7, 
IL-9, GM-CSF, G-CSF and GH receptors (10,11,16,23,33,37-39). Given the general 
occurrence of soluble receptor forms, they most likely have important biological 
functions. They may act antagonistically by forming complexes with secreted HGFs, 
thus preventing HGFs to interact with their target cells. Alternatively, soluble forms 
of receptors can also be involved in the formation of functional cellular receptors. 
This was demonstrated for the soluble forms of IL-6 and CNTF receptors. In the 
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presence of their respective ligands these receptors associate with the signal 
transducing gp130, to form high affinity receptor complexes (see below)(28,34). 
9.3 Formation of high affinity receptor complexes 
High affinity ligand binding involves the association of two or more receptor 
subunits (di- or oligomerization), a feature which was already shown to be essential 
for activation of tyrosine kinase receptors (25,39-47). 
In certain receptors, two identical subunits form a high affinity (homo)dimeric 
complex. For instance the high affinity G-CSF and EPO receptors are homodimers 
(24,42). Although the exact composition of the high affinity IL-4 and IL-7 receptor is 
not fully clear, it has been suggested that these receptors also form homodimeric 
complexes (8,48,49) (Fig. 2a). Receptor complex formation may also involve the 
heterodimerization of two distinct receptor subunits, a and ~. For instance, the 
receptors for human IL-3, GM-CSF, IL-5, IL-6, LIF, CNTF, and IL-11 receptors 
(2,11,13,19,28,50-53) (Fig. 2b). The ex-subunits are primarily cytokine binding proteins 
and bind their respective ligands with low affinity. The ~-subunits are affinity 
converters, required for the formation of a high affinity binding site and are 
primarily also responsible for signal transduction. Usually the a-subunits are 
expressed more abundantly on the cell surface than the ~ subunits. This explains 
why receptors of this group also have a low affinity ligand binding component in 
addition to the high affinity binding site. A third subunit, they subunit, for the IL-2 
receptor has been cloned. The IL-2-Ry is required to reconstitute a functional IL-2-R~ 
(5), which then can form the functional high affinity IL-2 receptor in association with 
IL-2-Rcx (Fig. 2c). The involvement of a third receptor subunit for high affinity 
binding has also been suggested, but not proven, for the IL-6, LIF, and OSM receptor 
system (53). The high affinity CNTF receptor appears to be composed of three 
subunits, the CNTF-Rcx, gp130, and the LIF-R (54,55). 
9.41L-3, GM-CSF, and IL-5 receptors: a common ~subunit involved in the 
formation of functional receptor complexes 
GM-CSF and IL-3 bind to high affinity and low affinity receptors, which are 
expressed on immature cells and monocytes (Chapter 1). A striking feature of IL-3 
and GM-CSF is their cross reactivity with each other's or common receptors on 
human AML cells, monocytes, eosinophils, and several human myeloid cell lines (56-
60,Chapter 7). Cross reactivity between IL-3 or GM-CSF and IL-5 binding has been 
reported on human eosinophils and basophils (61,62). In contrast to AML cells, 
mature granulocytes express a single class intermediate affinity GM-CSF receptor, 
which lacks IL-3 cross reactivity. This finding suggests that the status of the GM-CSF 
receptor is related to the stage of differentiation. Mechanisms that have been 
reported to affect the affinity of HGF receptors include glycosylation (EPO-R (27)) or 
the involvement of additional receptor structures (IL-2-R (5)). 
Following the molecular cloning of the GM-CSF receptor (17) it was shown that 
this receptor binds GM-CSF with the same affinity as the low affinity GM-CSF 
binding component on AML cells and monocytes. Expression of this receptor 
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Figure 3. {a) The heterodimeric GM-CSF receptor. The high affinity receptor complex is 
reconstituted by the low affinity GM-CSF receptor (a-subunit) coexpressed with KH97. (b) 
Relationship between ll-3, GM-CSF and IL-5 receptor subunits; CNTF, LIF, IL-6 and IL-11 
receptor subunits. The lines indicate possible associations of a and ~-subunits. 
subunit in factor dependent myeloid cell lines failed to reconstitute a normal 
functional high affinity GM-CSF receptor_ An important step forward came when 
another member of the hematopoietin family, KH97, was cloned. This protein, which 
by itself can not bind GM-CSF, was able to convert the low affinity GM-CSF receptor 
into a biologically functional high affinity GM-CSF receptor (19). In analogy to the 
IL-2 receptor system, the low affinity GM-CSF receptor was designated the a-subunit 
(GM-CSF-Ra) and KH97 the ~-subunit (Fig. 3a). Subsequent cloning of the IL-3-Ra 
and IL-5-Ra chains revealed that these subunits utilize KH97 to form high affinity 
receptors for human IL-3 and IL-5 (6,11,43). The heterodimerization of unique IL-3, 
GM-CSF and IL-5 a-subunits with a common ~-subunit explains how these cytokines 
can compete for binding to their receptor (Fig. 3b). Reconstitution experiments in 3T3 
cells or COS-1 cells show that indeed cross competition can be restored, if the 
expression of KH97 compared to the a-subunits is low (6). In this situation one 
ligand can inhibit the (high affinity) binding of another ligand by depleting the 
availability of the common ~-subunit. 
In contrast to the human system, two ~-subunits have been identified in the 
mouse: AIC2A and, the highly homologous IL-3 receptor-like protein, AIC2B (20,21). 
AIC2A was originally identified as the low affinity murine IL-3 receptor and shown 
to be part of the high affinity IL-3 receptor (63,64). In COS cells, AIC2B did not bind 
any growth factor at all. Since KH97 was cloned from a eDNA library using AIC2A 
as a probe, AIC2A and AIC2B were likely to be ~ subunits in the mouse. The cloning 
of the murine low affinity IL-3-Ra, GM-CSF-Ra and IL-5-Ra, confirmed that AIC2B 
was an affinity converter for the murine IL-3, GM-CSF and IL-5 receptors 
(7,18,44,45). AIC2B, thus appeared to be the murine homologue of the human 
common ~-subunit KH97 (Fig. 3b). AIC2A, which by itself already binds IL-3 with 
low affinity, appeared to be an unique affinity converter for the IL-3-Ra, thus 
reconstituting a high affinity IL-3 receptor that predictively lacks cross reactivity 
with GM-CSF or IL-5 (Fig. 3b). 
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9.5 Other cytokine receptor systems with common binding structures 
LIP, OSM, CNTF, IL-6 and IL-11 are pleiotropic factors with many overlapping 
biological functions and similar tyrosine phosphorylation patterns in neuronal and 
hematopoietic cells (30,52,53,65). Like the IL-3, GM-CSF and IL-5 receptor complex 
these overlapping actions are caused by the shared involvement of a ~-subunit, 
gp130, which was originally identified as the signal transduction and affinity 
converting component of the IL-6 receptor (28,52,53). Receptor subunits that 
specifically bind LIP, CNTF, IL-6 and IL-11 with low affinity have been identified, 
and have been designated LIF-R, CNTF-Rcx, IL-6-Rcx and IL-11-Rcx respectively (Fig. 
3c). Heterodimerization of these receptor subunits with gp130 results in the 
formation of a high affinity receptor complex. Analogous to KH97 and AIC2B, gp130 
alone has no affinity for ligand, except OSM which binds to gp130 with low affinity, 
and has been designated as the ~ subunit for the LIP, OSM, CNTF, IL-6 and IL-11 
receptor systems (52,53,65,66). Although the low affinity LIF-R associates to gp130, 
similar to CNTF-Rcx and IL-6-Rcx, it is being referred to as LIF-RJ1 because of its 
homology to gp130. LIF-R~ thus acts as an affinity converter subunit for the low 
affinity OSM receptor, gp130 (53). Formation of the high affinity CNTF receptor 
complex requires the association of CNTF-Rcx with the high affinity LIP receptor 
complex (gp130 plus LIF-R~; Fig. 3) (54,55). 
A third group that appears to employ common receptor subunits includes IL-7 
and TSLP receptors. Both receptor chains share a high degree of homology, but can 
only bind their own ligand with low affinity when in a monomeric status. From 
reconstitution experiments in hemopoietic cell lines it appeared that the high affinity 
IL-7 receptor complex is a homodimer of IL-7 receptor subunits, whereas high 
affinity TSLP binding requires the heterodimerization of IL-7 and TSLP receptor 
subunits (67). The fact that cells from homozygous mice, in which expression of the 
IL-7 receptor gene was knocked out, do not express TSLP binding suggests that more 
subunits are involved in the TSLP receptor. 
Thus, it appears that the promiscuous use of receptor subunits is a common theme 
among the members of the hematopoietin receptor superfamily. Although in the past 
many cross competition binding experiments have not indicated the existence of 
such receptor molecules, this may be caused by their relative overexpression. 
Conceivably, additional receptor structures shared by other HGF receptors will be 
identified in near future. 
9.6 G-CSF receptor 
G-CSF receptors are single class high affinity receptors (Chapter 1). Cloning of the 
G-CSF receptor resulted in the identification of only one receptor chain. When 
expressed in COS-1 cells this structure could transfer high affinity G-CSF binding 
(25). A functionally active receptor could be established in FDCP-1 cells by a hybrid 
receptor that contained the extracellular domain of human growth hormone receptor 
linked to the transmembrane and intracellular domains of the murine G-CSF 
receptor. Thus, the G-CSF receptor, in analogy to the GH receptor, requires homo-
rather than hetero-dimerization for signal transduction (46,47). The structure of the 
extracellular domain of the cloned G-CSF receptor is a mosaic of hematopoietic 
receptor, immunoglobulin and fibronectin domains. The transmembrane and 
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figure 4. (a) The folding of~ strands in the CRH domains. N- and (-domains, each containing 
7 anti parallel j)-strands folded into barrel shaped structures, are connected via two conserved 
pralines. (b) Configuration of extracellular domain of the hematopoietin receptor based on 
predictive analysis by Bazan and crystallography of the GH receptor; two CRH domains create 
a V-shaped ligand binding site. In addition the C-domains of each receptor subunit interact with 
each other. 
cytoplasmic parts are related to the IL-4 receptor, with a sequence homology of z50% 
(25). 
Several forms of G-CSF receptor mRNA with different lengths of their cytoplasmic 
domains can be produced by alternative splicing (22,23). As of yet, the roles of G-CSF 
receptor variants remain unclear. However, there is evidence that the cytoplasmic 
domain contains a region with differentiation inducing capacity and a proliferative 
competence regulatory region (68,69). Although the members of the hematopoietin 
receptor family have several conserved regions in the extracellular domains, a 
subgroup also has similar motifs in the cytoplasmic domains and perhaps similar 
mechanism of signal transduction. The differential expression of variants lacking 
certain cytoplasmic regions may represent a mechanism to modulate the G-CSF 
response. The presence of functionally different domains has also been identified in 
the cytoplasmic part of the EPO receptor. The EPO receptor contains non 
overlapping positive and negative growth regulatory domains (70). 
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Figure 5. The structure of GM-CSF. (a) Diagram showing the secondary structural elements: 
four a helices (rounded boxes A-D), 2 ~strands (arrows 1 and 2), and disulfide bridges (ss). (b) 
Drawing of GM-CSF folding as determined by X-ray crystallography. Nand C mark the termini. 
The axes show approximate dimensions of the GM-CSF molecule. (figure adapted from 
Diederichs 1991}. 
9.7 Domains involved in ligand recognition 
The extracellular CRH domain consists of two domains (N-domain and C-
domain), linked by a small loop containing two proline residues (3). Each domain 
contains 7 ~-strands, folded in two ~-sheets of 3 and 4 ~-strands respectively, that 
together form a sandwich (71)(Fig. 4a). The ~-sheets of each domain make two barrel 
shaped structures, that are positioned at an angle (Fig. 4b). The folding of these 
barrels results in an Ig-like structure. Because HGF receptors are rnultimeric 
complexes, presumably two CRH domains cooperate to form a high affinity binding 
site. Crystallography revealed that GH forces the two receptor molecules in the 
GH-(GH-Rh complex in a symmetrical orientation around an axis perpendicular to 
the membrane surface. In this complex the residues of theN-domain and C-domain 
on both receptors that interact with the GH molecule are essentially the same (71). In 
addition there is a substantial interaction between C -domains of the two receptors, in 
particular at the base of the C -domain. The specific involvement of the integral CRH 
domain in ligand binding was demonstrated by mutational analysis of the 
extracellular domain of the G-CSF receptor (72). These studies further showed that 
the Ig-like and FN III domains, but not the CRH domains, were dispensable for 
biological activity. Although both GH and G-CSF receptors are (homodimeric) 
members of the super family, it still remains unclear how the CRH domains of 
heteromeric receptors that use an a subunit together with a P subunit that does not 
bind any ligand, interact to form a high affinity binding site. 
The function of the consensus WSXWS box in the CRH domain has recently been 
studied. Mutational analysis of IL-2, IL-6 and EPO receptors has shown that single 
residues of the WSXWS motifs of the different receptors are essential for ligand 
binding (73-75). Initially it was suggested that the WSXWS box could be involved in 
ligand binding. However, in the GH receptor the WSXWS motif is located away from 
the ligand binding interface (71), but in close proximity of the hinge region between 
the two barrel-like domains of the CRH domain (Fig. 4b). Structure-function analysis 
of the human IL-6 receptor has established the importance of this hinge region for 
correct protein folding of the CRH domain (75). In this study it was shown that 
residues important for ligand binding had a tendency to be distributed to the hinge 
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region. Apparently the WSXWS motif determines how the two barrel structures of 
the CRH domain are positioned. The residues that are directly involved in ligand 
recognition are not conserved among different members of the superfamily. This is 
not unexpected, because each receptor has to interact with it own ligand. 
The ligands of the hematopoietin receptors display none, or very little similarities 
in their amino acid sequences. Nevertheless, a common structural feature of these 
ligands is a conformation that is rich in a helices, as is evident from predictive 
modeling of cytokine protein folds and X-ray crystallography. For example GM-CSF, 
IL-2, IL-3, IL-4, IL-6, G-CSF, EPO, PRL and GH all have four parallel a helices that 
form a barrel (76-84) (Fig. 5). This "four-a-helix bundle" is a common structural motif 
in globular proteins and provides the ligand its backbone topology, necessary for 
biological function (85). Of the four helices, in particular the most N-terminal a helix 
plays an important role in the high affinity ligand-receptor interaction and biological 
activity for IL-3, IL-5 and GM-CSF (36,86-89). Minor deletion or single residue 
substitution in the first a helix completely abrogate high affinity binding and 
biological activity. Comparison with the other cytokines, that have amino acid 
homology in the predicted amino terminal a helix, suggests that this region may 
contain the recognition element of cytokines for the high affinity binding sites on 
their multi-subunit receptors (88). 
9.8 Cytoplasmic domains of HGF receptors 
Contrary to the extracellular domains of the hematopoietin receptors, the 
cytoplasmic domains lack a common motif. The cytoplasmic tails vary substantially 
in length (41 to 569 aa, Table 1), and share no homology with other known 
sequences. Nevertheless, certain members of the superfamily share distinct 
homology of their intracellular domains. The cytoplasmic part of the IL-4 receptor 
has a similarity to that of the G-CSF receptor (22,25). However, homology between 
the cytoplasmic region of the G-CSF receptor and gp130, the affinity converter of the 
IL-6 receptor, is much more pronounced. Three stretches of amino acids (Boxes 1, 2 
and 3, Fig. 6) are conserved in these receptor molecules (72,90). These conserved 
sequences are consequently thought to play a role in signal transduction. Indeed two 
of these segments (Box 1 and 2) are essential for biological activity of the IL-6 and G-
CSF receptors (72,90). The conserved cytoplasmic regions can also be found in other 
members of the hematopoietin receptors. hu!L-2-Rp, EPO-R, KH97, AIC2A and 
AIC2B have regions which are highly homologous to Box1 and Box2 of the G-CSF 
receptor and IL-7-R, MPL and IL-4 have Box1 homologous sequences. For gp130 and 
the G-CSF receptor it was shown that Box1 and Box2 are essential for mitogenic 
signaling (68,70,72,90). Deletion mutants that lacked Box1 and Box2 could not 
mediate IL-6 or G-CSF induced proliferation in the murine IL-3 dependent cell lines 
BAF3 or FDCP-1. The function of the third conserved domain, Box3, is unclear. On 
the other hand, it appears that transduction of a HGF stimulus is conferred by other 
less well confined and non conserved parts of the cytoplasmic domain. For example 
a single point mutation in the cytoplasmic region of the EPO receptor between Boxl 
and Box2 completely abrogated its biological activity (91). Most members of the 
HRSF contain large serine/proline rich stretches that do not overlap with the 
conserved boxes. The serine rich region of the IL-2-RB subunit was shown to be 
CYTOKINE RECEPTOR SUPER FAMILY 
Boxl 
hull-2-R~ (249-262) 
AIC2A (473-486) 
mull-4-R (235-248) 
huGM-CSF-Ra (350-363) 
hull-3-Ra (326-339) 
KH97 (473-486) 
mull-5-Ra (326-375) 
huEPO-R (278-291) 
hull-7-R (249-262) 
hull-9-R (298-311) 
hu gp130 (648-661) 
huG-CSF-R (632-645) 
huLIF-R (866-879) 
MPL (177-190) 
Consensus 
BoxZ 
hull-2-R~ (296-307) 
AIC2A (536-546) 
KH97 (535-546) 
huEPO (327-337) 
hu gp130 (691-682) 
huG-CSF-R (672-683) 
huUF-R (909-920) 
Consensus 
Box3 
hu gp130 (772-787) 
huG-CSF-R (738-753) 
KH97 (864-814) 
AIC2A (895-813) 
Consensus 
K K V L K C N T P D P S K F 
Y R K W K E K I P N P S K S 
K K I W W D Q I P T P A R S 
L R I Q R L F P P V P Q I K 
R R Y W V M Q R L F P R I P 
R R K W E E K I P N P S K S 
H L W T R L F P P V P A P K 
K Q K I W P G I P S P E S E 
K P I V W P S L P D H K K T 
K R I F Y Q N V P S P A M F 
K K H I W P N V P D P S K S 
K N P L W P S V P D P A H S 
K E T F Y P D I P N P E N C 
R H A L W P S L P D L H R V 
K R W P I P D P K S 
I S P L E V L E R D K V 
V S P L T I E D P N I 
V S P L T I E D P - K H 
P A S L E V L S E R C 
V S V V E I E A N D K K 
L T V L E E D E K K P V 
V E V L E T R S A F P K 
v s L E I E K 
p s v Q V F s R S E S T Q 
p G P G H Y L R C D s T Q 
. -
. -
- L L 
- L L 
G E R P A D V s P T S p Q • E G L L 
G E P R E E V G p A s p H p E G L L 
s p L L 
91 
Figure 6. Amino acid sequence of hematopoietin receptors cytoplasmic domains. Three highly 
conserved segments (amino acid residues are given in parenthesis) are aligned; gaps have been 
introduced to maximize homology(-). 
essential for tyrosine phosphorylation (92) and substitution of positively charged 
amino acids in the region between Boxl and Box2 of gp130 by serine and glutamine 
completely abrogated the IL-6 responsiveness in BAF3 cells (90). 
Because IL-3, GM-CSF, and IL-6 are pleiotropic factors, conceivably different 
parts, i.e., for example the Box 3 domain or the "inter-Box" regions might be required 
for functions other than the growth signal. A common feature of all HGFs that use 
gp130, G-CSF receptor, or KH97 for signal transduction is the ability to induce 
myeloid maturation in normal progenitor cells. The particular involvement of Box3 
of the G-CSF receptor in granulocytic maturation was implied by the identification of 
a truncated G-CSF receptor form (68,93). This receptor lacks its C-terminal 
cytoplasmic domain including Box3, has lost it ability to induce G-CSF dependent 
terminal granulocytic maturation upon forced expression in L-GM cells. 
Homodimerization of the GH, EPO and G-CSF receptors is the first essential event 
in ligand-induced signal transduction (42,46,47,68,72). The role of homodimerisation 
of gpl30 in IL-6 signaling was recently verified: disulfide-linked homodimerization 
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of gp130 can be recovered from celllysates after IL-6 stimulation (94). Unlike the IL-6 
receptor, signaling by the CNTF and LIF receptor complexes depends on the 
heterodimerization of gp130 with the LIF binding protein (LIF-R) (54). These 
observations suggest that juxtaposition of two identical cytoplasmic domains create a 
binding site for a second messenger that triggers cell proliferation. In analogy with 
the formation of the ligand binding site by two CRH domains for the G-CSF receptor, 
it may be possible that this signaling domain (or multiple signaling domains) is 
composed of two identical domains (Box1, or Box2, or Box3); one from each receptor 
subunit. The interaction of two identical domains in the CRH region of the GH 
receptor was established by X-ray and MRI crystallography of the GH-GH-R 
complex (71). GH, a nonsymmetrical molecule, binds two copies of the receptor that 
use essentially the same binding determinants. Furthermore, the two receptor 
molecules in the GH-(GH-Rh complex contact each other via the same residues in 
the C-terminal domain of each receptor CRH region. This paradigm would predict 
for the heterodimeric receptor complexes that two homologous cytoplasmic domains 
associate to form an "active site" upon ligand activation. The two a and ~ chains of 
the high affinity GM-CSF receptor each contain a Boxl. T11is would suggest that for 
the high affinity GM-CSF receptor only the Boxl domains are required for signaling. 
Indeed it appeared that in KH97 only Boxl is sufficient for growth signal 
transduction in BAF3 cells and CTLL-2 cells (95). Although these cells cotransfected 
with the complete GM-CSF-Ra and the KH97 deletion mutant that lacked Box2 and 
Box3, showed a full proliferative response to GM-CSF, it appeared that the 
sensitivity to GM-CSF was reduced 1 or 2 log. This suggested that the region 
between Boxes 1 and 2 or Box2 contains some positive growth regulatory domain. 
On the other hand the loss of sensitivity could also reflect the effects of extensive 
truncation on the folding of the KH97 protein. Thus the precise roles of the Box2 and 
Box3 of KH97 in the IL-3, GM-CSF, and IL-5 receptor complexes are still unclear. In 
order to study the function and mechanism of action of HGF receptors in normal and 
abnormal hematopoiesis, investigations should first be concentrated on the 
delineation of functional domains of the IL-3, GM-CSF, and G-CSF receptors. 
9.9 Signal transduction 
Relatively little is known about the way HGF receptors can activate signal 
transducing pathways in their target cell. The cytoplasmic domains of HGF receptors 
do not contain sequences known to be important in signal transduction, such as 
tyrosine kinase domains or phosphatases. For other receptor systems these 
mechanisms have been (partially) dissected. The receptors for steroid hormones can 
be allosterically modified upon ligand binding, which allows the hormone-receptor 
complex to bind to its DNA responsive elements in the promoter region of a target 
gene. The requirement of tyrosine kinase activity for signal transduction has been 
well established in RTK family (96-98). Tyrosine kinase receptors such as c-kit and 
M-CSF receptor catalyze the phosphorylation of exogenous substrates as well as 
tyrosine residues within their own receptor chains. Autophosphorylation appears to 
be involved in the interaction between activated receptor and intracellular proteins 
involved in signal transduction such as phospholipase C-y, PKC, Phosphatidyl 
inositol 3-kinase, c-raf and GTPase activating protein (96-100). These proteins are 
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physically associated with cytokine receptors such as EGF, M-CSF and PDGF 
through a specific (non catalytic) domain, the SH2 domain, which was originally 
identified as the common motif of many RTKs (96,101). The stimulation of RTKs can 
rapidly both modify the expression, and activity of transcription factors like fos, jun 
and myc, which control genes that are important for cell cycling and differentiation 
(102). 
Many HGFs including IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, GM-CSF, G-CSF and EPO 
receptors have also been demonstrated to induce protein tyrosine phosphorylation in 
hematopoietic cells (103-113). For example IL-3 and GM-CSF both induce tyrosine 
phosphorylation of p42 and p44 mitogen activation protein (MAP) kinase and the 
proto-oncogene product Raf-1 and several other unidentified cytoplasmic substrates 
(103,112,113). Tyrosine phosphorylation plays a critical role in receptor function. This 
is demonstrated by mutations in the cytoplasmic domain of EPO and KH97 which 
concomitantly abrogated mitogenic signaling and tyrosine phosphorylation 
(91,95,114). KH97 contains two distinct regions in the cytoplasmic domain that are 
responsible for different signals, both of which seem to require tyrosine kinases. The 
membrane proximal region is essential for the induction of c-myc and pim-1, the C-
terminal region is required for activation of Ras, Raf-1, and MAP kinase as well as 
induction of c-fos and c-jun (114). IL-2 and IL-3 both regulate the activity of PTKs of 
the src family in human T-celllines CTLL-2 and TALL103/2 (115). Phosphorylation 
of these substrates in response to HGFs is very rapid, but none of these receptors 
have intrinsic tyrosine kinase activity, suggesting that these receptors must closely 
associate with secondary tyrosine kinases. Identification of these molecules is 
important for elucidating the mechanism of HGF signal transduction, and may 
reveal substrates that mediate distinct HGF functions. As of today there have been 
only few reports of signaling proteins that associate with activated HGF receptors. 
Recently, a novel PTK, jak2 was cloned (116). Using anti A!C2 antibodies jak2 is 
coprecipitated from DA3 cell lysates, only after !L-3 stimulation of the cell. These 
results indicate that jak2 physically associates with the murine IL-3 receptor and 
forms a link between receptor activation and signal transduction through protein 
phosphorylation. jak2 also associates with the EPO receptor and EPO induced 
phosphorylation of jak2 correlates with biological activity (117). Another protein-
tyrosine kinase implicated in the signaling pathway triggered by GM-CSF and IL-3 is 
c-fps/fes. In TF-1 cells, the proto-oncogene product c-fps/fes is tyrosine 
phosphorylated and activated by stimulation with GM-CSF and IL-3, and becomes 
associated with KH97 upon GM-CSF stimulation (118). 
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lO.liL-3-, GM-CSF, G-CSF and KL receptors in AML 
To date, the precise mechanisms that can lead to growth expansion and/ or 
differentiation block of hematopoietic precursor cells have remained largely 
unidentified. Several mechanisms have been postulated to contribute to unregulated 
neoplastic growth of AML in vivo, e.g. abnormal growth factor responsiveness. In 
this thesis the question was addressed whether HGF receptors may be overexpressed 
or have an altered ligand binding affinity as compared to normal hematopoietic cells. 
Overexpression of receptors, possibly leading to growth advantage has been 
postulated to play a role in the myeloproliferative features of AML. Data presented 
in Chapters 2, 3 and 4 have not shown evidence for overexpression or altered 
affinities of HGF receptors in clinical AML. Density as well as affinities of IL-3, GM-
CSF and G-CSF receptors in AML are of the same magnitude as those of normal 
hematopoietic cells. The higher average level of KL receptor expression on AML cells 
is a general feature of RTKs and is in agreement with the expression of e.g. M-CSF in 
normal hematopoietic cells (1). Although the expression of HGF receptors on AML 
cells did not always predict whether these cells would enter active cell cycling, it is 
clear that in most cases the cells have retained the ability to respond to HGF 
stimulation. Furthermore/ no clear correlation has been shown between the numbers 
of HGF receptors and the ability of the leukemic blast cells to proliferate in vitro in 
response to exogenous HGFs. However/ firm conclusions regarding this relationship 
cannot be made because of the narrow range of levels of HGF receptor expression 
and the heterogeneous cellular composition of AML. 
A fundamental defect in many cases of AML is the partial or complete loss of the 
capacity to mature. In vitro, AML cells generally respond to various HGFs including 
IL-3, GM-CSF, and G-CSF in a proliferative manner, but in contrast to normal 
progenitor cells, lack the ability to differentiate. One possibility is that although the 
receptors are still capable of transducing a mitogenic response, the receptors have 
lost the ability to induce maturation. As demonstrated by artificially induced 
mutations in receptor genes (Chapter 1), altered receptor function must be 
considered as one of the potential causes of abnormal hematopoiesis. Although in 
AML the binding characteristics of HGF receptors are normal; aberrant receptor 
function may also result from changes in the intracellular domain of a receptor, 
without affecting the binding characteristics (2). Impaired receptor function is also 
implied in a subgroup of AML cases. In 14-27% of AML cases, no proliferative 
response to HGF stimulation was observed despite apparent normal receptor 
expression (Chapters 2 and 3). In some of these cases, the cells already exhibited high 
spontaneous growth, which might have obscured the response to the HGF. The 
nonspontaneously growing cases, however, might for instance carry a defect at the 
level of signal transduction or transcription regulation of HGF-induced gene 
expression. Alternatively, these cells may express receptors that are unable to 
transduce a HGF-triggered mitogenic signal. Of note is the identification of a point 
mutation in the human G-CSF receptor, that was isolated from a patient with severe 
congenital neutropenia (SCN) (3). This mutation introduces a stop codon in the 
cytoplasmic domain of the G-CSF receptor resulting in a truncated receptor form. 
When expressed in murine myeloid cells, this mutated receptor exhibits normal 
binding characteristics, and can still transduce a mitogenic signal; but (in contrast to 
the wild type human G-CSF receptor) fails to induce maturation (3,4). Recently, a 
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naturally occurring form of the EPO receptor was identified in which part of the 
cytoplasmic region is deleted by alternative splicing (5). This receptor was able to 
transduce a mitogenic signal, but in contrast to the wild type receptor, failed to 
prevent programmed cell death in BAF3 cells. Another functional domain in the EPO 
receptor was identified, which appears to convey a negative effect on EPO-induced 
signal transduction. Truncation of this N-terminal40 aa serine rich domain allowed 
BAF3 cells to grow maximally in 1/10 the concentration required for growth of cells 
expressing the wild type receptor (6). The identification of such regulatory domains 
in the IL-3, GM-CSF or G-CSF receptors and subsequent screening for abnormalities 
of these domains may reveal a direct relationship between a defective receptor and 
the observed phenotype of the leukemic cells. 
10.2 HGF receptor modulation and regulation of AML growth 
Kit ligand (KL) (also called stem cell factor, mast cell growth factor or Steel factor) 
acts synergistically with several HGFs, including IL-3, GM-CSF, and G-CSF, to 
induce proliferation of primitive hematopoietic precursor cells and AML blast cells. 
As shown in Chapter 4 it appears that synergy between KL and IL-3, GM-CSF or G-
CSF neither results from induction of receptor expression nor from alterations in 
sensitivity to HGFs. These findings were confirmed in the human factor dependent 
cell line M07e. In these cells GM-CSF do not alter the number or affinity of surface 
GM-CSF receptors (7,8). Thus the molecular basis for the synergistic activity of KL is 
probably located further downstream the signaling pathways or involves pathways 
which are unique. Additional studies have focused on early events of signal 
transduction, i.e., phosphorylation of cellular substrates following HGF stimulation. 
These investigations indicate that IL-3, GM-CSF and KL stimulate (tyrosine) 
phosphorylation of several identical substrates in human myeloid cells, including 
Raf-1 kinase and p42 mitogen activated protein (MAP) kinase, however, no synergy 
or additive effects were observed on the level of protein phosphorylation (7,9-11). 
Also, no additional phosphoproteins were apparent after combined stimulation with 
KL and other HGFs compared to the individual factor alone. Possibly the synergistic 
stimulus for cell growth results from unique pathways, triggered by the individual 
growth factors, which finally can augment proliferation by transcriptional regulation 
of genes involved in proliferation. 
Tumor necrosis factor (TNF) is a regulator of inflammation and cellular immune 
responses and is an important mediator of immune responses. In AML TNF can 
enhance proliferation through the induction of HGF production (12). Moreover, TNF 
acts as a modulator of HGF controlled growth of normal and leukemic cells. TNF 
acts synergistically with IL-3 and GM-CSF-induced proliferation and colony 
formation of AML cells and CD34+ cells. Conversely, TNF inhibits the G-CSF 
induced proliferation of AML cells (13-15). These modulatory effects of TNF are 
probably the result of transmodulation of hematopoietic growth factor receptor 
expression (Chapters 5 and 6). In AML, high affinity GM-CSF and IL-3 receptors on 
AML cells are increased 3 to 6-fold after 18 hr's of exposure to TNF (Chapter 5). 
Probably enhanced proliferative response related to the modulatory effect of TNF is 
the result of recruitment of additional subpopulations which become receptor 
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positive. The exact mechanism of receptor upregulation by TNF is still unclear. In 
Chapter 5 it was demonstrated that the effect of TNF depends on active protein 
synthesis, and it has recently been shown that TNF upregulates the expression of the 
common ~ receptor subunit mRNA (16). Thus TNF may act through activation of 
transcription or stabilization of HGF receptor mRNAs in AML cells. TNF has been 
shown to increase the stability of mRNAs in hematopoietic cells (17,18), but the 
molecular mechanism responsible for the TNF effects on cytokine receptors needs 
further elucidation. 
Alternatively, it is possible that the modulatory effects of TNF are mediated at the 
level of transcription of genes that directly relate to cell proliferation. TNF has been 
shown to activate nuclear transcription factors like NF-KB, AP-1 and NF-jun, which 
regulate the transcription of jun (19-21). Expression of the c-jun gene in human 
myeloid leukemia cells is enhanced 4-fold by TNF (22). GM-CSF and IL-3 have also 
been shown to induce expression of (fos and) jun in myeloid cells (23,24). Immediate 
early response genes like fos and jun, whose products form a heterodimeric 
transcription factor complex called AP-1, are both involved in cell cycle progression 
(25-27). These results indicate that TNF is a pleiotropic factor and that the synergism 
with other HGFs may involve multiple levels of action. 
Interestingly, TNF also exerts negative effects on the proliferative response of 
AML. In Chapter 6 it was shown that the antagonistic effects between TNF and G-
CSF on AML cell proliferation are probably accomplished via transmodulation of G-
CSF membrane receptors. TNF downregulates the expression of G-CSF receptors on 
AML blasts and granulocytes. The effects of TNF on the expression of HGF receptors 
appear to be mediated through TPA activation of PKC, and could be blocked by 
protease inhibitors (Chapter 6). Most likely, the mechanism of receptor 
downmodulation is similar for G-CSF and M-CSF receptors. Activation of PKC by 
phorbol esters or physiologic inducers of PKC, such as the macrophage activator 
LPS, induce proteolytic cleavage of the M-CSF receptor in its extracellular domain 
near the membrane (28). The TNF induced transmodulation of the G-CSF receptor 
may represent an important regulatory function in G-CSF signaling. The loss of 
surface receptors will lower the sensitivity to G-CSF. Furthermore, because the 
ligand binding domain of the receptor released from the cells after proteolytic 
cleavage is still able to bind its ligand (29), competition of soluble receptors with cell 
surface receptors may render the AML cells or neutrophils more refractory to G-CSF 
stimulation. The biological effects of TNF are mediated via two specific membrane 
receptors, p55 and p75, both of which are expressed in AML (30-33). A recent study 
using antibodies against both TNF receptors has revealed that all TNF effects in 
AML, i.e., synergy and antagonism with HGFs, and HGF receptor up and down 
modulation are mediated via the p55 TNF receptor (33). 
10.3 Cross competition between IL-3 and GM-CSF 
Experiments dealing with cross competition between GM-CSF and IL-3 in human 
myeloid cells are presented in Chapter 7 of this thesis. AML cells and monocytes 
express both high and low affinity GM-CSF receptors. High affinity GM-CSF binding 
can be competed for by IL-3. Conversely, high affinity IL-3 receptors on AML cells 
and monocytes can be competed for by GM-CSF. The molecular basis of this 
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phenomenon lies in the KH97 receptor subunit that is shared by IL-3 and GM-CSF 
receptors. The role of the GM-CSF-, IL-3-, and IL-5-receptor ex chains in signal 
transduction per se, apart from their role in the formation of the high affinity 
receptor complex, is still uncertain. Reconstitution experiments have revealed that 
the high affinity GM-CSF receptor ex~ heterodimer, but not the low affinity ex 
receptor is responsible for signal transduction in BAF3 cells (34-37). The sharing of 
KH97 explains why IL-3, GM-CSF, and to some extent IL-5 have overlapping 
biological functions (Chapter 1) and induce phosphorylation of a common set of 
cytoplasmic substrates in myeloid cells (38-41). Apart from these common activities, 
IL-3, GM-CSF and IL-5 also exhibit biologically distinct activities. IL-5 specifically 
stimulates human eosinophil function (42). In human mature eosinophils IL-5 blocks 
apoptosis more efficiently than does IL-3 or GM-CSF (43). In AML t(8;21), IL-5 was 
able to induce eosinophilic maturation, whereas IL-3 and GM-CSF only promote 
proliferation in these cells (44). In another study it was shown that in some AML 
cases, IL-3 induced a high proliferative response, whereas GM-CSF was hardly 
effective (45). These divergent effects can to some extent be the result of unique 
cellular distributions of the receptor ex subunits. Different cells, which do not 
coexpress these receptors, may have different response abilities depending on e.g. 
stage of maturation. However, IL-3, GM-CSF, and to a lesser extent IL-5 receptors are 
generally coexpressed in myeloid progenitor cells (Chapters 1 and 7). This suggests 
that the specificity of the cytokine stimulus must result from unique signal pathways 
that do not involve KH97 alone, but requires the involvement of the unique ex 
subunits. The fact that all three HGFs induce identical tyrosine phosphorylation 
patterns in myeloid cells (38,46), suggests that ex subunits do not differentially 
activate tyrosine phosphorylation of cytoplasmic substrates. Thus, events other than 
protein tyrosine phosphorylation may play a role in the determination of the 
specificity of IL-3, GM-CSF, and IL-5 stimuli. This specificity may result from the 
interactions of a specific domain in the a subunit and a common domain on KH97. 
Alternatively, the ligand may determine the alignment in the complex of the ex and~ 
subunit, so that each time the same homologous domain of an a subunit is associated 
with different domains on the ~ subunit. Investigations focusing on structure and 
function of the cytoplasmic domains of the ex subunits are required to further address 
these questions. 
10.4 Alternative oligomerization of the GM~CSF receptor a and p subunits and 
consequences for cytoplasmic signaling 
IL-3 and GM-CSF have been recognized as pleiotropic factors. They act on 
immature as well as mature cells of diverse lineages. In Chapter 8, it was shown that 
the expression of high and low affinity GM-CSF receptors is restricted to the 
myeloblastic and promyelocytic stage of granulocytic maturation (47). Progression 
towards the metamyelocyte stage is associated with a transition to intermediate 
affinity GM-CSF binding, which lack cross competition with IL-3. The existence of an 
intermediate affinity GM-CSF receptor on mature peripheral blood neutrophils had 
become apparent from studies described in Chapter 7. COS cell transfections with 
the human GM-CSF-Rex and KH97 subunits indicate that this conversion is caused by 
the quantitative difference in expression of KH97 (47). The same phenomenon was 
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Figure 1. Alternative oligomerization of GM-CSF 
receptor a and ~ subunits. Increased expression of 
the GM-CSF-RP permits the formation of receptor 
complexes that contain two !3 subunits. 
observed for the IL-3 receptor, which converts from a high affinity receptor to 
intermediate affinity after increased expression of KH97 (48), and it may also explain 
the discrepancies in affinity that have been found for the native IL-5 receptor 
expressed human hematopoietic cells and the reconstituted IL-5 receptor in COS cells 
(37,49). Increased availability of KH97 may lead to the composition of distinct 
oligomeric complexes of a and ~ subunits. The exact composition of the high and 
intermediate affinity GM-CSF receptor complexes are unknown. However, it is 
conceivable that in a situation of restricted KH97 availability, e.g. in AML cells which 
express 10 to 50 times more low affinity than high affinity GM-CSF receptors, the 
high affinity receptor complex comprises one ~subunit and one a subunit. Increased 
levels of KH97 may convert this receptor complex into an intermediate affinity GM-
CSF receptor, which, in analogy to the CNTF and IL-6 receptors, comprises two ~ 
subunits (Fig. 1). This paradigm has important consequences for the activation of the 
GM-CSF receptor, in that it offers the GM-CSF receptor alternative ways of 
secondary signaling, via a~ interaction and via~~ interaction. Since the above model 
portrays a novel mechanism to modulate a HGF response, it would be attractive to 
further investigate this hypothesis. 
Alternative oligomerization of GM-CSF receptor subnnits raises the possibility of 
homodimeric interaction of two ~ subunits versus heterodimeric ap interactions, but 
the significance of alternative oligomerization for signal transduction is still 
unknown. Several questions remain to be addressed: (i) Does the intermediate 
affinity GM-CSF receptor have the ability to induce growth via the interaction of two 
~ subunits (versus a and ~ in the high affinity complex)? (ii) Does the intermediate 
affinity GM-CSF receptor mediate a qualitatively distinct signal as compared to the 
high affinity GM-CSF receptor complex? (iii) Are (signaling) domains on the a and ~ 
subunits alternatively involved in the different complexes? 
It was shown that homodimerization of G-CSF receptors that lack the cytoplasmic 
C-terminal region including Box3, fail to induce maturation in L-GM cells (3,4). An 
attractive hypothesis would be that the intermediate affinity GM-CSF receptor 
complex, via homodimerization of two KH97 C-terminal domains, is able to induce 
(granulocytic) maturation of myeloblasts or to induce functional activation in 
contrast to proliferation. Obviously, in the heterodimeric high affinity GM-CSF 
receptor, association of two Box3 domains cannot occur, since the a subunit lacks 
Box3. Accordingly, the only role of the high affinity GM-CSF receptor would be the 
transduction of a mitogenic signal via the interaction of Boxl of the a subunit with 
one of the cytoplasmic KH97 domains. The latter hypothesis would imply that both 
the intermediate affinity GM-CSF receptor as well as the high affinity GM-CSF 
receptor are able to induce cell growth. It would fit with the observation that AML 
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blasts, that have matured towards the metamyelocyte stage of differentiation and 
acquired intermediate affinity receptors, are still able to respond in a proliferative 
fashion to GM-CSF (Chapter 8). Thus, the level of KH97 expression may play an 
important modulatory role in adjusting GM-CSF responsiveness. 
Boxes 1 of GM-CSF-Ra and KH97 are indispensable for high affinity mitogenic 
signaling in primary transfectants (50). The ability of GM-CSF to signal via the 
interaction of two KH97 subunits, would predict that the signaling failure caused by 
the deletion of Boxl from GM-CSF-Ra, can be overcome by overexpressing KH97 
(hence an intermediate affinity GM-CSF receptor). Alternatively, signaling via 
dimerization of KH97 in the absence of GM-CSF-Ra can be achieved by crosslinking 
anti KH97 antibodies on BAF3 cells that exclusively express KH97. The qualitative 
differences of GM-CSF-induced signaling via intermediate or high affinity receptors 
may be investigated in the L-GM cell line model. Transfection of the GM-CSF 
receptor subunits in these cells may confirm whether overexpression of KH97 results 
in GM-CSF-induced maturation. 
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SUMMARY 
IL-3, GM-CSF and G-CSF stimulate proliferation of human acute myeloid 
leukemia in vitro, but patterns of response among clinical cases are diverse. As 
described in Chapters 2 and 3, numbers and affinity of IL-3, GM-CSF and G-CSF 
receptors on cells of patients with AML were assessed and correlated with the 
proliferative response of the cells to IL-3, GM-CSF and G-CSF. In 13 of 15 cases of 
primary AML high affinity receptors for IL-3 were demonstrable on the cells. The 
average numbers of IL-3 receptors ranged from 21-145 receptors per cell. Normal 
white blood cells showed IL-3 receptors on their surface at similar densities. IL-3 
receptor positivity often correlated with GM-CSF receptor positivity of AML, GM-
CSF receptors were demonstrated on the cells of 11 of 15 cases although average 
numbers of GM-CSF receptors were 10 times greater. The binding of G-CSF to 
normal and human AML cells was investigated in a series of 14 cases of primary 
AML. In all 14 cases specific receptors for G-CSF were demonstrated on purified 
blast cells. The average numbers of G-CSF receptors ranged from very low (specific 
binding scarcely detectable) to 428 receptors per cell. Normal granulocytes showed 
G-CSF binding sites on their surface at higher densities (703 to 1,296 sites/cell). G-
CSF receptors appeared of a single affinity type with a dissociation constant (Kct) 
ranging between 214 to 378 pM for AML blasts and 405 to 648 pM for normal 
peripheral blood granulocytes. The in vitro response of the cells to exogenous IL-3, 
GM-CSF or G-CSF was examined by measuring thymidine uptake. IL-3 and GM-CSF 
were potent inducers of DNA synthesis in vitro. In 12 of 14 cases including those 
with relatively low specific binding, G-CSF was a potent inducer of DNA synthesis 
of blasts in vitro; apparently relatively few receptors permit activation of AML cell 
growth. In a minority of cases however, the cells were unable to respond to IL-3 (4 of 
15 cases), GM-CSF (4 of 15 cases) or G-CSF (2 of 14 cases) in spite of normal receptor 
availability on the cell surface. The inability of the cells to respond to stimulation 
might be caused by the inability of the receptors to transduce a secondary signal into 
the cells. The results from these experiments taken together did not provide evidence 
for overexpression or gross changes in receptor affinity as an explanation for AML 
growth. 
Chapter 4 deals with the role of KL and c-kit in AML cell growth. The proliferative 
response to KL in relation to c-kit expression was investigated in 10 AML cases. 
Additionally, the mechanism of synergy of KL in combination with several other 
HGFs was studied. FACS analysis with antic-kit antibodies revealed KL receptor 
expression in 8 of 9 cases, often in a subpopulation of the cells. Scatchard analysis of 
KL receptors in two AML cases and the cell line M07e, indicated the presence of 
(mean) 1,460 to 120,000 binding sites per cell. The same class of high affinity KL 
receptors (Kct 40 to 160 pmol/L) was detected in all cell samples. KL stimulated DNA 
synthesis of purified leukemic blasts in 8 of 10 cases and colony formation in 4 cases 
in serum-free culture. KL synergizes with IL-3 , GM-CSF, but synergizes most with 
G-CSF. Synergistic effects of KL in combination with other CSFs were also seen in the 
colony assay. Antibodies against GM-CSF, M-CSF, G-CSF and IL-6 did not inhibit the 
KL response, suggesting that the stimulative effect of KL was not mediated through 
autocrine release of those cytokines. In contrast, the proliferative response to KL was 
abrogated in the presence of TNF (4 of 10 cases) and IL-4 (2 of 10 cases). The KL 
dose-response curve in the presence of IL-3 or GM-CSF resulted in a higher plateau 
of DNA synthesis, however no shift in the dose response was apparent. The 
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respective reciprocal dose response relations to GM-CSF, IL-3 or G-CSF were 
similarly elevated when KL was added. KL did not alter IL-3 and GM-CSF receptor 
expression, nor did IL-3, GM-CSF, G-CSF, TNF or IL-4 influence KL binding to AML 
cells. Apparently the mechanism of synergy lies at other levels of signal 
transduction. 
TNF acts as a potent enhancer of GM-CSF and IL-3-induced human AML growth 
in vitro. In Chapter 5 the question was addressed whether the TNF effects might be 
accomplished at the level of membrane receptors. Incubation of blasts from seven 
patients with AMLin serum-free medium with TNF and subsequent binding studies 
using radiolabeled IL-3 and GM-CSF, showed that TNF increases the specific binding 
of GM-CSF (30-280%) and IL-3 (40 to 600%) in all cases. From Scatchard plot analysis 
it appears that TNF upregulates (1) low affinity GM-CSF binding sites, (2) high 
affinity common IL-3/GM-CSF binding sites, and (3) high affinity unique (non-GM-
CSF binding) IL-3 binding sites. The effect of TNF becomes evident at 18 hours of 
incubation with TNF at 37 °C, but not at 0 'C. The GM-CSF dose response curve of 
AML-colony forming units plateaus at a higher level in the presence of TNF, which 
i.ndicates that additional numbers of cells become responsive to GM-CSF. Incubation 
of AML blasts with the phorbol ester TPA or fMLP (PKC activators) does not 
influence GM-CSF receptor expression, suggesting that receptor upregulation by 
TNF is not mediated through activation of PKC. On the other hand, the protein 
synthesis inhibitor cycloheximide abrogates receptor upregulation induced by TNF. 
In contrast to these findings in AML, TNF does not upregulate GM-CSF receptor 
numbers on blood granulocytes or monocytes. 
G-CSF stimulates the proliferation of AML in vitro and it may also induce 
maturation in some cases of myeloid leukemia. TNF acts antagonistically with the 
proliferative effects of G-CSF on AML blasts in vitro, and thus appears to be a 
negative regulator of the G-CSF-induced proliferation of AML cells. In Chapter 6 the 
mechanism that may explain the antagonistic effects between TNF and G-CSF was 
investigated. Incubation of blasts from 3 patients with AMLin serum-free medium 
with TNF, and subsequent binding studies using radiolabeled G-CSF reveal that TNF 
downregulates the numbers of G-CSF receptors by± 70%. G-CSF receptor numbers 
on purified blood granulocytes are also downmodulated by TNF. Downregulation of 
G-CSF receptor expression becomes evident within 10 minutes after incubation of the 
cells with TNF at 37 oc and is not associated with an apparent change of the 
dissociation constant. The TNF effect does not occur at 0 oc and cannot be induced 
by IL-2, IL-6 or GM-CSF. TNF probably exerts its effect through activation of PKC, as 
the TNF effect on G-CSF receptor levels can be mimicked by TPA. The PKC inhibitor 
Staurosporine as well as protease inhibitors completely prevent G-CSF receptor 
downmodulation. Thus it appears that TNF may act as a regulator of G-CSF receptor 
expression in myeloid cells and shut off G-CSF dependent hematopoiesis. The 
regulatory ability of TNF may explain the antagonism between TNF and G-CSF 
stimulation. 
It has been shown that a considerable degree of functional overlap between GM-
CSF and IL-3 exists, in particular on immature myeloid cells. In Chapter 7, specific 
experiments were conducted to analyze the properties of GM-CSF and IL-3 binding 
proteins in more detail. On AML blasts from 8 cases two types of GM-CSF receptors 
were apparent, i.e., one with low affinity (Kct 5.1 to 24.8 nmol/L) and one with a high 
affinity (Kd 31 to 104 pmol/L). These AML cells also expressed high affinity 
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receptors for IL-3 (Kct 24 to 104 pmol/L). Cross competition experiments with AML 
cells showed that an excess concentration of nonlabeled IL-3 completely prevented 
the high affinity binding of radiolabeled GM-CSF. Low affinity GM-CSF binding 
does not show this cross reactivity. Conversely, binding of radiolabeled IL-3 to AML 
cells could be reduced by nonlabeled GM-CSF. In certain cases, this competition was 
complete, whereas in others only partial (49 to 77%) reduction of the radiolabeled IL-
3 binding was seen. Cross competition occurred equally well at 37 oc and 4 oc, 
suggesting that the cross reactivity resulted from direct interference at the receptor 
level (rather than downmodulation). In contrast to AML, normal neutrophils express 
a single class GM-CSF receptor with intermediate affinity (Kct ~400 pmol/L), that can 
not be competed for by IL-3. In conclusion, four different receptors for IL-3 and GM-
CSF can be postulated: (i) low affinity GM-CSF receptors that do not bind IL-3, (ii) 
dual high affinity GM-CSF /IL-3 receptors, and (iii) high affinity IL-3 receptors that 
do not bind GM-CSF. The same receptor types could also demonstrate on normal 
monocytes, (iv) GM-CSF receptors incapable of binding IL-3 and with an 
intermediate affinity for GM-CSF ( ~400 pmol/L). Chemical cross linking revealed 
that GM-CSF and IL-3 both bind to proteins with Mr values of 130, 105 and 75, which 
provides additional evidence for the existence of a common GM-CSF /IL-3 receptor 
complex. 
It subsequently became clear that the high affinity GM-CSF receptor is a 
heterodimeric complex of a specific GM-CSF receptor a subunit and a ~ subunit 
(KH97). Cross competition between high affinity GM-CSF and high affinity IL-3 
binding is caused by the fact that both high affinity receptors share the common ~ 
chain, ~c ( KH97). The fact that immature cells express different binding features 
than do mature neutrophils (Chapter 7), raises the question at which stage of 
maturation the GM-CSF binding features are converted into those of the terminally 
differentiated neutrophils and what possible mechanism could underlie these 
changes. Chapter 8 describes the differentiation associated changes of GM-CSF 
binding characteristics in three models representing distinct stages of myeloid 
maturation: 1) primary AML cells that matured spontaneously in culture towards 
myelocytes, 2) chronic phase CML cell samples that contained myelocytes, 
metamyelocytes and band forms and 3) the promyelocytic cell line HL-60 in which 
retinoic acid (RA) induced neutrophilic differentiation. Upon maturation in culture, 
the primary AML cells lost the characteristic high affinity GM-CSF binding and 
acquired intermediate affinity GM-CSF receptors. Similar to the high affinity GM-
CSF-R of primary AML, these intermediate affinity GM-CSF receptors still showed 
full cross competition with !L-3. Intermediate affinity GM-CSF receptors that could 
be competed for by IL-3 were also observed in CML cells and HL-60 cells. Upon RA 
treatment of the HL-60 cells, !L-3 cross-competition was lost, leaving the 
intermediate affinity GM-CSF binding typical of peripheral blood neutrophils. Thus, 
high affinity GM-CSF binding is converted into intermediate affinity binding, which 
still cross reacts with IL-3, beyond the stage of promyelocytes. Also, during terminal 
maturation towards neutrophils, IL-3 cross reactivity is gradually lost. Further 
investigations were conducted to determine the mechanism underlying the affinity 
conversion of the GM-CSF-R. Northern analysis demonstrated the presence of 
mRNA encoding the GM-CSF-R a and GM-CSF-R ~subunits at every differentiation 
stage, indicating that the genes of both GM-CSF-R subunits are transcribed 
throughout neutrophilic maturation. Northern and reverse transcriptase-polymerase 
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chain reaction analysis of GM-CSF-Ra and ~c (KH97) transcripts did not provide 
indications for the involvement of GM-CSF-R splice variants in the formation of the 
intermediate affinity GM-CSF-R complex. Because immature myeloblasts express 
few high affinity GM-CSF receptors, whereas differentiated cells express much 
higher numbers of intermediate affinity receptors and because Northern analysis 
indicated that Be transcripts but not GM-CSF-Ra: transcripts increase with 
progressive maturation, the possibility that increased availability of Be caused the 
affinity changes was investigated. In COS-cell transfectants with increasing amounts 
of ~c in the presence of a fixed number of GM-CSF-Ra chains, the high affinity GM-
CSF binding converted into intermediate affinity GM-CSF binding. Although the 
exact composition of the high and intermediate affinity GM-CSF receptor complexes 
still remain unknown, we assume that the affinity shift is caused by increased 
expression of ~c subunits resulting in alternative oligomerization of the GM-CSF-Ra 
and ~c subunits. 
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SAMENVATTING 
De aanmaak van bloedcellen (hematopoiese) vindt onder normale 
omstandigheden plaats in het beenmerg. Hier bevinden zich de hematopoietische 
stamcellen die door celvermenigvuldiging en uitrijping de verschillende soorten 
bloedcellen kunnen voortbrengen die uiteindelijk hun taak in het bloed en in diverse 
andere weefsels moeten vervullen. Dit zeer dynamische proces/ verantwoordelijk 
voor de dagelijkse aanmaak van meer dan 1011 leukocyten en erythrocyten, wordt in 
belangrijke mate gereguleerd door hematopo!etische groeifactoren (HGFs), 
geproduceerd door o.a. monocyten, endotheelcellen en fibroblasten. Groeifactoren 
oefenen hun werking op de bloedcellen uit door aan specifieke membraanreceptoren 
te binden en deze vervolgens te activeren. Bij acute myeloide leukemie (AML) is de 
aanmaak en uitrijping van leukocyten gestoord. De leukocyten onttrekken zich aan 
de normale controlemechanismen en verdringen tevens de normale 
bloedcelaanmaak in het beenmerg. Omdat de hematopoietische groeifactor-
receptoren een crudale rol spelen in deze controlemechanismenf rijst de vraag welke 
rol deze receptoren spelen bij de pathogenese van acute myeloide leukemie. De 
studies die in dit proefschrift worden gepresenteerd behandelen de expressie, 
specifieke bindingseigenschappen, functie en regula tie van de receptoren voor drie 
hematopoietische groeifactoren (granulocyt macrofaag kolonie-stimulerende factor 
(GM-CSF), interleukine-3 (IL-3) en granulocyt kolonie-stimulerende factor (G-CSF)) 
bij AML en normale bloedcellen. In hoofdstuk 1 wordt een kort overzicht gegeven 
over normale bloedcelvormingf AML en hematopoietische groeifactoren en hun 
receptoren. 
In hoofdstuk 2 en 3 word! het onderzoek beschreven naar het voorkomen en de 
karakterisering van IL-3, GM-CSF en G-CSF receptoren op blasten van patienten met 
AML. Bij 13 van de 15 AML patienten werden hoog affiene IL-3 receptoren 
(dissociatie constante {Kct) 26 tot 414 pM) op de leukemische cellen aangetoond. Het 
gemiddeld aantal!L-3 receptoren per eel varieerde van 21 tot 145. Op leukocyten van 
gezonde proefpersonen werd een vergelijkbare expressie van IL-3 receptoren met 
dezelfde affiniteit gemeten. Bij alle 14 AML patienten die bestudeerd werden bleken 
G-CSF receptoren op de blasten tot expressie te komen. Gemiddeld varieerde de 
expressie van de G-CSF receptoren van zeer laag (specifieke binding aantoonbaar) 
tot gemiddeld 428 receptoren per eel. Op normale granulocyten kwamen hogere 
receptor aantallen voor (703 tot 1296 G-CSF receptoren per eel). De G-CSF receptoren 
bleken een enkelvoudige affiniteit te bezittenf met een Kct die varieerde van 214 tot 
378 pM op AML blasten en 405 tot 648 pM op normale granulocyten. De expressie 
van !L-3, GM-CSF en G-CSF receptoren werd vergeleken met de effecten van de 
groeifactoren op de in vitro proliferatie van de AML cellen. De mate van activering 
van AML eel proliferatie door IL-3, GM-CSF en G-CSF werd bepaald door de 
inbouw van radioactief thymidine te meten. IL-3, GM-CSF en G-CSF bleken in de 
meeste gevallen in staat om DNA synthese van AML cellen in vitro te stimuleren. 
Klaarblijkelijk zijn slechts weinig receptoren nodig om de AML cellen tot deling aan 
te zetten. In een aantal gevallen bleken de cellen niet in staat om op !L-3 (4 van 15 
gevallen), GM-CSF (4 van 15 gevallen) of G-CSF (2 van de 14 gevallen) te reageren, 
ondanks de normale expressie van receptoren. Het onvermogen van de cellen om te 
reageren op de groeifactorprikkel zou verklaard kunen worden door een blokkade in 
de signaaltransductie van deze receptoren op intracellulair niveau. De resultaten van 
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deze experimenten geven geen steun aan de hypothese dat overexpressie of een 
abnormale affiniteit van groeifactorreceptoren een rol spelen bij de aberrante 
celproliferatie bij AML. 
In hoofdstuk 4 wordt ingegaan op de rol van c-kit expressie in AML cellen in 
relatie met de effecten van de groeifactor kit-ligand (KL) op AML celproliferatie. 
Tevens is het synergisme van kit-ligand met andere groeifactoren onderzocht. Met 
behulp van anti c-kit antilichamen en FACS analyse werd KL receptor expressie in 8 
van de 9 gevallen waargenomen, vaak aileen in een subpopulatie van de cellen. 
Scatchard analyses van KL receptoren op twee AML celmonsters en de cellijn M07e 
toonden tussen de 1460 en 120.000 KL receptoren aan, in alle gevallen met hoge 
affiniteit (Kd 40 tot 160 pmol/L). Kit-ligand stimuleerde de DNA synthese van AML 
cellen in 8 van de 10 patienten en kolonie groei in 4 gevallen. Kit-ligand bleek 
synergistisch te werken met IL-3, GM-CSF en met name G-CSF. Daarentegen bleken 
de effecten van KL op AML proliferatie geremd te kunnen worden door tumor 
necrosis factor (TNF) (4 van de 10 gevallen) en IL-4 (2 van de 10 gevallen). 
Antilichamen gericht tegen GM-CSF, M-CSF, G-CSF en IL-6 bleken niet in staat de 
kit-ligand respons te remmen. Het is derhalve onaannemelijk dat de effecten van KL 
via autocriene stimulatie van deze groeifactoren tot stand komen. Om het 
synergisrne van KL met andere groeifactoren nader te karakteriseren werden titraties 
uitgevoerd van KL, al of niet in aanwezigheid van andere groeifactoren en vice 
versa. In de KL dosis-respons bereikte de mate van DNA synthese een hoger plateau 
in de aanwezigheid van IL-3 of GM-CSF, echter zonder dat de gevoeligheid voor KL 
zich wijzigde. Omgekeerd bleken oak de EDso waarden van GM-CSF, IL-3 of G-CSF 
niet te veranderen in aanwezigheid van KL. Tenslotte werd de mogelijkheid dat het 
synergisme berust op modulatie van groeifactorreceptoren onderzocht. De expressie 
van IL-3 en GM-CSF receptoren werd niet beinvloed door KL. De groeifactoren IL-3, 
GM-CSF, G-CSF, TNF of IL-4 bleken de expressie van kit-ligand receptoren op AML 
cellen evenmin te beinvloeden. Kennelijk is het mechanisme dat verantwoordelijk is 
voor het synergisme en antagonisme van kit-ligand met andere groeifactoren niet 
gelegen op het niveau van de membraan receptoren. 
Tumor necrosis factor (TNF) is in staat om de proliferatie van AML cellen 
gestimuleerd door GM-CSF en IL-3 in vitro synergistisch te verhogen. Onderzoek 
naar het mechanisme van dit synergisme wordt beschreven in hoofdstuk 5. Er werd 
onderzocht of deze effecten tot stand komen door modulatie van 
groeifactorreceptoren. In zeven gevallen van AML bleken de cellen na behandeling 
met TNF meer IL-3 (40 tot 600%) en GM-CSF (30 tot 280%) te binden. Uit Scatchard 
analyses bleek dat TNF de expressie verhoogt van (1) de laag affiene GM-CSF 
receptoren, (2) de gemeenschappelijke hoog affiene IL-3/GM-CSF receptoren 
alsmede (3) de hoge affieniteits, unieke (niet-GM-CSF bindende) IL-3 receptoren (in 
hoofdstuk 7 worden de verschillende typen receptoren nader besproken). De 
verhoogde expressie van deze receptoren treedt op na 18 uur incubatie met TNF bij 
37 oc. Bij oplopende concentratie van GM-CSF bleek de koloniegroei van AML 
blasten een hogere plateauwaarde te bereiken in aanwezigheid van TNF. Incubatie 
van AML blasten met 12-0-tetradecanoylphorbol-13-acetate (TPA) of formyl-Met-
Leu-Phe (fMLP) (beide proteine kinase (PK)-C activerende verbindingen) had geen 
invloed op de expressie van GM-CSF receptoren. Daarentegen blokkeerden 
eiwitsynthese-remmers, zoals cycloheximide, de verhoogde expressie van receptoren 
door TNF we!. De effecten van TNF op de GM-CSF receptoren komen dus 
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klaarblijkelijk niet tot stand via de activatie van proteine kinase C, maar wel na 
activatie van eiwitsynthese. In tegenstelling tot de resultaten bij AML cellen, bleek 
TNF niet in staat om de expressie van GM-CSF receptoren op granulocyten of 
monocyten te verhogen. Het effect van TNF op de GM-CSF en IL-3 receptorexpressie 
is beperkt tot een bepaald rijpingsstadium van myeloide differentia tie. 
G-CSF stimuleert de proliferatie van AML in vitro en kan in sommige gevallen 
ook myeloide uitrijping induceren. TNF blijkt de door G-CSF geinduceerde 
proliferatie van AML cellen in vitro te remmen. In hoofdstuk 6 word! ingegaan op de 
rol van G-CSF receptoren in het antagonisme tussen TNF en G-CSF. Incubatie met 
TNF van celmonsters van 3 AML patienten bleek het aantal G-CSF receptoren met± 
70% te reduceren. Ditzelfde fenomeen werd ook bij normale granulocyten 
waargenomen. Het effect van TNF op de G-CSF receptor expressie treedt binnen 10 
minuten op bij 37 oc en heeft geen invloed op de affiniteit van de G-CSF receptor. De 
verlaagde expressie van G-CSF receptoren trad niet op bij ooc en werd niet met 
andere cytokinen zoals IL-2, IL-6 of GM-CSF verkregen. Met TPA (PKC activerende 
verbinding) kon het effect van TNF nagebootst worden, terwijl Staurosporine (PKC 
remmer) het TNF effect teniet doet. Kennelijk oefent TNF zijn werking op de G-CSF 
receptor uit via activering van PKC. Het door TNF of TPA geinduceerde effect op de 
G-CSF receptorexpressie bleek ook met protease remmers geblokkeerd te kunnen 
worden. Mogelijk komt de reductie van het aantal G-CSF receptoren tot stand 
doordat het extracellulaire domein enzymatisch van de receptor wordt afgekliefd via 
een door PKC geactiveerd protease. De resultaten in hoofdstuk 5 en 6 suggereren dat 
TNF een regulerende rol speelt in de hematopoiese. Via regula tie van IL-3 en GM-
CSF receptoren op myeloide cellen kan TNF de proliferative activiteit verhogen. 
Anderzijds, via regula tie van G-CSF receptoren op myeloide cellen, kan TNF G-CSF 
afhankelijke hematopoiese blokkeren. 
Eerder is aangetoond dat de activiteiten van IL-3 en GM-CSF elkaar voor een 
groat dee! overlappen. Een mogelijke verklaring hiervoor is dat beide groeifactoren 
aan dezelfde receptor binden. In hoofdstuk 7 wordt nader ingegaan op de specifieke 
bindings eigenschappen van de receptoren voor IL-3 en GM-CSF. Op AML cellen 
afkomstig van 8 patienten bleken twee typen GM-CSF receptoren voor te komen: een 
met een !age affiniteit (Kd 5,1 tot 24,8 nmol/L) en een met hoge affiniteit (Kd 31 tot 
104 pmol/L). Op dezelfde AML cellen komen ook IL-3 receptoren met hoge affiniteit 
tot expressie (Kd 24 tot 104 pmol/L). Uit kruiscompetitie experimenten met AML 
cellen bleek dat een grate overmaat niet-radioactief IL-3 de hoog affiene binding van 
radioactief gemerkt GM-CSF volledig kon blokkeren. De binding van GM-CSF met 
lage affiniteit werd daarentegen niet door IL-3 beinvloed. Omgekeerd bleek ook dat 
de binding van radioactief IL-3 door niet-radioactief GM-CSF geremd kon worden. 
In een aantal gevallen, was deze remming volledig, terwijl bij de overige gevallen 
van AML slechts gedeeltelijke (49 tot 77%) remming van de radioactief gemerkt IL-3 
binding optrad. Het feit dat deze kruiscompetitie zich zowel bij 37'C als bij 4 oc 
voordoet, sluit receptor transmodulatie uit en geeft aan dat er sprake is van een 
competitie op het niveau van receptor binding. Neutrofiele granulocyten bleken een 
geheel andere GM-CSF bindingskarakteristiek te hebben. GM-CSF receptoren op 
neutrofiele granulocyten vertonen een intermediaire affiniteit voor GM-CSF (Kd -400 
pmol/L) en Iaten geen kruiscompetitie zien met IL-3. Er zijn dus 4 verschillende 
receptortypen voor IL-3 en GM-CSF te onderscheiden: (i) laag affiene GM-CSF 
receptoren die geen IL-3 binden, (ii) gemeenschappelijke hoog affiene IL-3/GM-CSF 
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receptoren (iii) hoog affiene IL-3 receptoren die geen GM-CSF kunnen binden (deze 
drie type receptoren werden naast AML cellen ook op monocyten aangetoond) en 
tenslotte (iv) GM-CSF receptoren met intermediaire affiniteit die geen IL-3 kunnen 
binden. De betrokkenheid van een gemeenschappelijk GM-CSF /IL-3 receptor(keten) 
werd verder geillustreerd door chemische crosslinking van radioactief ligand aan de 
receptor. Zowel GM-CSF als IL-3 bleken aan drie membraan eiwitten met identieke 
molekuul massa's te binden (130, 105 en 75 kDa). 
Uit werk van andere onderzoeksgroepen werd duidelijk dat de hoog affiene GM-
CSF receptor bestaat uit een heterodimeer complex van een GM-CSF specifieke a 
keten en een, door andere receptoren gedeelde, ~ keten (KH97). De kruisreactiviteit 
tussen GM-CSF en IL-3 werd hiermee ook verklaard; zowel de IL-3 receptor als de 
GM-CSF receptor gebruiken beide deze ~ keten (~c of KH97). In hoofdstuk 7 is 
beschreven hoe het expressiepatroon van GM-CSF receptoren op myeloide cellen 
afhangt van de differentiatiegraad. De vraag rijst in welk rijpingsstadium deze 
veranderingen plaatsvinden en welk mechanisme hieraan ten grondslag ligt. 
Hoofdstuk 8 beschrijft de veranderingen van de GM-CSF receptor expressie in drie 
modellen die elk opeenvolgende stadia van myeloide uitrijping vertegenwoordigen: 
1) AML cellen die in vitro van blasten naar myelocyten uitrijpen, 2) chronische lase 
CML cellen die verschillende stadia van myelocyten tot segmentvormige 
granulocyten omvatten, 3) de promyelocyten-cellijn HL-60 waarvan de 
promyelocyten onder invloed van retinoidezuur tot functionele granulocyten 
kunnen uitrijpen. De AML cellen bleken na in vitro uitrijping tot (pro)myelocyten 
hun kenmerkende hoge en laag affiene GM-CSF receptoren te verliezen om 
vervolgens intermediair affiene GM-CSF receptoren tot expressie te brengen. Net als 
de hoog affiene GM-CSF receptoren bleken deze intermediaire receptoren ook IL-3 te 
binden. Ook bij CML cellen en HL-60 cellen bleek GM-CSF binding met 
intermediaire affiniteit voor te komen, die kruisreageren. Na inductie met 
retino!dezuur van de promyelocytaire HL60 cellen tot uitgerijpte granulocyten bleek 
de intermediaire GM-CSF receptor ongewijzigd tot expressie te komen, echter, de 
kruisreactiviteit met IL-3 was verdwenen (overeenkomstig de situatie in normale 
granulocyten). Voorts word! in hoofdstuk 8 het mechanisme onderzocht dat 
verantwoordelijk is voor de veranderde affiniteit van de GM-CSF receptor. Met 
behulp van Northern analyse konden mRNAs van de GM-CSF-Rrx en ~c (KH97) 
ketens in alle stadia van neutrofiele differentiatie worden aangetoond. Verdere 
analyse met reverse transcriptase-polymerase kettingreactie van GM-CSF-Ra en ~c 
mRNAs toonden geen splice-varianten aan. Kennelijk zijn de ongemodificeerde a en 
~ receptorketens betrokken bij de vorming van het intermediair affiene GM-CSF 
receptor complex. Uit Northern analyse bleek dat het expressie niveau van de ~ 
receptorketen mRNA toenam met gelijkblijvend niveau van de a keten bij cellen met 
een hogere differentiatiegraad. Door in COS cellen met een constant expressie niveau 
van de GM-CSF-Rrx de expressie van ~c te vergroten bleek de GM-CSF binding over 
te gaan van een hoge naar intermediaire affieniteit. Het lijkt aannemelijk dat de 
relatieve kwantitatieve expressie van ~c ten opzichte van GM-CSF-Ra de affiniteit in 
het GM-CSF receptor complex bepaalt. 
Hoofdstuk 9 geeft overzicht waarin de verschillende functionele en structurele 
eigenschappen van de familie van de hematopoietische groeifactorreceptoren en in 
het bijzonder van de GM-CSF, IL-3 en G-CSF receptoren worden besproken. Aan de 
orde komen: het voor deze familie kenmerkende CRH domein, het voorkornen en de 
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rol van splicevarianten van HGF receptoren, de vorming van hoog affiene 
receptoren, ligandherkenning, het cytoplasmatisch domein en signaal transductie. In 
de discussie (hoofdstuk 10) word! ingegaan op de rol van IL-3, GM-CSF, G-CSF en 
KL receptoren in leukemogenese. Het gemeenschappelijk gebruik van een 
receptorketen door twee receptorsystemen, waarvan de competitie tussen de GM-
CSF en IL-3 voor receptor binding het gevolg is, word! besproken, alsmede de 
consequentie hiervan t.a.v. de specificiteit versus redundantie van de GM-CSF en IL-
3 stimuli. Tenslotte wordt de mogelijke betekenis van alternatieve complexvorming 
van de GM-CSF receptor B keten voor ligand binding en signaaltransductie 
bediscussieerd. 
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